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It is, perhaps, ironical. that while influenza was 
probably the first animal virus to be studied in detaiJ. 
there is still little known conceming its behaviour. In 
many ways it represents a model of difficult immunization 
problems. Now that so many of the most lethal and 
dramatic of the infectious diseases are susceptible to 
control attention is being focused upon the control of 
the next rank of disorders. This includes those 
conditions which cause ill-health and discomfort only to 
such an extent that the cost and severity of measures of 
prevention must be carefully weighed against the effects 
of the disease process itself. The solution of the 
technical, administrative and ethical problems of 
influenza control will, in addition, greatly assist the 
struggle against numerous other ailments. 
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CHAPTER I 
HI TORICAL INTRODUCTION 
THE STORY OF INFLUENZA: 
It would seem that influenza has long been with 
mankind. Edmund Parkes (186 ), in Reynolds' ttA System of 
Medicine", attributes its description to Hippocrates and 
discerns influenza in the malady of the ill-fated Athenian 
expedition to Sicily. August Hirsch (1883) cited 
epidemics as far back as 1173 that tallied with influenza. 
In the wealth of description the clinical picture of 
influenza has remained constant. It is not surprising 
that the ~uotation by Thomas Short (1749, cited by 
-Thompson, 1852) of a description of an outbreak in Madri 
in 1557 has figured so much in the literature for it keeps 
its lucidity to-day. "There it began wi t h a roughness of 
the jaws, small cough, then a strong fever, with a pain of 
the head, back, and. legs; some felt as though they were 
corded over the breast, and had a weight at the stomach, 
all of which continued to the third day at farthest; then 
the fever went off with a sweat, or bleeding at the nose. 
In some few, it turned to a pleurisy, or fatal 
peripneumony. tt 
The epidemic nature of influenza has always. been one 
of the most striking features of the disease. Hirsch 
2 
- __ ..;.__ 
wrote that in i ta pandemic character n •••• influenza takes. 
~ 
an exceptional place among the acute infective diseasestt. 
Many of the. early names. expressed the concept of novelty 
as in l558 the ttnew burning ague tt or in 1562 the a.ccount. 
- ~ 
from the court of Mary Queen of Scots. of ttthe newe 
acquaytance". 
With these recurring epidemics went a peclllliarly high 
attack rate and .these combined to impress the chroniclers 
of the disease. ttit attacked at once, and raged all over 
. 
Europe, not- missing a family, and scarce a pars.on tt wri tea 
-
Short (1749) of the outbreak of 1510. Hu:x:ham (1758, cited 
by Thompson, 1.852) reflected upon 1.733, ttabout this time a 
-
dis.ease invaded these parts, which was the most compleatly 
epidemic of any I remembe.r to have met with; not a houae 
was free of it; the baggar's hut, and the nobleman's 
palace were alike subject to its attacks; scarce a person 
escaping either in town or country; old and young, strong 
and infirm, shared the same fate. tt The Royal College of 
-
Phys.icians in London reported in J. 783, cited by Thompson 
(1852): ttThe universality of the influenza was remarkable, 
. 
the proportion of the inhabitants affected by it being in 
some places estimated at three-fourths, in other places, 
at four-fifths of the whoJ..ett. 
Despite the numerous cases the mortality was 
recognized to be gene~ally low. Huxham. continued his 
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account· mentioned abov~ tt •••• but still considering the 
" great multitude that were seized by it it was fatal to but 
few, and that chiefly infants and consumptive old peopl.e". 
The Ambasaador in Scotland to Queen .Elizabeth the First 
wrote that "There was no appearance of danger, nor manie 
that. die of the disease, excepte some old folks tt (Brit. 
med. J., 1919). 
TH NATURE OF EPIDEMIC : 
In the last century with the greater organisation and 
enumeration of populations the spread of epidemics has 
been more readily established. It has become clear tha.t 
world-wide pandemics occur at fairly long intervals of 10-
20 years but in be.tween these major waves, which are 
associated usually with variation of the virus, come more 
localis.ed outbreaks restricted to a country, a province, a 
town or even a comm.unity. 
Certain general predictions may be made in that 
influenza epidemics tend to avoid the summer. A pandemic 
will t.end to rage in the winter in one hemisphere and 
invade the other with the change of s.eason. In the 
tropics the seasons. have much less influence. 
However, even a superficial study of the major recent 
pandemics shows. a marked variation in behaviour for 
reasons. at present unknown. 
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:Before the era of viral identification, the pandemic 
of 1918-1919 presents an extraordinary picture. Influenza 
was reported in April 1917 (Ireland, 1928) in the United 
States. A high incidence of a relatively mild disease 
occurred during the winter of 1917-1918, in the northern 
hemisphere, rising to a peak in April 191.8. This then 
fell to a low level in June 1.91.8. At this time the 
disease changed its character on both sides of the 
Atlantic simultaneously and in the following months the 
immensely lethal epidemic raged despite the summer season 
and spread about the world. 
In 1.946 a new ttfamil.ytt of viruses was ushered in 
quietly in Australia. These spread across the Pacific and 
invaded the United States in the northern winter and 
spring. However, Britain was, relatively, spared in that 
winter and, with continental Europe, was much more 
affected the following winter when an epidemic sprang from 
a multicentric source in Sardinia. The most severe wave 
in Britain of the same family of viruses occurred in 1950-
1951. Thua the pandemic phas.e of this variant was of a 
.much more insidious nature. 
In contrast, the Asian pandemic of 1957 spread across 
the world in text-book fashion, affecting China and Japan 
in. the winter and spring, causing many daa~s in South 
America and South Africa in the southern winter and 
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creating widespread epidemics in the northern hemisphere 
in the au t.umn. 
Frequently, during these pandemic phases it was 
possible to trace the spread of infection along the lines 
of communication - of shipa from New Zealand to Fiji in 
1918 (Thomson and Thomson, 1934), of aircraft from the Far 
East and Hawaii to California in 1947 (Sartwell and Long, 
1947). It is also possible to aee examples of that 
explosive spread, faster than travel, which so puzzled 
older epidemiologists and led them t~ feel that influenza 
. was not spread by human con -cact (Parkes, 1866). This was 
the effect of the "s.eeding"hypotheaia of Andrewes 
(Andrewes, 1953) well shown in the United States in 1957 
. 
(Langmuir, 1961) and in numerous lesser outbreaks before 
and since (Forsyth, ~962). 
While it is possible to see a mechanism for pandemic 
spread operating in the phenomenon of antigenic variation, 
it is, as yet, impossible to do more than speculate on the 
significance of the wider epidemiological oscillation shown 
by tuart-Harris (l953 - pp. 95-98). Here the evidence is 
put forward for a period of 50 years, f'rom J.847 to 1889, 
without influenza which has been followed by our present 
cycle of epidemics. We cannot know the cause of this or 
the relation of it to our present observations. 
6 
INFLUENZAL MORBIDITY: 
- ~ • ,.. ,r • r ,r ,. . - . 
In Thompson's "Annals of Influenzatt (1852) various 
authors give their opinions on the age distribution of 
influenza but their accounts are conflicting. ydenham in 
1675 remarked. "No one escaped then, whatever might be his 
age or temperam.enttt. The Royal College of hysicians of 
London, ciuoted before, felt " •••• it was by no means partial 
to any age, sex or temperament. In London, however, it was 
observed to affect a much smaller proportion of children 
than o:f adu.l ts 11. Molyneux, in Dublin, howeve·r, reported of 
' 
the influenza of 1693 that " •••• it rather favoured the very 
. 
old, who seldom were attacked with it"'. 
However, it is only in this century that more detailed 
and reliable evidence of age-specific attack rates have 
become available. The data from the United tates have 
been analyzed by Collins (1944, 1957). Although 
differences may occur in diff erent epidemics an overall 
pattern exists. 
Rising from a high level in infancy the maximum 
incieience occurs in the age group 5-9. From here there is 
a fall to a lower figure lying between the ages of 15 and 
25. This is followed by a slight rise to 30-35 with a 
falling incidence with advancing age (Francis, 1953). The 
most constant features are the low attack rate in old 
people and the high rate in young school-children. In the 
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Asian epidemic of 1957 the rather older school-children 
appeared to be affected more (Langmuir, 1961, Fry, 1957). 
This distribution is probably the resultant of the two 
factors of resistance and exposure and the weight of each 
factor is still controversial. The theories of Francis and 
associates, to be described below, place much weight upon 
resistance, arguing that it is the antibody spectrum of 
older people that accounts for their low influenza attack 
rate. 
However, it could be argued that the high level of 
infection in school-children is, at least in part, 
associated with the increased exposure to which they are 
subjected and that the schools may act as epidemic 
"detonators", so to speak. 
~ 
Thomson and Thomson (1.934) review the opinions 
-
expressed after the 1.91.8-1919 pandemic and these are fairly 
divided, with some feeling that the schools are important 
and that closing the schools is associated with a reduction 
in the epidemic, while others feel that schools are little 
concerned in the spread of influenza - E.O. Jordan (1927), 
in his book, inclines to the latter view. Hope-Simpson, in 
a discussion at the Royal Society of Medicine (1951), felt 
that his study on the 1951 epidemic in Britain showed that 
influenza, unlike measles, is not brought home from school 
to the family. However, when w.s. Jordan (Jordan, Denny, 
8 
Badger, Curtiss, Dingle., Oseasohn, and Stevens, 1958, 
Jordan, 1961) reviewed the mechanisms of spread of Asian 
' 
influenza he noted that in Grea~ Britain, Japan and the 
United States outbreaks occurred primarily among school-
children and then spread to younger children and adults. 
The times of the outbreaks were related to the dates of 
the school terms in a positive manner. The family study in 
Cleveland showed that school-children brought the infection 
into the home in 83% of family episodes. This 
interpretation is supported by Philip, Bell, Davis, Beem 
and Beigelman (1961) who, over five years, carried out a 
community study of influenza. These workers showed that 
"school-age children comprised the most important link in 
the chain of infection between the family and the 
community". This concept is supported by Chin (Chin, 
Mosley, Poland, Rush, Belden and Johnson, 1963) in his 
studies during outbreaks of influenza B. 
It would . seem that the mo t comprehensive and most 
careful studies appear to favour the importance of schools 
as epidemic centres. 
Whereas Davenport and Hennessy (1960) have pointed out 
, 
that an influenza epidemic is not a light matter to 
children, a community is most severely affected by the 
morbidity among the working population with the subsequent 
financial loss. 
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Norwood and Sachs (J..947) stress that respiratory 
. ,. 
infections head the list of m~dical causes for employee 
absenteeism and that epidemics of influenza may quickly 
incapacitat$ so many employees as to make the operation of 
a plant extremely difficult or impossible. In an era of 
increasing productivity fewer people are responsible for 
more output and the effect of an attack rate of 20% is 
extremely serious (Shephard, 1961). McDonald (1963) 
estimated that 50 days of lost time per 100 people per 
annum throughout Western Europe were caused by influenza 
from 1.955-1959. The effect of the Asian epidemic on 
absence from work due to sickness was described as 
"drastic" (Fortuin, Soeters and Van Beek, 1962). Fry 
~ . . 
(1957) calculates that in his practice of 5,500 people, 
4,000 working days were lost in this epidemic. 
The cost of influenza in industry is felt by the 
J 
employer in absenteeism causing loss of production and 
10 
increased costs in overtime rates and by the community in 
loss of wages and in sickness benefits paid out. Roden 
(1963) points out that in September through November, 1957, 
new sickness bene:ti t claims rose to li million above the 
usual level. Less susceptible to calculation is the effect 
of pos.t-influenz.al depression, which Stuart-Harris felt was 
a well recogni ed aequel to influenza (Stuart-Harris, 1961). 
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INFLUENZAL MORTALITY: . 
.. - ..... - - --
It has been mentioned above that the mortality rate of 
influenza is low. However, in view of the high attack rate 
the actual incidence of deaths complicating influenza is by 
no means insignificant. The Public Health Laboratory 
Service of England and Wales estimated that during 
September, October, November, 1957, there were 16,000 excess 
deaths in England and Wales although the case fatality was 
no higher than 1:1000 (Public Health Laboratory Service 
Report, 1958). 
The peaks in the death rates that occur with influenza 
epidemics are well known (Stocks, 1935, Francis, 1953). 
Stuart-Harris has shown (Stuart-Harris, 194 T, . Stuart-
Harris, Franks and Tyrrell, 1950} that whanever the 
certified influenza death rates in the Great Towns of 
England and Wales have been over 100 per week laboratory 
tests· for influenza have been positive. Investigations 
have shown the connection of pneumonia and influenza 
(Stuart-Harris, 1947, Stuart-Harris et al., 1950, Finland, 
Barnes and am.per, 1945) and have supported the contention 
that the influenza-certified deaths do constitute a valid 
index of deaths due to this cause. Indeed, there is 
evidence that ~eaths certified as due to influenza form 
only a proportion of the deaths that are in fact caused or 
precipitated by that di~ease, because the rise in mortality 
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so greatly exceeds the expected seasonal rate (Collins, 
1957, Roden, l963). This points out the risk of epidemic 
influenza to certain groups, :particularly - as Short (17 49) 
would have said 1tsuch as •••• had unsound viscera" . 
.Although Martin (1950) has pointed out that the 
mortality due to influenza in :Britain showed a progressive 
decline from 1919-1949 it remains a potent cause of death 
in the community. McDonald (1963) applying a conservative 
calculation estimates that influenza caused 3% of all 
deaths in estern Europe from 1955-1959. 
However, the age-diatribution of deaths is quite 
unlike that of the attack rate. ith one outstanding 
example the deaths at ributed to influenza are massed at 
the extremities of life. This was noted by observers in 
centuries past - Arbuthnot (1733, cited by Thompson, 1852) 
wrote"···· and everywhere the disease was particularly 
fatal to aged peoplett, and John Huxham of 1743 (1758, cited 
-
by Thompson, 1852) "···· sometimes not a little fatal to 
old men and children who had weak lungs". However, it ia 
much more satisfactorily displayed in the charts of 
Collins (1944, 1957). 
· In the description of Asian influenza in a general 
practice by Fry (1957) the concentration of complications 
in older age groups is clearly shown. 
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Al though unproven, i .t is generally accepted that the 
pandemic of ·1918-1919 was c:aused by an infl.uenza A variant:. 
(Andrewes, 1950, Francis, 1953). In that epidemi~, briefly 
discussed above, the most extraordinary feature was the 
high mortality in the 25-35 year age group during the 
autumn of 1918. This resulted in age-specific mortality 
rates (Collins, 1944) quite unlike those in any other 
influenza epidemic. In some U.S. military camps a case 
mortality rate of 3.3% was noted during the autumn of 1918 
(Ireland, 1928). 
' 
The world-wide death roll of this epidemic has been 
estimated at between 15 and 20 millions - thua · conaidjrably 
improving upon. the ingenuity of man from 1914-1918 - and 
the epidemic of this normally ttmildtt disease entered 
history along with the Black Death and the Plague of 
Justinian. 
Prevention of Influenza: 
Thus, the disease once called the ngen tle correction tt 
is shown to be a potent cause of death to the old and the 
young, a plague to the achool-child, a financial blow to 
the industrialiat., a burden to the medical officer of 
heal th, a gene.ral spend thrift of life, time and money and 
to many in their sixth decade it may be a dreadful memory. 
In these circumstances it is right t o seek rational 
methods of prevention. 
1/· Sanitation 
Inf1uenza, like many other viral diseases dependent 
upon the proximity of person to person, has not been much 
affected by the removal of sewage from that proximity . .. 
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Measures of air sterilization (Stokes and Henle, 1942) 
have not been al together successful. in practic·e. 
2./ Quarantine 
·The universal nature of the disease makes quarantine 
normally out of the question, particularly as spread can be 
caused by the apparently healthy as seen in the Ocean 
Island inciaent (Isaacs, Edney, Donnelly and Ingram, 1950). 
However, the fact that the spread of influenza is from 
person to person does mean ~hat total severance of outsi~e 
connections can protect. This was shown in several 
aanatoria and inst.i tut es and even remote towns in the 
United tates and Britain during 1918 (Jordan, 1927), where 
freedom from infection continued while vigorous isolation 
was practised. Australia operated elaborate maritime 
quarant ine from October, 1918, to May, 1919, and escaped 
the extreme virulence of the epidemics which raged in outh 
Africa and New Zealand during October to December. When 
influenza occurred in January to June, 1919, it carried a 
lesser mortality. A similar picture was seen in Israel 
during the Asian influenza epidemic when the infection did 
not cross from the neighbouring Arab countries, cut of:t by 
the political situation, but was finally introduced from 
America later. S:outh Africa maintained a maritime , 
quarantine but the epidemic spread overland after a short 
delay (P~ne, 1961). 
~ 
Whereas isolation of the necessary degree is 
impossible for many countries and possible only for a short 
while for others, in some cases quarantine could delay the 
introduction of infection and enable other preventive 
measures to be organis.ed. 
3/ ahemotherapy 
During the last few years a number of agents active 
against viruses in vivo have been produced. These also 
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have their disadvantages in that viruses have rapidly 
become resistant to some (Melnick, Crowther and :Barrera-Oro, 
1961, Loddo, Schivo and Ferrari, 1963, Smith, 1963) and, 
presumably, prevention of infection would entail taking 
regular doses. However, these agents will undoubtedly be 
developed successfully. 
Recently a promising ant.i-influenzal agent has been 
announced (Newsweek, April 27th, 1964, p. 35) and while the 
development of this and similar agents is still at an early 
stage a new era of influenza prevention m~ be at hand. 
4/ Vaccination 
In those virus infectio,ns of man where methods of 
quarantine and of breaking th.e chain of transmission have 
failed, vaccination has been the most effective manne·r of 
protecting individuals and communities. The success of 
poliomyelitis vaccines, in particuJ.ar, has stimulated 




The discovery of the influenzal agent 
The development of influenza vaccines had, 
necessarily, ~o ait upon the iso~ation, identification 
and cultivation of the agent responsible. The 
' "renaissance" of influenza int at late 19th century 
-
stimulated enquiry and Pfeiffer (1893) described a small 
17 
cocco-bacillus, later to be called Haemophilus influenzae, 
as the cause of influenza. However, as early as 1900 
Rosenthal (quoted by Thomson and Thomson, 1933) was of the 
opinion that Pfeiffer's bacillus was only a secondary 
invader. During the great pandemic of 1918-19 H. influenzae 
was only one of the organisms to be isolated from the sputum 
and lungs of cases and most vaccination attempts using 
various organisms including H. influenzae yielded highly 
equivocal results (Ireland, 1928). From their study of the 
pathology of fatal cases Winternitz (Winternitz, Wason and 
McNamara, 1920) and Goodpasture and Burnett (1919) stressed 
the "toxic" effect of the "true etiological agent". The 
latter authors quoted Leichtensten's (1899, cited by 
. 
Goodpasture and Burnett, 1919) opinion that there was a 
primary influenzal ~neumonia produced by the poison of 
influenza. The opinion of- these pathologists was that the 
18 
' . 
bacteria were secondary invaders. 
Numerous attempts at isolating infective agents were 
made during the pandemic. One of the most interesting 
concerned the isolation by Olitsky and Gates (1921 a&b) of 
Bacterium pneumosintes. 
As late as 1933 Thomson and Thomson (1933) reviewing 
the immense literature concerning various organisms 
proposed as the aetiological agent were unable to express 
any more than vague opinions. 
Although the virus of swine influenza in the United 
tates was isolated by Shope (1931) in pigs, it was not 
until 1933 when Smith, Andrewes and Laidlaw (1933) ,followed 
-
by Francis (1934), isolated influenza in ferrets by intra-
f nasal i culation, that any fundamental knowledge 
concerning influenza in man could be acquired. 
Since that time studies en influenza viruses over 
three decades have shown that the impo.rtant agents of 
influenza can be divided into two fundamentally different 
types, A and B. Within each type antigenic variations have 
been shown to occur. These variants can be grouped into 
"families" on the basis of close relation. These families 
' 
are more sharply distinguished in Type A virus and have 
been named A, Al (previously A-prime) and A2 (Asian). 
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Immunity to Influenza 
It was shown that convalescent ferr.e:ts were initially 
refractory to repeated infection but after some six months 
could be re-infected with the same strain. However, the 
disease tended to be milder and, in the case of inoculation 
under anaesthetic the convalescent animals were protected 
from lung involvement (Smith et al., 1933, Smith, Andrewes 
and Laidlaw, 1935). It was also shown that the convalescent 
ferret possessed a high titre of virus neutralizing anti-
bodies (Smith et al., 1933). 
The adaptation of influenza virus to mice by the intra-
nasal route (Andrewes, Laidlaw and Smith, 1934) made 
possible the development of a practicable neutralization 
test (Andrewes et al., 1934, Laidlaw, Smith, Andrewes and 
-
Dunkin, 1935) for the identification and assay of antibody 
and of infective virus. Mice could .also be passively 
protected by the administration of neutralizing antibody. 
Surveys in human populations showed that neutralizing 
antibodies (Smith et al., 1913) to influenza virus were 
- - . 
widespread (Andrewes, Laidlaw and Smith, 1.935) and that 
there was a definite age distribution in that antibodies 
were rare in young children, then increased in frequency 
until the mid-thirties, and then declined towards old age. 
Infants up to six months of age possessed the antibody 
levels of their mothers ('.Francis and Magill., 1936). 
It was shown that antibodies could be elicited in 
ferrets, mice, horses (Laidlaw et al., 1935) and rabbits 
. . 
(Francis and Magill, 1935 b) by parenteral inoculations 
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with virus containing material either derived f rom infected 
mouse-lung or from a Maitland type tissue culture (Francis 
and Magill, 1935 a) without the animals developing clinical 
disease. It was also possible to use virus inactivated by 
formalin but not by heat or by methylene blue (Smith et al., 
1935). Opinions differed about the eff icacy of form.alinized 
,• 
virus (Smith et al., 1935, A,.~drewes and Smith , 1937, Francis 
-
and Magill, 1936) and this led to rather different approaches 
to the task of producing antibodi sin man. 
THB EVOLUTION OF I NFLUENZA VACCD{oS 
American orkers felt that only a vaccine composed of 
active virus would suffice and while Francis and Mag1.ll 
(1936) used the super natant flui d of an infected Ma.i tland 
type of tissue culture as a source of V":i:rus - believing 
that this would be less likely to contain contaminants -
Chenoweth, \val tz, Stokes and. Gladen (1936) employed a 
' 
filtrate of' infected mouse lung. Francis and Magill 
inoculated 23 adult vo.lunte,ers with mul ti:ple doses of t heir 
preparation. I n Chenoweth's experiment a large number of 
children at a state institution were the subjects. 
However, the ~ritish workers (Stuart-Harris, Andrewes 
and Smith, 1938), mindful of Shope's experience when live 
f 
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swine influenza vaccine had spread from vaccinated swine 
and caused clinical disease in the rest of the herd 
(Shope, 1936), used a formalized vaccine prepared from 
mouse lungs. Special precautions were taken to avoid 
contamination with the virus of lymphocY:ti.c ch~omeningitis. X 
The step of adapting influenza virus to grow in 
embryonated eggs was inspired by the success of Goodpasture 
and Woodruff (Goodpasture, Woodruff and Buddingh, 1931, 
Woodruff and Goodpasture, 1931) with fowl-pox. Burnet was 
able to grow influenza strains first on the chorio-
allantoic membrane (Burnet, 1936) then in the amniotic 
cavity (Burnet, 1940 ~. and b, 1941 a.). This was to 
provide a much more simple method of isolating virus 
(Hirst, 1942 c, Burnet and Stone, 1945). . Apparently,- the 
. 
work of Scott (1938) with swine influenza virus had been 
-
n-gored because it was only in 1941, when Nigg (Nigg, 
Wilson and Crowley, 1941) and Henle and Chambers (1941) 
were followed by Burnet (1941 b), that the potentialities 
~ 
of using the high titres of virus obtained in the allantoic 
fluid for vaccine production were appreciated. 
The employment of chick embryos for growing the virus 
led to the discovery of its haemagglutinating properties 
(Hirst, 1941, 1942 a and b, McClelland and Hare, 1941) 
which provided a convenient method for the assay of virus 
and of antibody. 
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At this stage a curious development in influenza 
vaccines took place. Horsfall and his associates 
accidentally noticed that influenza virus grew to higher 
titres in the tissues of a ferret simultaneously infected 
with a certain strain of canine distemper (Horsfall and 
Lennette, 1940). The observation formed the basis for the 
production of a "complex vaccine" consisting of formalized 
- -
allantoic fluid from embryos infected simultaneously with 
influenza and the specific distemper strain. Trials were 
carried out on animals and on progressively larger numbers 
of humans. Although the initial reports on this unusual 
mixture were favourable (Horsfall, Lennette and Rickard, 
1941, Horsfall, Lennette, Rickard and Hirst, 1941) later 
experience (Martin and Eaton, 1941, Hirst, Rickard, 
Whitman and Horsfall, 1942) did not encourage further 
development of this idea. 
Concentrated Vaccines: 
It had previously been shown that, within limits, the 
antigenic efficacy of an influenza vaccine was directly 
related to the amount of virus in the dose (Francis, 1939, 
Hirst et al., 1942). Therefore the use of methods of 
concentrating virus to achieve better responses was 
inaicated. As knowledge of the properties of influenza 
virus increased so did the possible methods of 
concentration and purification. 
One of the first to be attempted used the fa.ct that 
~ow, cold thawing of froz en infected allantoic fluids 
released a precipitate containing the greater part of the 
virus (Hare, McClelland and Morgan , 1942, Hirst, Rickard 
and Whitman, 1942). This was developed sufficiently to 
produce vaccines ~>n a small scale (Hare, I\forgan , Jackson 
and Stamatis, 1943) but on a larger scale difficulties 
2 3 
wi th bacterial contamination limited its use (Francis, 1945). 
Francis and Salk (1942) showed that the 
haemagglutination reaction mentioned above could be adapted 
for concentration by utilizing the property of the virus, 
previously absorbed on erythrocytes, to elute after 
incubation into a smaller volume if re~uired. This red 
cell elution method was used for the preparation of 
vaccines on a large scale for the U.S. Armed Forces 
Epidemiological Board in the trials from 1942-1944 and was 
only gradually supplanted. 
Other methods for the precipitation or absorption of 
virus that have been described and used to a greater or 
lesser extent include protamine (Chambers and Henle, 1941), 
calcium sulphate (Salk, 1941, 1945, Stanley, 1945a), alum 
(Bodily, Corey and Eaton, 1943) calcium sulphate (Tovarnizky 
anG.-Chalkina, 1944), alcohol (Cox, van der Scheer, Aiston 
and Bohnel , 1947), aluminium phosphate (Himmelweit, 1960) 
and barium sulphate (Dresche~, Hennessy and Davenport, 
1962, Mizutani, 1963). 
At an early stage it was shown that high speed 
centrifugation brought down the influenza virus particle 
associated with infectivity ana haemagglutination (.Elford 
and Andrewes, 1936, Henle and Wiener, 1944). Adaptation 
of the Sharples centrifuge to handle infected allantoic 
fluid yielded a me,thod capable of producing concentrated 
and purified virus on a large scale (Stanley, 1944, 1945 
and Taylor, harp, McLean, Beard and Beard, 1945). 
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The use of these techniques combined with the 
knowledge of how to achieve optimal titres of virus in 
eggs (Beveridge, 1944 a, McLean, Beard, Taylor, Sharp, 
Beard, Felter and Dingle, 1944, Miller, 1944, igurdsson, 
1944) unaerlie the modern success in producing vaccines on 
a commercial scale. 
djuvan ~ Vaccines: 
The use of simple, inactivated influenza virus in a 
saline or aqueo,us base is subject to distinct limitation . 
ome of t hese are the toxicity of the virus particles, the 
cost of producing antigens and the relatively transient 
nature of the serum antibody elevation. Besides, in time 
of emergency the amount of antigen that can be prepared ia 
small and the need may be large. Therefore, it was 
logical to try and explore methods of potentiating the 
action of the antigen. 
:sy · far the most promising method involved the use of 
mineral-oil emulsions. Freund (Freund and McDermott, 
i942, Freund and Bonato, 1944, Freund and Walter, 1944) 
indicated that by forming a water-in-oil emulsion with 
mineral oils, kiJ.led ;r.trcobacteria and an emulsifying age_nt 
and the antigen in the aqueous phase the antibody response 
could be enormously enhanced. Friedewald (1944) showed 
that this ap~lied to influenza antigen as well and Henle 
and Henle (1945) excluded the Mycobacteria from the 
adju~ant and found, in human volunteers, that the same 
applied. Salk improved upon the procedure and the 
ingredients and applied the principle for the immunizatio~ 
of animals and then man (Salk, Lewis, Youngner and Bennett, 
1951, Salk and Laurent, 952). 
~ 
Oil.y adjuvant vaccines have now been officially 
licensed in the United Kingdom for general use. 
THE ~FFICACY OF INFLUENZA VIRU VACCINES 
The purpose of a vaccine is to protect the recipient 
against the disease. In this, the various parameters to 
be considered are the protection ratio, the duration of 
protection and the lag, between administration of the 
vaccine and the onset of protection. These are all most 
convincingly teated when the vaccinated population, 
~ogether with suitable controls, is exposed to the natural 
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disease. However, with influenza, the epidemic nature of 
the di ease, the difficulty of certain diagnosis, the 
variation in attack rate and the phenomenon of antigenic 
variation all tend to aggravate the difficulties of 
arranging a well-controlled trial and making the success of 
it unauly dependent upon chance. 
Therefore vaccines are frequently most conveniently 
judged by their antigenicity or their ability to elicit an 
increase in specific antibody titre which can be readily 
measured. The relation between serum antibody titre and 
immunity varies from one disease to another. In the case 
of influenza this is clearly not absolute. The aome.wha,t 
heroic experiments of Smorodintseff, Tuahin ky, 
Drobyshevskaya, Korovin and Osetroff (1937) indicated that 
while antibody titre was an indication of resistance the 
possession of antibody by no means signified immunity. 
Rvidence from the 1918-1919 pandemic (Ireland, 1928, 
Jordan, 1927) and from later comm.unity studies (Pickles, 
Burnet and McArthur, 1947, Jordan, Badger and Dingle (1958) 
show some degree of immunity to be conveyed by natural 
infection but that this seems to be transient. So much 
information about the relation between antibody titre and 
immunity has been obtained from vaccine trials that the 
efficacy of vaccines will be described from both aspects 
together and the subject discussed later. 
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Early Vaccine.a 
The subjects in .the pioneering trial of Francis and 
Magill (1935-6 ) had been selected for their low level of 
neutralizing antibody and responded to multiple inoculations 
of active virus derived from tissue culture supernatant by 
an increase in antibody titre. In a fu.rther similar trial 
(Francis and Magill, 1937) pre-inoculation aera were 
compared with samples taken at in-cervals after the last 
inoculation. Here the level of antibody was aignifieantly 
raised at the time the first sample was taken, remained 
constant for two months and then declined. 
Meanwhile, Chenoweth, Stokes and associates (Chenoweth 
et al., 1936, Stokes, Chenoweth, Waltz, Gladen and Shaw, 
· 1937, and Stokes, McGuiness, Langner and -Shaw, 1937) had 
been conducting trials in an institution with groups of 
controls and others inoculated with three doses of either 
A/.PR-8 or A/Swine virus. Only with t~e former virus was a 
rise in antibody detected and this in only 31~ of those 
vaccinated. However, an outbreak of respiratory disease 
involved 25% of the institution during the winter and, 
considering febrile cases, ~ttack rates were:-
aontrols (550) 
A/Swine vaccine (138) 
. ' 
PR-8 tt (110) 
-
12.4% 
ubsequent serological tests showed the outbreak to 
have been caused by influenza. 
In Britain, Stuart-Harris et al. (1938), using their 
formaJ.i~ed mouse lung vaccine, found that the antibody 
response was of the same order as that with natural 
infection and that a second inoculation did not lead to 
higher titres. How:ever, their attempt to gauge the 
protection afforded with a trial in 1936-1937 yielded 
quite inconclusive results partly because the influenza 
occurred before vaccination was complete and partly because 
of antigenic variation. It was clear that absolute 
protection was lacking. Using the same vaccine in Hungary, 
Taylor and Dreguss (1940) produced a similar result. Two 
years after the first attempt a second trial also failed to 
show protective value ( tuart-Harris, mi~h and Andrewes, 
l.940). 
iegel and others. (Siegel and Muckenfuss, 1940, 1941, 
Siegel, Muckenfuss, Schaeffer, Wilcox and Lieder, 1942 a) 
embarked upon a long, complex trial in a large institution. 
Initially, two influenza vaccines were used and some of the 
vaccinated group were re-vaccinated annually. Appropriate 
serum samples were taken so as to establish the antibody 
response to the vaccines and to natural infections over a 
protracted period . Both of the vaccines, despite marked 
individual variations of the recipients, produced a three-
fold increa.ae in antibody but complement-fixing (G.F.) 
ti res returned to the in~tial ~evel in 2 months. lhis 
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pat~ern was repeated in f9~lowing years . ~wo inf~uenza 
epidemics occurred during the period of study. One of 
these took place af~er tne subjects had been vaccinated. 
t this time the antibody levels of the community had 
declined from their post-vaccination peak anu tne effect 
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of the epidemic was to return antibody levels to that peak 
before they started to decline again. The vaccines showed 
no protective effect. In a con~inuation of tneir programm~ 
this group tested the "complex vaccine" of Horsfall (Siegel 
et al., 1942 b). In agreement 'With Dalldorf, Whitney and 
Ruskin (1941), they found no protection indicated by their 
results. As previously mentioned the experiments of Hirst 
(Hirst et al., 1942 b) showed that the addition of 
distemper virus had no effect. 
Concentrate~ Influenza Vaccines 
Concentrated formalin-inactivated vaccine prepared by 
the precipitation of virus from frozen allantoic fluid was 
tested by Hirst (Hirst et al., 1942 a) and by Hare and his 
- p 
associates (Hare et al., 1943). Both groups showed the 
superiority of the concentrated vaccine in eliciting anti-
body and the latter confirmed the results of Stuart-Harris 
et al. (1938) by showing that no better response was 
achieved by multiple doses of vaccine. A trial to test 
the protection afforded by this vaccine by Hare, tamati 
and Jackson (1943) was nullified in the absence of a claar-
cut influenza epidemic. 
Thus, by the early 1940's, it had been established 
that vaccines of various types caused a rise in serum 
antibodies whether measured by neutralization tests in 
mice (Francis and Magill, l937, Stokes et al., l937) 
on the chorio-allantoic membrane of chick embryos (Bu~net, 
Keogil and Lush, 1937), in the amniotic cavity (Bu,rnet, 
1941 a), or allantoic cavity (Hirst, 1942). Haemagglutin-
ation - inhibition (H.I.) tests were also satisfactory 
~ 
(Bodily and Eaton, 1942) but there was some evidence that 
C.F. tests were less satisfactory ( aton and Rickard, 
> 
1941). The antibody response to vaccination was similar 
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to that resulting from natural infection (Rickard, Lennette 
and Horsfall, 1940, Horsfall and Rickard, 1941). 
On several occasions it had been noticed that the 
antibody response to vaccination was greatest in those 
with the lowest initial antibody level (Eaton and Martin, 
1942, Horsfall et al., 1941 a and b) and the latter author 
found the diagnosis of influenza in those with high initial 
titres difficult because of the lack of further antibody 
response. 
It had also been shown that cases of influenza tended 
to occur in those with low titres of antibody (Burnet and , 
Foley, 1940, Rickard, Horsfall, Hirst and Lennette, 1941), 
but antibody level ~alone did not appear to be an absolute 







1937, Horsfall et al., 1941b) and therefore, the concept 
of a critic al level (Francis, Magill, Rickard and Beck, 
1937) was not wholly acceptable . 
Challenge Experiments 
In order to test the protective value of vaccines 
under controlled conditions a number of experiments were 
devised in which vaccinated individuals inhaled live 
influenza virus and their responses to this were compared 
with unvaccinated controls. 
Stokes and the Henle ' s (Stokes and Henle, 1942, 
Henle, Henle and Stokes, 1943) conducted experiments on 
children vaccinated by various schedules and challenged 
either 2 or 4 months later with an inhalation of about 1.8 
million mouse L D 50· 10 of 28 control and 1 of 44 
vaccinated children had clinical influenza, and 
haemagglutination-inhibition (H.I.) tests showed 10 of the 
11 cases occurred in the children who had antibody titres 
of less than 1:256 before challenge. 
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Francis, Salk and associates carried out rather similar 
trials on adults . Difficulty was encountered in standard-
izing the challenge dose. An expe riment where unvaccinated 
individuals were challenged 4 months after an initial 
exposure showed rather little ·residual i mmunity. After 
vaccination with concentrated virus vaccines the experiments 
seemed to show that immunity to influenza B was intact 4i 
months after vaccination but immunity to influenza A was 
waning. Al groups that had been vaccinated showed rather 
less severe disease but because the febrile response was 
universal the observations were rather difficult to 
interpret (Francis, Salk, Pearson and Brown, 1944, 1945, 
Salk, Pearson, Brown and Francis, 1944 b, 1945 b). 
Major Vaccine Trials in United States Forces 
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In the light of the experience accumulated the United 
States Armed Forces Epidemiological Board embarked upon 
major trials of influenza vaccine. The absence of an 
influenza epidemic in 1942-1943 made the first trials 
futile. However, the following year, using the resources 
created by war-time mobilization,many thousands of service-
men at universities in different parts of the United States 
participated in a controlled trial of · an inactivated vaccine 
containing A/FR 8, A/Weiss (Salk, Menke and Francis, 1944 a) 
and B/Lee (Francis, 1940 b) strains. The vaccine was 
, 
prepared from infected allantoic fluid and concentrated by 
red-cell absorption and elution (Commission on Influenza 
1944, Francis, 1945). 
" 
Epidemic influenza A, preceded by herald cases the 
previous spring (Salk et al. , 1944 a.), was widespread in the 
United tates from November, 1943 to January, 1944. Although 
the clinical disease was mild, the attack rate, particularly 
in the younger and older age groups, was high (Collins, 1944) 
and, thus, ideal conditions existed for the vaccine trial. 
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The -protective vaJ.ue of the vaccine was clearly 
demonstrated at most of the localities and by most groups 
of workers (Hale and McKee, 1945 b, Hirst, lummer and 
Friedewald, 1945, Ma.gill, Plummer, millie ana Sugg, 1945, 
Rickard, Thigpen and Cro~ley, 1945, 'alk, Menke an~ Francis, 
1945 b). Overall, the ~ttack rate was 7.11% in the 
controls and 2.22% in those vaccinated. More than 11,000 
men took part in the trial (Commission on Influenza, 1944). 
At two centres the epidemics started during the course 
of vaccination and it appeared that protection was afforded 
in. about a week after inoculation (Hale and McKee, 1945 b, 
Hirst et al., 1945). Antibody was shown to persist at high 
-
levels for at least three months ( alk et al., 1945 a, 
Magill et al., 1945). Hirst's group argued that immunity 
waned eight weeks after vaccination a.s. the difference in 
attack rate between the control and vaccinated group 
diminished. However, Salk pointed out tha.t this could be 
due to sub-clinical infection and the exhaustion of the 
susceptiblea among the controls. In California, however, 
no protection by the vaccine was demonstrated. This result, 
it was suggested, could be attributed to either the lapse 
of six weeks between vaccination and the epidemic or to the 
fact that s.tra.ins of virus isolated during the epidemic. 
we.re clearly dis.tinguishable from PR-8 or Weiss atraina 
antigenicall.y (Eaton and Meiklejohn, 1945). 
... 
34 
The relation of antibody to susceptibility during 
these studies was examined by Salk and by Hirst. In alk's 
group of cases 82% o.f clinical disease occurred in the 48% 
of the population with an antibody titre of l in 64 or less. 
It appeared that antibody titres produced by the vaccine 
were similar to those induced by infection. However, Hirst 
noted the occurrence of 38 cases who had mean acute phase 
titres of l in 558. 
In addition, the 1943-1944 epidemic afforded some 
evidence on the duration of the vaccine's effect because 
groups inoculated for the previous winter were followed up. 
The vaccine then lacked the Weiss strain isolated in 1943. 
Hirst (Hirst, Rickard and Friedewald, 1944) studied a 
prison population and found that H.I. antibodies to PR-8 
rose by 2 weeks after inoculation to 6 times the initial 
titre. In 11-14 months the levels were at 3 times the 
original titre. However, the protection ratio was only 35%. 
Salk (Salk, Pearson, Brown, Smyth and Francis, 1945 c) 
-
demonstrated the maintenance of vaccine-derived antibody by 
showing that the percentage of subjects with titres of 1:256 









During the course of the year the composition of his 
test population altered -to make a reliable estimate of 
,. 
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attack rates difficult. 
The data was as follows (Salk and Francis, 1946):-
No. wards Total Attack Rates 
population Overall Maximum 




vaccinated 20 1916 6.5% (In 16/20 
wards, 
Rate 4-4%) 
The authors felt that this suggested that the 
presence of individuals vaccinated a year previously had 
reduced the intensity of the epidemic and thus afforded a 
measure of protection to the whole community, vaccinated 
and unvaccinated alike. 
It is apparent that differences of opinion occurred. 
From the available evidence Hirst. felt that it was 
essential to vaccinate in the face of an epidemic because 
of the rapidly waning immunity. , alk appeared to believe 
that immunity declined more gradually, parallel with the 
antibody titre. 
In brief, this first major trial showed that 
influenza vaccine could produce very substantial but by no 
means absolute protection with a single inoculation. It 
confirmed that the titre of circulating antibody and 
imm.uni ty were, in the main, related. The length of time 
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needed for vaccination to etake effect was demonstrated. but 
no definite answer was provided concea:ning the duration of 
the immunity conferred. 
Influenza B, 1945-46. 
The end of the world war in 1945 was accompanied by a 
fear that the chaos :prevalent might somehow tend to favour 
the occurrence of a lethal influenza pandemic. It we.a 
noted that the lapse of time between 1890 to 1918 was not 
dissimilar to that from 1918 to 1945 ana. an intensive 
influenza surveillance scheme was commenced in Britain and 
elsewhere. 
However, the epidemic. that arrived was of influenza B, 
spreading from the ast and causing epiaemics in the 
Pacific, Australia, Alaska and the Caribbean (Burnet, 
. ' 
Stone and Anderson, 1946, Jackson, 1946) between Mar.ch 
, 
and November, 1945. harp epidemics occurred in the United 
tates in November and December and in Britain from 
December, 1945, to March, 1946. Although strains of virus 
isolated were only partly related to the Lee strain used 
British and American workers were able to ina.icate that the 
stana.ard vaccine had provided substantial protection. 
Hirst, Vilchers, Rogers and Robbins (1947) comp_ared 
the attack rates occurring in two groups at Yale 
University. Francis (Francis, alk and -Brace, 1946) 




Yale 12.5% 0.5% 
Michigan 9-9% l.15% 
-
Dudgeon, in Britain (Dudgeon, Stuart-Harris, Andrewes, 
. . 
u-lover and Bradley, 1946) was. able to compare attack rates 
in Glasgow and at Woolwich although vaccination was not 







Influenza A, 1946-1947. 
Vaccinated 
tudies of t he periodi ci t y of inf luenza (Commis sion on 
Acute Respiratory Diseases, 1946) had led to the 
. ~ 
expectation of influenz~ A·in 1 946-7. As a result trials 
involving tens of thousands of subjects on both sides of 
the Atlantic served to illuminate the limitations of the 
current vaccine the more sharply. 
The epidemic spread from the East once more with out-
breaks in Australia, Japan and Korea in 1946. The United 
tates was i nvaded in J anuary , 1947 , and many mili t ary 
establi shments had outbreaks during the next two months. 
There was no evidence t hat t he cur r ent infl uenza vaccine 
had been effective (Sartwell .and Long, .1948). i/hen i;he 
-
civi.Lian popu.1.ation was affected , further reports of the 
failure of the vaccines occurred (FowLe and eigh~man, 
1947, Francis, Salk and uilligan, l947, Loosli, 
·choenberger ana Barnett , 1948, Sige.L , 'chaffer, Kirber, 
Light, ana Henle , 1948). 
In the Unit~a Kingdom monavelent virus vaccines 
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containing either PR-8 or Mel (Burnet , 19}5) had been used. 
20,000 people had been inoculated. The attack rate was so 
low as. to render much of the work useless but outbreaks at 
achools and army camps showed the vaccine to be virtually 
ineffective (Mellanby, Dudgeon, Andrewes and Mac!C8Y', 1948). 
trains of the. epidemic virus isolated in the United 
tates, e.g. F.M_1 (Rasmussen, Stokes and madel, 1948) and 
the C ~ strain isolated in ustralia in 1946 were foun to 
be similar and these were markedly different from the 
older strains PR-8 , Weiss, etc. Although infection with 
the new strains was shown to cause an anamnestic rise in 
ani;iboaies to the PR- 8 strain (Stuart-Harris, Laird, 
Tyrrell, Kelsall, Franks and Pownall, 1949) the degree of 
antigenic relation was insufficient for the older vaccines 
either to elicit antibody to, or protect mice from, the 
new variants. 
Although during this epidemic the attack rates were 
relatively low and the clinical disease generally mild the 
degree of antigenic variation that had occurred was a 
highly significant discovery. Previously, although minor 
antigenic variation had been shown to take place both in 
Type A (Magiil and Francis, 1936, Burnet, 1937, Magill and 
-
Francis, 1938, Francis and Magill, 1938, Stuart-Harris~ 
al., 1938, Taylor and Dreguss, 1940) and Type E (Eaton and 
Eeck, 1941, Gordon, 1942) the overall success of the trials 
in 1943 and 1945 had led to this being-discounted as a 
factor in vaccine production. It had been thought that it 
was only necessary to select a highly antigenic and 
"intermediate" strain of each type ( mith and Andrewes, 
-
1938). 
Vaccines against Ai Strains 
3 9 
When the new strains were incorporated into vaccines 
it was noticed that they were not necessarily as efficient 
antigenically as the older PR-8 (Salk, Laurent and McGinnis, 
1949) .and that vaccination against a completely new variant 
presented difficulties (Meiklejohn and Bruyn, 1949, Appelby, 
Himmelweit and Stuart-Harris, l951). However, a series of 
trials were prepared to examine the efficacy of the new 
vaccines. 
In 1947-8 the work of Salk and Suriano (1949) seemed 
to show, in rather unfavourable conditions, that, unlike 
the old vaccine, a vaccine containing A/FM1 gave protection. 
Using monovalent vaccines containing PR-8 or :EM1 
Meiklejohn, Weiss, Shragg and Lennette (1952 b) . further 
studied the relation between the old and new families of A 
virus. The following winter the same group showed that an 
F.M, vaccine conferred protection in contrast to a PR-8 
vaccine and to controls. The tendency for clinical cases 
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to occur in those with low titres of H.I. antibody was 
confirmed (Meiklejohn, Kempe, Thalman and Lennette, 1952 b). 
At this time the Medical Research Council, in Britain, 
set up a Medical Research Council Committee on Clinical 
Trials of Influenza Vaccine (M.R.C. 1953) to study the use 
of inf luenza vaccines. A series of field trials were 
organised in which varying preparations of vaccine were 
investigated. An outstanding feature of these trials was 
that large numbers of volunteers were used in many parts 
of the country and from varied walks of life. Attack 
rates tended to be low but it was shown that vaccines 
containing A1. strains conferred protection against the 
homologous virus (M.R •• l953, 1957). Hawkins, Hatch and 
McDonald (195 6 ), however, showed much more dramatic 
results in a school epidemic. Attack rates were as 
follows:-
Groups Numbers Attack rates 
Uninoculated 344 20% 
Vaccinated in 1954 120 12% 
. 
tt " 1955 100 8% 
tt " 1954 and 1955 100 2% 
It appeared here that some degree of protection was 
provided by vaccination a year previously. 
Asian Influenza 
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Therefore, when reports from ingapore, Japan and 
Taiwan in 1957 gave warning of epidemic influenza A virus 
of a grossly different antigenic character (M~er, Hilleman, 
Miesse, Crawford and Bankhead, 1957, Jensen, 1957 a) much 
knowledge concerning vaccine manufacture was available and 
great efforts were made to produce suitable vaccine. 
The rapidity of spread, combined with the delayed 
reporting of the new variant (Payne, 19 1) made it very 
difficult to arrange large scale trials. However, an 
experimen~ in which vaccinated volunteers in the United 
States were challenged with live virus from human sources 
showed that protection or modification of the disease 
occurred (Bell, Ward, Kapikian, Shelokov, Reichelderfer 
and Huebner, 1957). 
It was possible as a result of chance or del.iberate 
trial to examine the effect ·of vaccines containing older A 
strains (A/Swine, A, and A,l) and compare this with the 
. ~ 
result of the somewhat hastily prepared Asian (A 2 ) type 
vaccines. ome differences of opinion occurred. Whereas 
A 2. vaccines showed a protection effect in all cases 
Gundelfinger, Stille and :Bell (1958) felt that the older 
type also exerted some slight effect. However, in a 
troopship outbreak (Schreiber, 1957) no benefit was 
conferred by the older vaccine and British studies in 
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schools (M. R. C. 195 8) confirmed this. Like _G·undelfinger et al 
-
(1948) Culver (Culver, Nitz and Lennette, 1957) showed 
that monovalent A 2 type vaccine became effective 10 d8i9"S 
after inoculation. 
Culver also demonstrated, in the same trial, that as 
with the early Al vaccines, serological response to 
vaccination was poor. In an investigati~n after the 
autumn epidemi~ of · Asian influenza it was s~own (Holland, 
Isaacs, Clarke and Heath, 1958) that the antibody response 
of volunteers to vaccine was conditioned by their previous 
experience with the antigen. Peopl~ who had no pre-
inoculation antibody responded poorly to the firs.t 
inoculation. Those who had antibody before the first 
injection produced higher titres of antibody but did not 
show a further response to a second inoculation. De:spi te 
this poor antibody response to a single inoculation 
protection was shown to be conferred by this (M.R.v. 1958). -
In addition to the lack of time the poor titres of 
virus that were ili:i tially found. in the allantoic cavity of 
infected· eggs ,resulted. in a ,shortage of vaccine. As a 
result attempts were made to "stretch" the vaccine by 
using smalle r doses intra.de-rm.ally Love, 1957, Sigel, 
.Edwards, chl.aepfer, Wellinga and Beasley, 1957 , anger, 
1959). This 4ad been originally suggested by Van Gelder, 
- ' 
Greenspan and Dufresne (194 7, cited by anger, 1959) and 
discounted (Bruyn, Meiklejohn and Brainerd, 1949, Appel.by 
et al., 1951). While at this time of. need the technique 
4 3 
of intradermal ino·cula.ti,on regained adherents and rather 
confusing results. were published Boger and Liu (1957) 
showed that .l ml. of vaccine administered intradermally 
gave a rather poor serological responae. Mccarroll and 
Kilbourne (1958) studied this problem carefully and showed 
that intra.dermal inoculation possessed no distinct 
advantage over the subcutaneous route and that the antibody 
response was related to the mass of antigen administered. 
' However, in the case of the new antigen more than one 
inoculation was needed to produce an adequate antibody 
response. 
Adjuvant Vaccinea 
xperiments. with influenza vaccines made up in the 
form of water-in-oil emulsions have been in progreas for 
the last 20 years. From the firs.,t animal experiments. by 
. ·, 
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Friedewald (1944) it has been repeatedly demonstrated that 
r 
vaccines in this form have achieved much higher titres 
than those in a conventional aqueous bas·e (Henle and Henle, 
1945, alk, Bailey and Laurent, 1952, Himmelweit, 1960), 
that a much smaller antigenic mass will achieve a 
satisfactory response (Salk, Contakos, Laurent, Sorenson, 
Rapalsk, Simmons and aandberg~ 1953, Davenport, Hennessy 
and Bell, ·1962) and that antibody levels are better 
maintained ( alk et al., 1953, M.R.C., 1957, Davenport~ 
al., l.9o2). Vlhereas Salk (Salk et al., 1.953) felt that 
with vaccines "adjuvanted" thus, the antibody response was 
-- ...... 
ttbroader", Davenport (Davenport and Hennessy, 1957, 
Davenport et al., 1962) showed that this was only true 
within a "family" of viruses. 
However, there is not a great deal .of evidence 
concerning the protective value of these vaccines. Philip 
et al., (1957) seemed to show that definite protection 
against infLuenza B was afforded 13 weeks after an adjuvant 
vaccine, but against influenza A, 60 weeks after vaccination, 
the value of the vaccine, while present, was less evident. 
' Davenport's trial in 1954-1955 (Davenport, Hennessy, Houser 
and Cryns, 195b b) was complicated by the emergence of a. 
new family of Type B viruses (Woolridge, DeMeio, Whiteside 
. 
and eal, 1955) and because so many cases occurred less 
. 
than a week after vaccination. The following year a. trial 
in Britain (M.R.~., .L957) seemed to indicate that the 
adjuvant vaccine gave no protection against influenza a 
year later alth.ough the attack rates were very low a.nd the 
mode of diagnosis would tend to weigh the results again t 
the vaccine (McDonald and Andrews, 1955). 
t present there does not appear to be clear evidence 
that the adjuvant vaccines can give protection for as long 
as the . raised. serum anti body titres would seem to indicate. 
The Components of Vaccines 
It .is, eloquent of the problems raised by the variable 
nature of influenza virus that there exist fundamental 
; 
disagreements on the basic concepts of making up influenza 
vaccines. 
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In Britain the antigenic ingredients of vaccines. are 
governed by the feeling that vaccines must attempt, if with 
imperfect success, to keep pace with the antigenic 
variations of the influenza 'virus. It is pointed out that 
Type viruses and, to a le~s marked. extent, l!Y'pe B viruses, 
can be classified in "'sets" or "'families". (Jensen, 1957 b). 
r 
en each new "family" arises it domina~es the influenza 
scene for 10 to 15 years and is itself replaced. Great~r or 
smaller degrees of variation in antigenic and other 
... ' 
characters occur within the family. Vaccines, and the anti-
body produced, specific for one family will afford little or 
no protection againat the next. family and that some of the 
"intra-familiar" variations also may, to a less extent, 
) 
render vaccines ou~-of-date. 
In the light of this belief, and the feeling that 
extraneous antigens merely divert the antibody forming 
mechanism and may re.duce the specific response (:Sri tish 
Medical Journal, 1961), it is felt that vaccines should 
contain representatives of those types of atrains which are 
moa t likely to cause influenza in the coming season. It is 
hoped that from the surveillance centring on the World 
Influenza Centre (Andrewes, 1953) an attempt should be made 
to predict these. 
In the United States of Amerio.a a diff-erent view, that 
of the "'Ann Arbor" school, exists, which has been proposed 
by Francis (1953, 1954, 2959), Davenport and Hennessey 
. 
(Davenport ana Hennessey, l960) and is responsible for the 
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concept governing vaccine manufacture in that country. This 
opinion holds that the British School is pessimistic as it 
can only always be behind the influenza virus (Davenport, 
1958). On the contrary, it is felt that the available 
evidence points _ the way to a schedule of vaccination that 
would protect against influenza of all types. 
It is felt that experiments with absorbed sera show the 
presence of numerous minor antigens which cross-react with 
atr~ins of widely differing chronological eras and that 
although certain dominant antigens may characterize a 
ttfamily" those antigens .wi1:l still be present in other 
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I 
families (Jen~en and Franci,s, .L953, Jensen, 1957 b). Thia 
leads to the concept that the range of ·antigehic variation 
of either of the two types, A or :B, is limited·. Therefore, 
epidemic influenza is felt to have a cy.c ical basis (the 
Einsteinian or "Franciscan" curve of Andrewes, 1957) so 
. 
that; in response to selection pressures different groups 
of an ti gens dominate in turn. From ."this it shou.Ld be 
possible to incorporate all the important antigens "that can 
Chtiracterize inf.Luenza to form a totipotential vaccine. 
The lower incidence of influenza among o.Lder people ia 
held to be due to the nature of their antibodies to 
influenza viruse. The antibody heritage of the first 
infection in .life will dominate "the antibody picture there-
after so "that a chrono.Logical map of inf.luenza can be drawn 
up showing when "sets" of strains were prevalent. This is 
the "doc:tirine of original antigenic sintt (Davenport, 1958 . 
. 
However , repeated infection with different strains leads to 
a broad-based composite antibody which is respon ible for 
the relative in usceptibility of olde r people (Davenport, 
Hennessy and Francis, 1956, Henness ey and Davenport, 1961). 
The "Ann Arbor" school feels that vaccine policy should be 
- ~ 
directed at creating a similar type of antibody in younger 
people by incorporating mu.L tiple strains of each ;type. In 
this context i"t is believed that the trial reported by 
-
Gundelfinger et al. (1958), . which appeared to show that a 
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vaccine contaiping A and A1 antigens only gave par t ial 
protection against an A2 epidemic, indicated that the minor, 
shared, antigens were important and lent support for the 
concept of a polyvalent vaccine. 
Mulder and Masurel (1958) reported that old people in 
~ 
Holland possessed antibody to the A2 influenza virus before 
the epidemic. Davenport (1958) confirmed this finding in 
America and both groups sugge ted,. on his basis, that the 
epidemic ·of 1889-1890 had been caused by an Asian type of 
virus and therefore the full range of major antigenic 
variations wittun the capacity of type A influenza virus have 
now been displayed. 
REACTIONS 
Although the more lurid pictures of the anti-cowpox 
vaccination cartoonists, depicting people ' turning into cows, 
did n.ot turn out to be jus tified, it is true that the use of 
any vaccine may be limited by undesirable reactions and side 
effects. 
These reactions mey· clearly be caused by the mode of 
administratio'n (e.g.' inoculation),' the vehicle (e.g.' 
- ~ 
aqueous, alum absorbed, or adjuvant), extraneous impurities, 
the toxicity of the antigen ·its elf, or, in_ the case of 
I 
living vaccines, may resu.1-t from the normal or abnormal 
' ' 
multiplication of the vaccinating agent or contamination 
with undetected organisms. 
Early Vaccines 
From the earliest trials critical observers noted 
reactions to the administration of vaccines. Francis and 
Magill (1935-1936, 1937) using a preparation of live virus 
grown in tissue culture recorded mild erythema and some-
times slight tenderness over the site of the inoculation. 
No pyrexia was noted in their volunteers. Stokes et al. 
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(1937 b) found that with a vaccine of active mouse lung a 
mild local reaction occurred in a few of their 250 subjects. 
One person had a marked reaction locally. When a tissue 
culture vaccine was used these workers noted no local 
reactions but a few of. their numerous subjects had common-
cold-li~e .symptoms after inoculation. tokes' trials were 
carried out on feeble-minded children which might have 
affected the recording of responses. 
With similar subjects and a similar vaccine Siegel and 
Muckenfuss (1941) found a 15% incidence of local redness and 
swelling which disappeared within 24 hours. General 
reactions were rare but .several children complained of 
headache and head colds 24-48 hours after inoculation. 
Reactions were not recorded in the earliest British 
trials ( tuart-Harris et al., 1938) where a formalized 
mouse lung vaccine was used. However, with a similar 
vaccine in 1939 (Stuart-Harris et al., 1940) only mild 
local reactions were observed. 
.. 
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By the 1940's vaccin~s based upon infected allantoic 
fluids became available and Brown (Brown, Eaton, Meiklejohn, 
' -
Lagen and Kerr, 1941) recorded that following the use of a 
formolized "complex 11 distemper-influenza vaccine, local 
- -
tenderness for 3-4 days was common. 
Concentrated Vaccines 
With the introduction of form.olized vaccines 
concentrated by various means (and, possibly, also more 
carefully studied trials) the reactions observed increased 
in frequency and severity. While Hare's subjects (Hare et 
al., 1943) noticed a considerable amount of stinging -
probably from excess form.aldehyde - loeal reactions were 
common but general reacti.ons were very few. Hirst et al. 
(1944) found that 1 in 200 of those receiving l ml. of 
vaccine developed a fever of l 0-100. 5° F. and a mo·derately 
sore arm with redness and swelling for 24 hours at the site 
of inoculation was common. With vaccine prepared the same 
year Salk et al. (1945 c) reported that systemic reactions 
' 
occurred in 2% (3 persons having a temperature of 101 ° F.) 
ana local reactions occurred in 65~ of 60 subjects after 
vaccination. No reactions occurred in controls who were 
inocttl~ted with a. placebo. 
During the large scale trial of 1943-1944 different 
groups paid differing degrees of attention to reactions. 
Those in the trial received either l ml.' of vaccine sub-
cutaneously or .a similar volume of saline containing 
formalin at the same strength as the vaccine. Salk (Salk 
et al., 1945 ) noted that while the control inoculation 
produced virtually no ill effects 1.46% of the vaccinated 
group reported sick and of 50 of these, 9 had a fever of 
100° F. or more. On questioning, 48% reported a systemic 
~ 
reaction and 73% local reactions consisting of tender areas 
with erythema and induration. 
aton and MeikJ.ejohn (1945)° interviewed samples of 116 


















Of the whole group of 1,761 men, 40 reported to the 
dispensary as a result of inocula.tion. 
Rickard et al., (1945) inoculated 1,206 men and 
circulated questionnaires to both vaccine ana control groups 
48 hours after vaccination. 
No Local Systemic 
Number Replies Reaction Reaction Reaction 
Controls 607 539 90% 10 0 0 . 7 0 
Vaccine 599 550 9i 91% l.8% 
Four men receiving vaccine were sufficient_ly ill to be 







In the Iowa University study of 599 receiving vaccine 
39 had general symptoms and 32 had sufficiently s.evere 
local reactions to limit the use of an arm for a day (Hale 
and McKee, 1..945 ,a). 
It is clear that the number of reactions was 
significant. In addition it was clearly demonstrated in 
the controls that neither the injection nor the formalin 
was responsible for the symptom. 
In an industrial group with a more mixed population 
Norwood and Sachs (1947) found that whereas rea.ctions. 
-
sufficiently severe to cause loss of time from work were 
rare a formidable number of complaints appeared in an wer 














It is not surprising that Salk and Francis (1946) 
-
equated the reactions to influenza vaccine with those 
caused by typhoid vaccine. However, in a trial in 1947 
Francis (Francis et al., 1..947) inoculated lO,O O students 
, 





















vaccine was. of similar haemagglutinating potency (5,120 
H. A. U.) to that used in 1943 it is perhaps significant that 
it was due to expire shortly after it was used. 
It had been shown on several occasions that influenza 
virus shows. an inherent toxicity (Henle, lz. and Henle, w., 
1944, 1946, Hale and McKe e, 1945 b, Evan and Rickard, 1945, 
and later, ugg, 1949). Many of these studies showed that 
the toxicity was destroyed by formalin. However , the 
. studies of alk (194.7, 1.948) established that the febriil.e, 
~ 
influenza-like symptoms that had been noticed in a 
proportion of those rec~iving vaccin were a property of 
the virus, not of the impurities that might be present. 
The nature of the reaction was not aett~ed but the 
evidence seemed to suggest that a rttoxic tt effect was 
-
involved rather than sensitization. · 
In an extensive survey ·of reactions aduak, Bassett 
and Meddaugh (1949) compared two vaccines, one prepared by 
r 
red cell elution and one by centrifugation techni~ues. The 
vaccines both seem to have contained a very large antigenic 
mass - 1,400 chicken cell agglutinating units (C.C.A.) 
(Hirst and Pickels, 1942, Miller and tanley, 1.944) . No 
difference was found between the vaccines but females and 
the younger age groups of this large office employee 
population were more affected than males and people of 25 
years and older, respectively. In this trial also,, 
aystemic reactions were reported in up to 36%, and local 
reactions in 60% of those inoculated. 
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British trials at variou times (M.R .• , 1955, 1958, 
Himmelweit, 1960, Cope, l960, Norman and Rainsbury, 1960) 
showed the .proportion of reactions occurring with aqueous 
based vaccines. In 1953 a saline vaccine containing 20,000 




Erythema - welling Induration 
45% 32.8% 
In four cases the inct.uration persisted for a year. 
Norman and Rain bury (l9o0 ) recorded a few complaint 
of painful arms for two or three days only and in a series 
of 3,209 studied by Cope (1960) about tthalf a dozen"' were 
, ~ -
absent from work for 1-2 days after vaccination. Two of his 
patients reported extensive local reactions. 
Hinnnelweit's series with 400 volunteers, mostly less 
than 25 years old, showed systemic reactions in 2% and 
local reactions in 3. 6%. These figures are markedly lower 
than in the American figures but whereas the report of the 
trial in senior schoolboys by Hawkins et al. (1956) does 
not contain a note about reactions it appears that these 
were fairly severe. 
Two interesting revi ews of reactions in the United 
States armed forces were published ,by eal (1955) and 
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Griffin (l959). Seal report~d on the effects of influenza 
vaccine at Naval and Marine training centres and showeu. that 
the proportion of those hospitalized in 1955 was considerably 
under 1:1000. However, in one group 80% complained of some 
symptom referable to the inoculation. More, detailed studies: 
on smaller groups of officers and hospital corpsmen confirmed 
a high ~ncidence of reactions. 
Griffin surveyed vaccination in the A.rmy- and noted the 
difficulty of getting reliable accounts, showing that in 
1945 the incidence of generalized reactions in different 
reports varied from 7% - 85%! Therefore, Griffin u ed time 
lost from duty as an index and counted the number of 
attendances: at out-patients after inoculation with 
influenza vaccine from 1953-1955 . During this period about 
3-i mil:I._ion doses of influenza vaccine were given . Reactions 
which caused the recipient to attend out-patients occurred 
in 0. 6%. 97% of these reactions were trea~ed while the men 
remained on duty. In regard to reactions, influenza 
vaccines were shown to be s.tric.tly comparable with booster 
doses of typhoid or tetanus vaccines and much less prone 
to cause reactions than small-pox vaccination. An 
interesting fact is revealed by the steadily decreasing 
rate of reactions, from 11. 83/.LOOO in 1953 to 2. 83/1000 in 
l955. 
Influenza Vaccine in hildren 
Although some of the earliest trials were carried out 
in children these vaccines, by later standards, contained 
very little antig$n. Grant (1940) and alk (1947) pointed 
,. 
out that infants and young children suffered worse 
reactions with less virus. uilligan and colleagues 
(Quilligan, Minuse and Francis, 1948) had to alter the 
doses u ed in an investigation in children because of the 
aevere febrile reactions and confirmed the frequency and 
aeverity of them (Quilligan, Francis and Minuse, 1949). 
In a group of children, average age 3.2 yeari;j, gi ven 
vaccine wi n J., 02~ H. • U., ·74~ deveLoped temperatures of 
over 10 ° F. Even 128 H .• u. given as a first inoculation 
caused fever in nearly 20% o th~ recipientc. 
Higgons , i gg , tlyde anQ Mann (1948) tried various 
dos.es and. routes of adminis.tration in children aged .. from 
3 mon hs to 12 years. Doses of 0.1 ml. intradermally, and 
. 
0 . 2 ml. sub-cutaneously were well tolerated but the anti-
body response was very poor. 0.5 ml. sub-cutaneously 
caused febrile reactions in nearly 40% bu"t a.11 those with 
higher fevers ( 100.8° F.) were less than 5 years of age. 
- " 
Bruyn, Meiklejohn and Brainerd (1949) made a careful 
' 
study comparing sub-cutaneous doses graduate for age, 
and in"tra-dermal vaccine. With sub~cutaneous vaccine 
abou~ 5.0% of all ages had systemic reactiond of one sort 
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or another and l ocal re ~ct ions caus ing limitation of arm 
movement in a t hird . 
Davenport and Hennessy (19o ) recommend low dosage 
~ 




The early experiments of Henle (Henle and Henle, 1945, 
Henle, Henle, Hampil, Mauris and Stokes, 1946) showed that 
with the adjuvant vaccines they used, the great advantages 
in antibody production were off-set by the high inciuenc 
of local reactions wi t h residual nodules and sterile 
abscesses. However, the finding that administration in oil 
emulsion reduced the toxicity of other substances (Halbert, 
mo.Lens and Mudd-, 1945) and the possibil ity of being able 
to use a smaller antigenic mass to obtain the same antibody 
response awakened the promis~ . of reduced systemic reaction. 
alk ( alk et a.1_; 1951, alk, Bailey and Laurent, 1952, 
Salk and Laurent, 1952) showed that by using Arlacel A, 
which Freund had used (Freund, . Thomson, Hough, Sommer and 
Pisani, 1948, Freund, Thomson, ommer, Walter and Pisani, 
i948), as an emulsifying agent and Bayol Fas mineral oil 
and injecting the emul sion intramuscularly, he could avoid 
the unuesirab.Le reactions that were reported previously 
and retain the antibody response associated with the water-
in-oil emul ion. 
58 
Further trials in people were commenced both in the 
United Stat$s and Britain using Arlacel A and Bayol F, but 
in both countries there were reports of chronic reactions 
(M.R •• , 1955, Philip et al., 1954i, In Britain, the two 
, 
cases were of a minor nature but in the American trial a 
number of sterile abscesses occurred, particularly in 
negroes. The much larger British trial of 1954-1955 
produced rates of chronic reaction of 0. 2% and 0. 5% in two 
groups given adjuvant vaccine (M .R. C. , 1957'). In 9 
volunt eers the sterile abscesses that resulted required 
surgical treatment. A retrospective survey of U. S. Anny 
cases at Fort Dix revealed a total incidence of cystic 
complications of nearly 3.0% (Beebe, Simon and Vivona, 1964). 
It was found that early batches of Arlacel A were toxic and 
in further studies in America a partly purified Arlacel was 
used and Drakeol 6 VR subs ti t uted for Bayol F. This, 
however, still resulted in an incidence of cysts of 0.1% 
(Philip et al., 1954, Bell, . Philip, avis, Beem, Beigelman, 
ngler, Mellin, Johnson and Lerner, 1961). Smaller trials 
since have not repor~ed this complication ( avenport et al., 
1956 , Hennessy and Davenport, 1961) and Hi~elweit (1960) 
observed no immediate or delaJTed reactions in his group_ of 
180 volunteers who were examined a year after .inoculation 
with these reactions in mind. However, Furstenberg (1963), 
reviewing the use of emulsions for desensitization, reported 
that cysts still occur. occasionally but no details were 
supplied. 
Allergic Reactions 
In view of the ·fact that a p~oportion of the 
population is sensitive to egg protein fears were aroused . 
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that allergic reactions might occur with vaccines pr~pa.red 
from allantoic fluid (Knight, 1944). Plotz (1946 ) 
surveyed the history of the numerous vaccines prepared in 
eggs and ci~ed a case of anaphylactoid death after 
influenza vaccine in a soldier who had a life-long history 
of egg sensitivity. 
Ratner and Untract (1946) tested a group of highly 
~ 
allergic children and found that all the cases who reacted 
to skin tests with influenza vaccine were hypersensitive 
to egg white. They felt that of their total group of over 
a hundred, influenza vaccination would be hazardous in 
4.6%. Sadusk et al. (1949) skin-tested 79 of their 
volunteers who suffered from asthma, hay fever, egg or 
chicken sensitivity or had had a reaction with influenza 
vaccine previously. After testing , only 1 6 were rejected 
and the reactions in the rest, who were vaccinated, were 
no worse than in the general group. However, Seal (1955) 
reported 2 anaphylactic reactions occurring ·in egg 
sensitive individuals and Griffin (1959) found 3 such 
cases in his survey of inoculations in 1945, two of which 
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were fatal. Warren (1956) reported a case with . 
encephalopathy of probab+e allergic background and Denny 
(1948) described a case of severe urticaria in an infant 
without any previous history of allergy and advised that 
routine precautions should be taken when influenza vaccine 
was being given . 
Davenport (1962) summarized the situation stating 
that influenza vaccine shoula. not be administered to 
people who could not eat eggs because of hypersensitivity. 
Sic:1.e-Effeets 
In addition to the varied reactions that are directly 
. and readily attributable to influenza vaccines some other 
possible undesirable effects have been dis cussed. 
A) It has been suggested by Springer and Tritel 
-
(19 o.2) that as chick embryo tissue contains group A-
substance and as the vaccine material is derived from egg 
allantoic fluid sufficient A- substance could contaminate 
the vaccine to immunize recipients who are Group O or B. 
It was further implied elsewhere that this could lead to 
A.BO haemolytic disease in infants of mothers thus 
immunized. Evidence of a rise in anti-A isoagglutinins in 
response to inoculation of a concen rated and dialysed 
extract of influenza vaccine was presented . 
However , it was stated by other authors (Influenza 
urveillance, 1962, Mathi~son, Banner and Harris, 1963) 
that this had not been obaerved to ftappen. In addition, 
ussman anu Pretshold (19 3) failed to find Group A 
r 
substance in ' the influenza vaccines supplied by two 
manufacturers. 
B) Various long-term side-effects that could be 
associated with the use of adjuvants have been suggested. 
First, the possibility has been raised that the 
mineral oil used may be carcinogenic particularly as it is 
insusceptible to destruction or disposal by metabolic 
action. a.l.k (1961) pointed out that these oils are 
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straight-chain hydrocarbons without cyclical. rings and are 
free from that fluorescence in ultra-violet light 
associated with carcinogenic hydrocarbons. Also, similar 
oils have formed deposits in people using them as laxatives 
or nose-drops but have not been ass9ciated with neoplastic 
disease. Potter and Boyce (196 2) shoV'{ed that the intra-
peritoneal inoculation of adjuvants .into BALB/cAnN mice 
causes plasma cell tumours. ·However, Lieberman (Lieberman, 
Mantel and. Humphrey , 19 1) found that this property ia 
'•. 
restricted to this rather specialised strain of mice and 
feels that the carcinogenic action of oily adjuvant mS3" be 
strain specific for this breed. The follow-up studies of 
Beebe (Beebe et al., 1964.) showed that the incidence of 
neoplasms in those receiving adjuvan-c vaccine was less than 
in the group getting ~~ueous based vaccine. However, the 
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authors add the reserv:ation that the study has only lasted ' 
ten years. 
econd,' it was feared that the presence of adjuvant 
. 
might cause sensitization to extraneous stimuli and 
.possibly be associated with auto-immune disease. The 
experimental work · of Rothbard and Watson (1959) is cited as 
showing the effect of adjuvant in potentiating the effect 
of the effect of anticollagen serum. On follow-up there is: 
no suggestion in the samples surveyed by :Seeb.e et al. 
(19o4) of an increased incidence of collagen dis.ease or 
au,to-imm.une disease. Howe.ver, there are indications of an . 
excess .of allergic phenomena, particularly to penicillin, 
occurring in those people given vaccine between 1951 and 
1953. It is not clear whether this could be associated 
with I4inute amounts of penicillin in the vaccine or 
whether the presence of the ~djuvant predisposed the 
individual to become hypersensitive to material given 
quite a~ventitiousiy . . In this connection Freund (Freund 
and Walter, 19-44, Freund, 1957) foun·d that adjuvants 
·, 





PLAN AND ORGANI ATION OF TRIALS 
Thi study was undertaken for a number of reasons. 
1 To examine reactions arising from the use of current 
commercial influenza vaccines. 
The review by Griffin (1959) seemed to indicate 
that influenza vaccines were improving and causing fewer 
reactions. However, i~ has always been difficult to 
6 
compare American vaccines directly with British ones partly 
because of the polyvalent nature of the former but also 
because of the different units used. The .• A. unit use 
in the United tates is not exact y comparable with the H.A. 
unit used in Britain. Differing estimates for the 
equivalence have been given:-
1 C. C.A. unit= 10 H.A. units (Francis, 1959) 
, . 
1 C.C.A. unit= 25-40 H.A. units (M.R.C., 1958, 
Himmelwei t -, 1963) 
In addition, the method of assessing reaction _ has 
differed markedly from one worker to another and it is 
difficult to compare the results. ith large numbers of 
people a questionnaire system is the only one practicable. 
Thia has its advantages in eliciting the subjective 
feelings of those inoculated but also tends to select out 
" 
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those with complaints -and simultaneously suggests reactions_ 
that might occur. 
It is not easy for workers to be objective in 
reporting the effecta of a prophylactic whose use they 
have proposed. When the observations of Clarke (1962) and 
of Meichen (Meichen, Rogan and Howell, 1962), which 
indicated surprisingly high levels of severe rea.ctions, 
came to view it was felt that a prospective study waa 
•'.. 
required to assess these directly without the complicating 
factors present in induatrial populationa. For instance, 
a "home matchtt might have a startling effect upon absences. 
due to vaccine reaction. 
2 To examine the ·antibody response to commercially 
~vailable influenza vaccine. 
In addition to the difficulties introduced by 
divergences in composition and unitage as mentioned above 
many trials, have been performed, with univalent vaccines. 
As British commercial vaccines contain both influenza A 
and B material it was felt that it would be fruitful to 
examine the respon1:>es to both components of the vaccine. 
J To observe the effect of influenza vaccines upon the 
titres of anti-A isoagglutinins. 
As the article by Springer and Tritel (1962) 
appeared while the first trial was in progress the 
' 
opportunity was taken to parry out limited investigations 
on the eff-ec't of influenza vaccines on antibo ies to A.-
substance. 
lan of Trials 
Two separate trials were run over the winters 1962-
1963 and 1963-1904. 
Part I 
Trial 1 (Novemb r, ~9 2,Novemb~r, 9 3) 
.t:'rogramme 
A. Volunteers were bled and inoculated with one of 
two vaccines at a morning session. 
B. Volunteers were examine for reactions 
i ome hours after inoculation (i.e. the same 
afternoon) 
ii 1 day after inoculation . 
iii 2 days after inoculation 
iv 3 days after inoculation 
V 7 days after inoculation 
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21 days after inoculation volunteers were bled and 
examined for reactions. 
Part II (2 months after commencement of art I) 
A. The ame volunteers as in Part I were bled and 
inoculatea with one of two vaccines in a morning session. 
B . olun"teers were examined 1·or r~ cti onl:;j as in 
J:lart I.-
28 days after inocu~ation volunteers were b~ed ana 
examined for reaction;::i. .. 
D. 9-lO months after inoculation volunteers were 
bled and examined for delayed reaction~. 
Volunteers 
Volunteers were drawn from s"tudents of the first to 
fifth years of the Facul.ty of Medicine at the ueen' 
University of Belfast. 
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Each class was addressed verbally and support for the 
trial was requested. Explanatory sheet~ and Consent Forms 
(Appendix 1) were circulated ana the latter were collected 
by the class representatives when comple"ted. I,; was 
explained that people who were sensitive to eggs or who 
suffered from asthma were to be exclu ed. 
Vaccines 
The vaccines were kindly supplied by Glaxo 
Laboratories Ltd. 
Part I 
Two vaccines were sent labelled as "W" and 11R". 
The vaccine fluids were indistinguishable to cursory 
exa.mj_nation. The nature of each was not revealed by the 
supplier until after the trial was over. 
"W" was a placebo, · c,onsisting of phosphate-buffered 
saline. 
11R11 was a saline-based (aqueous). formalin-inactivated 
vaccine containing.: 
750V H.A .. U. 




B/England/939/59 5000 H.A. U .• per millilitre. 
This ,was a commercially marketed product. The viruses 
were grown in the a.:!,.lantoic cavities of embryonated eggs, 
inactivated with formalin, concentrated and purified by 
differential centrifugation and diluted to the required 
concentration with phosphate-buffered saline~ The final 
product did not contain free formalin but had 0.013% 
thiomersal added as a preservative. 
In Part I of the trial 0.5 ml. of either were given 
by deep sub-cutaneous inoculation over the triceps. 
Part II 
Vaccines were supplied by the same firm. 
11R11 was an aqueous vaccine identical to that in 
Part I. 
110" was a water-in-oil emulsion vaccine 
dispensed in single dose cartridges . Thia: 
adjuvant vaccine contained: 
1 Aqueous phase: 
A/Singapore/l/57 1500 H.A.U. 
A/England/1/61 50 H.A.U. 
B/England/939/59 1000 H.A.U. per dose 
2 Oil phase: 
Drakeol 
Arlacel A 





The aqueous and oil . phases are blended in equal 
·volumes. and emulsified by a spring-loaded piston mechanism 
similar to that illustrated by Himmelweit (1960 ). 
·. Drakeol 6 VR is a light, white mineral oil produced 
by. the Pennsylvania Refining Company. Arlacel A is 
mannide mono-oleate supplied by the Atlas Powder Company. 
Both are especially prepared for use with vaccines and are 
batch teste~ for toxicity in animals. terilization is by 
filtration to avoid the production of toxic by-products 
during heating. In addition to sterility tests, the final 
adjuvant vaccine preparations are tested for toxicity by 
the intra-peritoneal inoculation of mice. 
In Part II· of the trial volunteers received either 1.0 
ml. of aqueous vaccine, RR", sub-cutaneously or 0.25 ml . 
. (one .dose) of "0", the adjuvant vaccine, by intramuscular 
inoculation into the belly of the triceps. 
Mode of random selection 
The vaccine which ·a volunteer received was determined .,. 
by· date of birth. 
Part I 
Those with odd-numbered days of birth (e.g., 1st, 3rd, 
5th, . etc. qf the month) received "R11 vaccine. Those with 
even-numbered d~ys of birth recei v:ed the placebo' nwn. 
Part II 
Those with dates of. birth in the first half of the 





and those born in the second half of the month had aqueous 
vaccine, "R";: · 
This method ensured that the volunteers would be 
' 
randomly distributed between the vaccines in both parts 
of the trial and in relation of one part of the trial to 
another. 
yringes and needles 
For inoculation: 
For aqueous. vaccines "R" and "W" 2 ml. disposable 
" teriseal" (Shrimpton and Flatcher, Ltd.) syringes were 
. 
used. 
For the adjuvant vaccine 11Mi trex" (Medical and 
- "' -
Industrial Equipment, Ltd.) cartridge syringes with Luer 
. ' 
fitting nose pieces were used. After use the detachable 
nose piece was boiled before re-use. The plunger thread 
was exposed so as to permit it to be engaged with the 
pis ton of the car·tridge. This allowed withdrawal of the 
piston after the needle was in erted to avoid intra-
vascular inoculation. 
In Trial 1 "Steristar" (Smith and Nephew - Southalls, 
. 
Ltd.) d1sposable needles of 23 gauge x 1 inch were used 
throughout. 
For bleeding: 
10 ml. "Steriseal" disposable syringes and 
"Scimitar" _(Gillette Surgical, Ltd.) No. 1 disposable 
' 
' 
needles of 21 gauge x ~i inches were used. 
Bleeding, 'inoculating and examining sessions 
The ,times and places of sessions were arranged after 
I< '< ,-.,, ! 
consultat~an with the class representatives and the 
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teaching departments who would be concerned. To allow for 
the successive examining sessions the initial inoculation 
session had to be on a Monday or a Tuesday. 
The fourth and fifth year classes were inoculated and 
bled on Monday , November 12th, and the third year class on 
Tuesday, 13th. The first and second year classes were 
inoculated on the following Monday. A similar plan was 
adopted ·£or Part II of the trial. Considerable effort was 
required to reconcile the trial with the diverse class 
programmes. A.:!-1 sessions were held during normal hours 
and close to ,where the students were working~ Inevitably, 




Organisation of Sessions 
Inoculation session: 
aiting volunteers were handed:-
A Universal container , with a blank label - for name 
and the date. 
(b) A special record card (Demonstration l ), with space 
for the volunteer's name, address, and age in years. 
(c) A small pink card . - for the vo unteer's name and 
I 
date of birth. 
' c.. ' \ 
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fter these had b~en filled in the volunteers were 
checked off a list at a desk and directed singly to one of 
three stations where they were inoculated with the vaccine, 
as determined by inspection of the pink card, and bled. 
; 
epafate members of the medical staff bled and inoculated. 
. . 
The volunteers were not aware of the mothod of selection 
nor 'of the number of different vaccines. Most appeared to 
think that the different stations represented different 
vaccines. Thi s impression seemed to ho~d even in the 
econd part of the trial when the adjuvant vaccine wa . 
being administered with ~he cartricige syringe which was. 
obviou ly different . 
The record cards did not have any reference to the 
date of birth of the volunteer or of the vaccine, 
administered until after the relevant part of the trial 
was over. The pink cards with dates of birth on them were 
stored separately until the trial was over. 
During inoculation essions adrenaline and al 
vol~ti1e ,we~e kept ready in case of need. In the case of 
the first year students there was. a considerable incidence . 
of fainting both while being bled and while waiting before 
any .procedure was started~ Later sessions were organis·ed 
so that the volunteers did not watch others being bled and 
the problem was largely solved. 
,, 72 
Checking sessioos: I / 
Th€ volunteers' record cards were kept, class oy 
class, in tickler boxes and were hana.ed out to the 
volunteers to take to an examiner. aards were marked, 
usually by an assistant, on the instructions of the 
examiner. 
Co,nsiderable efforts were made to encourage full 
attendance at sessions for checking reactions and post 
cards were sent to remind defaulters of their obligations. 
Sera 
Blood specimens were allowed to clot overnight at 4° 
and the following d9¥ sera were separated and stored at 
-20° 
A.t the initial bleeding of Part II of Trial 1, 1-2 mls. 
of blood was collected separately in 3.5 x 0.4 inch tubes 
for blood grouping and these were taken to the Blood. 
Transfusion ervice Laboratory s·oon after the· session. 
Trial Z (November, 1962 - November, 1963) 
rogramme 
A.. Volunteers bled and inoculated with adjuvant. 
influenza vaccines. 
I 
B. Volunteers examined for reactions to inoculation 
i 2 days after inoculation 
ii 7 days after inoculation 
28 days after inoculation volunteers were bled and 
examined •. 
D. 3 mon-ths after inoculation volunteers were bled 
and examine.a f'or reactions. 
Volunteers 
These were drawn from:-
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First year students in the Faculty of Medicine at the 
ueen 's Uni vers'i ty of Belfast. tudents who were repeating 
the year and who had received vaccine during the previous 
winter's. trial were excluded:. 
13. Nurses at the Royal Victoria Hospital and Royal 
Maternity Hospital who had volunteered to receiv~ influen~a 
vaccine. 
As before, explanatory sheets ·and consent forms were 
ci~culated. The explanatory sheets were modified from the 
previous year (Appendix 1). 
Vaccine 
It was originally intended to test two adjuva.nt 
vaccines of identical components but of differing viscosity. 
However, the more viscoua a.nd more stable emulsion did not 
pass toxicity tests, and all the volunteers received 
adjuvant vaccine precisely similar to "0" mentioned above 
but containing the following antigens:-
A/Singapore/L/57 l50U H.A.U. 
~ngland/J./61 500 H.A.U. 
B/England/939/59 1000 H.A.U. 
B/Tai watA-/6 2 500 H.A.U. per dos~ 
Note the influenza B component haa been augmented by 
the addition of B/Taiwan/4/62. The dose of 0.25 ml. waa 
administered into the upper portion of the long head of 
the triceps.. 
yringes and Needles 
For iq-ocu1a.tion i 
ttMi trex.•t syringes were used as before with 
l • - ... 
either Johnson's No. l (Johnson's Ethical Plastics, Ltd.) 
.. - .~ 
21 gauge Lf inch or Scimitar ( Gillette Surgical, Ltd. ) N·o. 
12, 2} gauge, 13/16 inch disposable needlea. These were 
designed to cater for different dimensions of arm so that 
a lo~ger needle was available to reach muscle adequately 
in the arms of fat people. In the event the nurses were 
all inoculated using the larger needle. 
Bleeding: 
10 ml. disposable. syringes (Johnson's Ethic.al 




Blood taken was partly all.owed to clot overnight 
and the serum separated and stored a.a before. At ' each 
bleeding s:.ession 2 mls. of blood were kept in a separate 
tube- and transferred to the Blood Transfusion Laboratory 
as soon as possible. In cases where there was some delEzy 
these bloods were kept ,at 4° C. 
Bleeding, inoc.ula~ing and examining aessiona 
The times and places of sessions were arranged with 
the first year class representative. Those for the 
nursing staf,f were OJ;'ganised by the taff !lledical Officer 
in the case of t~e three bleeding sessions. However, 
because the hours on duty and places of work of the 
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nursing staff altered constantly it was often not possible 
to arrange sessions for all nurses and si:acial arrangements 
had to be made for various groups. This was only possible 
because 0£ the modified schedule of examining for reactions. 
SECTION B REACTIONS 
Materials and methods: 
Trial 1 
The record card (Demonstration ~ ) had spaces for recording the 

















Gastric Symptoms (e . g. G 
Nausea, Vomiting) 




Allergic manifestations Al 
"Other" 0 
Spaces "S" and"?" were for answers to questions . 
Reactions were graded according to severity between O - 3 where 
this was applicable . Any reaction not covered by a code letter could 
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Demonstration 1. Card f'or recording 















Examination for Reactions: 
The Examiners: 
The examination for reactions was carried out by members of the 
scientific and medical staff of the Department of Microbiology. Vlhen-
ever possible they had assistants to write the results on to the cards. 
The system of recording and scoring of lesions was explained to the 
examiners before the trial began. However, these different examiners 
undoubtedly introduced an element of variation but it is likely that 
those who gave low scores were balanced by those who ma ked lesions 
higher. This factor could explain recordings that appear rather 
surprising on examining the cards. 
The mode of examination : 
The inoculated arm was exposed and examined for erythema, swelling 
or bruising. The volunteer would be asked how his arm was to ascertain 
subjective pain and the inoculated area was firmly palpated to detect 
induration, swelling or tenderness. The last was ascertained by 
questioning and observation. In addition a non- specific type of 
question such as, "And how are you?", was put, searching for evidence 
of systemic reaction • 
.An attempt was made to discover reasons for absence from defaulters 
but answers were not regularly obtained • 
Measu.rement of arms: 
.An attempt was made to establish an objective index of reaction 
by measuring both arms before inoculation and at each session for 
examining reactions. However, it soon became clear that the degree of 
l 
. ..... 
error in measurement was so great and the degree of swelli..~g so small 




At the check 7 days after inoculation volunteers were asked whether 
the inoculation had interfered with work, play or social activities . 
t the final check of a series (21 or 28 days after inoculation) 
volunteers were asked whether they thought that the inoculation was worth 
while if it kept influenza away. If further explanation was sought 
volunteers were asked whether the trouble they had had with the injection 
was , in thPir opinion, justified if they were kept free of influenza. 
Answers were recorded as "Yes" , "No" or "Don ' t know" but in the first 
trial reasons for their decision were not requested. In addition , 
volunteers who had taken part in both phases of the first trial were 
asked 28 days after their second inoculation whether the first or second 
inoculation had been worse. 
Significance tests : 
In these results and in other sections of this study tests for 
significance were read at the 51 level . The chi- squared (X2) test 
(performed according to Snedecor , 1946) was generally used, with 
grouping of results where necessary. Yates ' correction was not applied. 
Where the chi- squared test would be inadmissable as , for instance , where 
the "Expected" value fell below 5 an Exact Probability was calculated. 













Complete and Incomplete Records : 
In each part of 'l'rial 1 there v,ere 7 sessions for the volunteers to 
attend. In both parts a considerable number of the volunteers did not 
.attend all the sessions. In the firs.t part only 73.9;1 had complete 
records and in the second only 78 . 1%. This display of independence 
introa_uc·ed considerable complications into the analysis of the results . 
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To simplify, those who defaulted from one or more sessions could 
have done so :- 1/ Because the reaction caused was so severe as to either 
keep them away or to engender dislike or distrust of the trial . 
2/ Because so little reaction occurred that they were 
not reminded of the inoculation or felt that it was not necessary to 
attend - despite exhortations. 
3/ Because they forgot about the session or simply did 
not come to University that day for reasons of their onn. 
Observations on this point revealed that there was no significant 
association between the inoculation received and students defaulting. 
( o. 3>P)'(). 2 and 0. 95>P70. 9 in Parts 1 and 2 of the trial respectively) . 
Absenteeism was generally associated with the inconvenience of attending. 
For example , there was always a crop of defaulters on a Wednesday. This 
is the traditional half- day and some students simply fail to att end 
classes at all . 
Inevitably, the existence of defaulters will introduce a source of 
error whether the results are included or not. If they are excluded 
one may be excluding reactions , if included they may weight the result 
unduly. In fact , in most cases the distribution of "maximum lesions" 
' 
,,. 
in those with complete and incomplete records were similar and where 
dissimilar the incomplete records showe<)1.3ss severe reactions. 
compromise has been adopted in the presentation of results . 
For 11Ma.ximal lesion" tables ,results are shovm separately and combined. 
In "C.umulative percentage" and "Daily record" tables the total of all 
observations, whether on people with complete or incomplete records , 
was used. 
Exclusion of certain results : 
.After the assessment of reactions was over the actual inoculation 
received was deduced from the volunteer ' s date of birth. In a few 
cases this introduced problems. 
In a few cases the date of birth written on the pink card was 
illegible and therefore it was uncertain how it had been interpreted 
or what inoculum had been given. In such cases the records of that 
subject were not included in the relevant part of the trial . In one 
case a student gave dates Qf birth which differed in regard to both day 
and month at the two dif'ferent parts of t he trial. However, on both 
pink cards the writing was clearly legible and therefore each was 
interpreted accora.ing to the face value . From the antibody results it 
seemed highly probable that another student received vaccine when he 
should have had placebo . The records of this volunteer were included 
in the group indicated by his date of birth; 
RESULTS 
Part 1 










whom received placebo("?" and 19l~ vaccine_ ( 111 11 ). The numbers and 
sexes were distributed among the classes as follows:-
Pla.cebo Vaccine R Class 
Male 33 30 
Female 9 14 1 
(Total 86) 
Hale .30 29 
Female 7 15 2 
(Total 81) 
Yale 28 24 
Female 10 11 3 
(Total 73) 
~!ale 27 27 
Female 5 7 4 
('.l'otal 66) 
I.ale 25 31 
li'emale 12 6 5 
- (Total 74) 
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Local Reactions : 
(a, ERYTHEMA: 
Erythema around the inoculation site was scored as follows :-
1 indicated an area of erythema of up to 15 mm. in diameter 
2 II II 
II " II 11 more than 15 mm. in diameter. 
This was occasionally as much as 50 mm . 
3 would indicate widespread erythema about the arm. No records 
of "3" were made . 
"Maximal Lesions 11 : 
Here the numbers and percentages of people are shown with their 
maxirral lesion recorded during the trial:-
Placebo ( [ Vaccine c~ 
0 1 2 0 1 2 
Males : Complete Records 102 78 9 18 
Incomplete Re cords 4D 31 1 5 
Females : Co~plete Records 31 18 14 9 
Incomplete Records 13 6 1 2 
Total 186 133 27 34 
~ 
Males : Complete Records 1oq 74. 2 8. 6 17.2 
Incomplete Records 100 83 . 7 2. 7 13. 6 
Females : Complete.Records · 100 41 . 5 37.5 21 .0 
Incomplete Records 100 66. 6 11.2 22 . 2 










"Cumulati ve Percentages : " • 
s signs and symptoms heve duration, as well as incidence and 
grade of severity, this has to be indicated. Cumulative percentages 
are calculated on the total number of records of a particular grade 
during the first four examination sessions for reactions against the 
total number of examinations done during the four sessions . Only 
results from the first four examinations were included to avoid diluting 


























This records the number and grade of observations at each session. 
The total number of volunteers seen at each occasion varies inversely 
with the number of defaulters . 





.. .-. ··•· .-.;..·!' ~-----. 
positive observations with one type of inoculation is significantly 
































P =0. 248 
P < 0.0005 
P <0.0005 
P <U. 0005 
P : 0.248 
It will be seen that women showed erythema to a greater extent 
than men (53 . 8~ as against 23 . ~). Erythema was maximal on the first 
and second days after inoculation and was still present in three 
persons a week after inoculation. This reaction was seen only in 
association with vaccine . , 
(b) PUN : 
85 
This was essentially judged on subjective grounds and people differ 
' 
in their reaction to discomfort . It was assessed by asking volunteers 
about their arms . Sometimes they moved their arms about to see if they 
felt the inoculation. Pain was scored as O, ! (minimal) , 1 (slight) , 
2 (moderate) and 3 (severe) . The "!" scorLng v,as introduced to cover 
those who were merely aware of having been inoculated. A grade of 3 
would have indicated marked discomfort on using the arm. No scores of 
3 were give~ . Pain was differentiated from tenderness as being hurt 
experienced at rest or with use but without contact . 
"?~aximal Lesions" 
Placebo vl Vaccine R 
0 1 1 2 0 1 1 2 2 2 
Males 
Compl et e Records 80 10 11 1 82 11 11 1 
Incomplete II 35 2 3 - 27 5 4 1 
Females -
Complete Records 27 1 3 - 25 8 9 1 
Incomplete II 10 1 2 - 7 2 - -
Total 152 14 19 1 141 26 24 3 
>,i 
Males 
Complete Records 79 . 3 9.8 9. 9 1.0 78 .1 10 .5 10. 5 0. 9 
Incomplete II 87. 5 5.0 7.5 - 73 .0 13. 5 10.8 2.7 
Females 
Complete Records 87.0 3. 2 9. 8 - 58 .o 18. 7 21 .0 2. 3 
Incomplete II 77.0 7. 7 15 . 3 - 77. 8 22. 2 







Placebo vl Vaccine R 
No . No. ~ 
Totals 685 714 
0 648 :, 94 . 6 640 89. 6 
1 17 2.5 36 5. 0 2 
1 1.9 2. 8 34 4. 8 
2 1 0. 1 4 o. 6 
"Daily Record": 
Placebo W Vaccine R 
2 1 1 0 0 1 1 2 'f 2 
Hours 1 15 12 148 151 11 18 1 O. 7>P>0 .6 
D~y 1 4 5 171 X 150 18 11 3 0.01>P 
.:> 0.005 
2 162 X 169 4 3 P = 0.015 
3 167 170 3 2 P = 0.061 
7 177 190 
21 181 192 
. It will be seen that a 'f'ew hours a.f'ter inoculation the pain 
caused by both placebo and vaccine were similar. However, on the two 
days following there were signi'f'icantly nore complaints with the 
vaccine . Complaints had returned to the level o'f' cha.nee distribution 





There was no signific.ant difference between records for men and 
women over all (0.2'>P>Q.1), but in response to Vaccine "R" women 
suffered more than men (0 .05>P>0.025). 
(c) TENDERNESS: 
The presence and grade of tenderness was deduced by the response 
to questioning and firm palpation. Occasionally, when the general 
area of inoculation was not tender a record was made when tenderness 
se 
was e~icited by direct pressure on the site of the need.le entry. 
Tenderness, again, was mainly a subjective response but less so than 
pain, as the reaction to pressure could be observed. This was the 
commonest sign of reaction as tenderness persisted longer than a feeling 
of pain or discomfort . However, no one was severely aff'licted, as 
with primary vaccinia lesions or with typhoid inoculation and no 
records of grade "3" were made. 
"Maximal lesions" 
Placebo W Vaccine R 
0 1 1 2 0 1 1 2 < ? 2 
?,!ales ' 
" 
Complete records 98 4 69 18 16 2. 
Incompl ete records 39 - 1 24 10 3 -
Females 
Com l ete records 25 2 4 17 7 18 1 
-
I ncom l ete . ' records' 11 - 1 1 4 5 - -
Total 173 6 6 1 114 40 37 3 
Placebo W Vaccine R 
·o 1 1 2 0 1 1 2 2 2 
- - % 
l~ales " . , . 
-
Com lete records 96.1 3.9 65.7 17.2 15.2 1.9 
Incom lete records 97.5 2.5 
' 
~4-.9 27. 8 .1 -
Females 
Complete records 80 . 5 6.5 13 39.5 16.2 4-2.0 2.3 
I 
Incomplete records 84.6 7.7 7.7 44.2 55. - -
'.:'ot 1 93.0 3.2 3. 2 o.6 58.5 20.7 19.2 1.6 
~ 
~ omen sho.1ed significantly more reactions than men even considerin 
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Pl~cebo (w) Vaccine (R) 
2 1 1 0 0 1 1 2 2 2 
Hours 1· 4 171 X .166 7 7 1 0.05 > P';::I' 0.025 
Day 1 3 177 X 138 23 21 P< 0.0005 
I 
2 1. 1 ·160 X 142 · 18 14 2 P< 0.0005 
3 1 2 164 X 143 18 14 P4(0.0005 
7 2 2 173 185 2 3 
28 1 181 191 1 
Records of tenderness show a marked difference between the inocula 
from a few hours after inoculation tmtil after the third day. Tender-
ness at a week, however, seemed to be a function of the injection 
itself rather than the vaccine. 
(d) INDURATION AND SWELLING: 
Induration and swelling were recorded tmder "Other" and were not 
graded for severity. _However, it is clear that these were not found 
in many people and it shows that although swelling was only found in 
association with the vaccine the attempt to use it as an index was 
found to fail. 









2 Induration 5 
3 ' In duration 6 
7 .. 
21 
( e) BRUISES: 
Bruising at the site of inoculation occurred with injections of 
both placebo and vaccine. Bruises varied considerably in size from 
small circumscribed areas less than 5 mm. across, arotmd the needle 
mark, upwards~ Some clearly stemmed from the puncture, of cutaneous 
blood vessels during inoculation. 
N.o specifications were laid down governing bruises so that the 













· Placebo W · 
1 1 0 2 
1 · · 175 
s· 4 ' ' 170 
' . ' 
3 159 




0 1 1 2 2 
178 1 1 
176 . 2 3 0.2.:>P>0.1 
, 
170 1 4· 
x 1 156 5 13 o.os>P>0.025 
186 3 
192 
' It is possible that the large incidence of bruises recorded on 
the ' third day may be partly due to the interpretation of fading and 
discoloured erythema as a bruise. With the exception of this cia¥ the 
incidence of bruises is rather evenly spread between the two inocula. 
(f) LYMPHADENITIS: 
. 
Two volunteers receiving vaccine reported a feeling of mild 
fullness in the regional axillary nose area on the .day after 
inoculation. On the same day one student in the placebo group is recorded 
as having "axillary pa.in". This might have been a similar complaint. 
Systemic Reactions: 
(a) ALLERGIC REACTIONS 
No immediate allergic manifestations occurred. Other 
dis~rders of a possible allergic nature that occurred during this part 





















1 case "itching" 
1 case "itching" 
1 case urticaria 
1 case transient rash 
There was no indication on the record cards whether any of the 
cases of "itching" were anything more than localized itching at the 
site of inoculation. Both volunteers who had urticaria suffered 
regularly :from this complaint. In the case who had vaccine the 
urticaria was mild and localized, but in the other the complaint was, 
more gener alized and involved different parts of her bocy- over a 
period of several days. 
(b) CORYZA: 
Under this heading are included all non-specific mild upper 
respiratory affections such as colds, coughs and sore throats where 






Placebo (W) Vaccine (R) 
Hours 1 
Dey- 1 4 3 
2 1 
3 1 2 
7 5 I 1 
21 15 16 
Those listed under Day 7 or Dey- 21 include all those colds 
suffered in the period since the previous inspection. For the· last 
two weeks of observation this represents an incidence of just over~; 
( c) MALAISE .AND " 'FLU": 
This section include.d all report!'s of fever or shivers an~, 
probably, would include nearly all those responses described, non-
specifically, in the literature as "syste~c reactions". 
Placebo (W) Vaccine (R) 
Hours 





Some of the complaints listed here were very non-specific and 
include, on the day following inoculation, a case of headache. Among 
those receiving vaccine at 21 days one record was of malaise and 
' .  
aches after playing rugby. 
Miscellaneous: 
• number of varied conditions were encountered. In the group 
who were given placebo there were two cases of migraine, one, 1 day 
and the other, 7 days after inoculation, one attack of paroxysmal 
I 
95 
tachycardia which came ·on during a game of squash 2 days after 
inoculation and at 21 days there was one report each of "gastric 'flu", 
Bornholm .disease and food poisoning. A female student was admitted 
to hospital with pneumonia about 2 we~ks after inoculation with placebo. 
f . e t those who received vaccine there was a report of one 
· volunteer with diarrhoea 1 day after inoculation and another case of 
diarrhoea and vomiting between the 7th and 21st days. 
General Responses: 
In . assessing the answers to the question as to. whether the vaccine 
interfered with normal activities, replies that indicated that the 
voltmteer fol.llld sleeping on the inoculated arm uncomfortable, or that 
he was glad that he had not been inoculated in the arm which he used 
for writing, were recorded as signifying interference with normal 
activities. Five complaints were received; three :from those receiving 
placebo and two :from the vaccine group. 
Trial 1 Part 2 
Inoculations in the second part of the study were carried out in 
the first }:lalf of January, 1963, two months after .those of 1;he first 
part. There ·were fewer volunteers for the second part than for the 
first. 34.2 took p~t and 267 had complete records. Three students 
joined the trial for the first time, having not received any vaccine 
previously, and 41 left. · The records of these 41 volunteers were 
studied to see whether their reactions had been worse than the average. 
Of this 41, 26 had had placebo and 15 vaccine. When the incidence 
of various reactions in these were compared with those shown by the 
volunteers who remained in the trial no significant differences were 
found. The probabilities that the reactions shown by those falling 





Pain 0.9>P:;;,,0.8 0.6 >P)'0.5 
Tenderness p = 0.088 O. 7)'P>0.6 
(In some of the probabilities chi-squared was calculated 
despite rather low values in one cell. of the , table.) 
Of those in the second part of the trial 158 were given the 
adjuvant vaccine "O" and 184 received 1.0 ml. of the aqueous vaccine "R". 
The numbers and sexes ,were divided among classes as :follows:-
Adjuvant "O" Aqueous "R" Class 
. I 
Male 20 32 . 1 
Female 5 14 
(Total 71) 
Male 25 28 2 
Female 11 11 
(Total 75) 
/ 
Male 17 30 3 
Female 9 12 
-~Total 68) 
Male 25 26 4 
Female 4 7 
(Total 62) 
Male YJ 18 5 



































0 1 2 3 
94 4 7 
29 1 
30 4 6 
8 1 
161 10 13 
89.5 3.8 6.7 
96.7 3.3 
75 10 15 
88.9 11.1 







































































10 7 P< 0.0005 
6 5 0.01 > P> 0.005 
1 I+ P = 0.062 
Only one vol'W'lteer receiving adjuvant vaccine showed erythema • 
. . 
The incidence of erythema with 1.0 ml. of aqueoua vaccine (R) in the 
second part of the trial was significantly less than with 0.5 ml. of 
the same vaccine in the first part (P< 0.0005). This did not seem to 















erythema in the second par:t of the tria.l is examined in relation to 
the inoculum received in the first:-
First Pa.rt Eryth8!1Ui in 
Second Part 
Inoculum No. No. 
' ·" 
No vaccine or placebo ''W'' 88 12 13.6 
Vaccine "R" 95 11 11.6 
This distribution could have occurred by cll&nce (0. 7'>P >o.6) , 
(The divergence in numbers of volunteers is because the 
inoculum received by one student in the first part is 
uncertain.) 
(b) !:£!!: 























non Aqueous "R tt 
2 0 1 1 2 2 
2 32 31 20 3 
1 11 18 2 2 
12 12 10 1 
2 2 
3 57 63 32 6 
















Adjuvant 11 011 
1 - 1 2 
.. 
19 .8 22. 1 
21 . 2 3.0 
40.0 28. 6 
25 25 






















2 0 1 1 2 2 
14 
-
2.3 47.6 25.7 22. 9 3.8 
2.0 40.0 40.0 16.7 3. 3 
35.0 20 ·32.5 12.5 
66. 7 11 . 1 22. 2 
1.9 44.6 26.1 23.9 5.4 




87 12. 7 
55 8.0 




Adjuvant "O" Aqueous "R." 
2 1 1 0 0 


















X 104 41+ 
120 26 
X 152 14 










o.005~ P7 0.001 
154 182 
28 158 184 
Women were more affected than men overall (0.005)7P;::,-0.001). 
Whether the volunteers had had vaccine or placebo in the first part 
had n effect upon the complaints in the second part (with "O", 
0.9::>'P>0.8; with 1'Rtt, O. 77P)"0.6). 
The aqueous vaccine gave rise to sympt ms earlier but these 
persisted longer with the adjuvant vaccine. 
(c) TENDERNESS: 
Tenderness was frequently elicited. The mode of examination and of 
scoring was as in part 1 of the Trial. H waver, examiners were warned 
to palpate for the presence of cysts or sterile abscesses, in 






































1 1 2 2 
31 20 3 
18 2 2 
12 10 1 
2 - -
63 32 6 
" 
36.0 23.3 3.5 
54.5 6.1 6.1 
34.3 28.6 2.8 
50 
39.9 20.3 3.7 
Adjuvant 11011 .: 







0 1 1 2 2 
25 48 27 5 
9 ·15 5 1 
6 13 18 3 
1 4 3 1 
41 80 53 10 
23.8 45.7 25.7 4.8 
30.0 50.0 16.7 3.3 
15.0 32.5 45.0 7.5 
11.1 41+.4 33.3 11.1 
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38 101 




























P = 0.131+ 
There was n significant difference between the results of the two 
vaccines except n the first day when tenderness was more marked with 
the aqueous vaccine. The Cumulative Percentages seem to indicate that 
the effect of the aqueous vaccine was more marked when the first three 
.days are considered. However, some degree of' tenderness was clearly 
very camn n. The greater effect n women rather than men was, in this 
case, only just discernable (0.05>P>0.025). 
( d) SWELLmG AND mmm.ATION: 
Once again, these signs were only present in those getting 
aqueous vaccine. This could probably be ascribed to the site of' 





Total records of swelling and induration: 
Adjuvant 0 Aqueo'4,S R 
H•urs ·. 
Day 1 Induration 4 
Sw~lling 2 
2 Induration 1 
Swelling 2 
3 Induration 2 
Swelling 2 
7 Induration 1 
28 
It will be noticed that indurati n at the site of inoculation 
was still present a week after inoculation. 
;, 
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( e) BRUISING: 
Bruising at the site of inoculation occurred as in the first part 
of the trial, but occurred more frequently with the adjuvant vaccine. 
. ~ 




































One case of axillary lymphadeni tis was recorded on the 3rd day. 
The volunteer had received aqueous vaccine. 
Systemic Reactions 
(a) ALLERGIES: 
Again no immediate allergic affects were noticed. All the 
cases with symptoms of a possibly allergic nature occurred in the 

















The "urticaria" above consisted of a single wheal near the elbow. 
The record card had a suggestion that this was caused by scratching. 
Both the volunteers who (after one· inoculum or another) had urticaria 
in the first part of the trial received adjuvant vaccine in the second 
without any allergic symptoms. 
' 
The volunteer who reported a rash occurring between the 7th and 




































Colds., coughs and sore throats appeared to be mor.e common ainong. 
those given aqueou:s vaccine. 
( c) MALAISE AND t1 'FLU" : 
As in the first part this group includes headache (except migraine) 
and all non-specific conditions where :fever or t1 shivers" were reported. 
Adjuvant "O" Aqueous ''R" 
Hours 1 Headache 
Day 1 1 Sore throat & shivers 
1 Headache 
1 Dizziness & malaise 
2 1 Malaise 
3 1 Malaise 
7 2 "Flu" 
28 2 "Flu" 
The student who :felt dizzy and unwell on the first day a:f'ter 
inoculation felt the same tJ:ie next day and went to bed on the third 
day. (This is recorded on all three days.) Symptoms were quite non-
specific and on examination nothing abnormal was detected. A similar 
incident had occurred some years previously in association with a cold. 
This student had had no reaction to 0.5 ml. of vaccine in the first 
part of the trial. 
(d) MISCELLANEOUS: 














afternoon after inoculation, one had sinusitis on the second day and 
a third had diarrhoea and vomiting three days after inoculation. One 
case of possible glandular fever occurred between the 7th and 28th days.· 
In the group given adjuvant vaccine, 11 011 , there were cases of 
"gastric ' flu" recorded. One occurred on the 7th and the other near the 
28th day. 
Of more direct interest, a painless , subcutaneous lump was found 
near the olecranon of an African student 3 days after she had received 
adjuva.nt vaccine. The student asserted that this had followed a yellow 
fever inoculation in that site and this had preceded the influenza 
vaccine. This lump disappeared two months after the influenza vaccine 
inoculation. In addition, one student developed symptoms of radial 
nerve irritation following the intramuscular inoculation. These symptoms 
of para.esthesiae disappeared in three days. On examination there was no 
altered sensation, nor any objective weakness. 
General Responses: 
No volunteer claimed that the inoculation had interfered with work ' 
play or social activities. Apparently, the student who had three days 
of non-specific malaise was disinclined to attribute this to the 
inoculation. 
In both parts of the trial, at the time of the final examination, 
the students were asl_ced whether they thought the inoculation was worth 
while. · 
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Placebo (W) Aqueous 
Vaccine (R) 
0.5 ml. 
( 186) , ( 194) 
801' 84.~ 
3.8% 4.81' . 





Vaccine (o) Vaccine (R) 
1.0 ml. 





There was no significant difference between the answers for placebo 
and 0.5 ml. of a-queous vaccine in the first part (0.5 >P> 0.3) nor 
between adjuvant and 1.0 ml. of aqueous vaccine in the second part 
(o.8;:,,P~O. 7). There is a significant difference between the answers 
for the two parts of the trial even when those cards without answers 
are eliminated (0.025:;::,,P~o.01). 
The reasons for negative answers were not systematically recorded. 
Some said that vaccination was not worth while because they never got 
influenza or got it so rarely. One is recorded as saying that he would 
prefer an attack of influenza to the vaccine. 
Where it was applicable volunteers were asked to compare the two 
inocula.tions ·they received. This was asked at the final examination 
28 days after the second injection. Four groupings were possible. 
-· 
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First Part Placebo Vaccine ''R" 




Better 21 28. Bf4 18 20.45% 24 28. 9% 32 33. ?fo 
Worse 29 39. 7 39 44.3 30 36.1 34 35.8 
Don't know 9 12.3 13 14.8 15 18.1 18 18.9 
No answer 
14 19.2 18 recorded. 20.45 
14 .16.9 11 11.6 
· These f'igures do not reveal significant preference for one vaccine 
or another (o. 7.>P?0.6) or even for placebo over vaccine (0.2:;:>P:;:>0.1) 
even when non-committal answers are excluded. 
In October 1963 an appeal was made to the volunteers who had ta.ken 
part in the second part of the trial to cane forward to be bled once 
more to furnish information regarding antibody titres. 30'f of the 342 
were bled. 143 had received adjuvant vaccine and 158 aqueous vaccine. 
At this time the students were questioned about reactions and their 
arms were examined for cysts, thickenings of the muscle or sterile 
abscesses that might have followed adjuvant vaccine. No such lesions 
were detected. 
Trial 2 
Several modifications were introduced into the second trial. 
1/ Because of the absence of a control vaccine and the relatively 
r 
small numbers involved it was felt that less information concerning 
reactions could be ob~ained. Therefore less stress was placed upon 
this aspect of the trial. ·Fewer examinations were made but more 
questions were asked azrd the record card redesigned to allow the 
answers to be more easily recorded (Demonstration 2). 
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Space for the recording of bruises and swelling was also provided 
(llllder "B" and "S") but several other columns were deleted. 
2/ With the reduced number of examining sessions the problem of in-
complete records did not assume the same importance. However, it was 
not always possible to see all the vol\lllteers on the correct day. 
The varied programme of duty of the nursing staff constituted a 
particular difficulty as during the trial sane were transferred to 
different hospitals and others went on night duty or on leave. One 
female medical student missed the examination at 7 days and a male 
student missed that at 28 days. 
3/ In order to avoid the possibility of inoculations involving the 
radial nerve and at the same time to retain the advantages of the 
tri'ceps site for assessing reactions, a member of the Anatomy Department 
was consulted (Dr. W.R.M. Morton) and it was decided to inject into the 
upper part of the long head of the triceps. 
Name: 
Address: 
INFLUENZA VACCINE TRIAL 1963-1964 
No. 
Age(yrs) 
Yes When last I No 
Previous influenza vaccine~~--"----~ ....... ~~~-----
Reactions 




No Yes Details 
Hindrance ], 2 3 
Loss of activity 












Demonstration 2: Card used for recording reactions
 





Volunteers were distributed in the following numbers:-
Source 











.23 ' (68) 
29 (97) 
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The examination for reactions was carried out in the same manner 
as in the previous trial but on the 2nd and 7th days after inoculation. 
At the 7th day volunteers were asked: 
1/ "Did your arm trouble you?" If the answer was in the affirmative 
an indication of the grade (slight, moderate or severe) was 
obtained and recorded. 
2/ "Did the inoculation cause you to miss any work, pley or social 
activities?" Space was le~t ·for the answer and any details. 
3/ ''Would you have this vaccine again if'· it kept inf'luenza a.wey?" 
For the event of negative answers space was left for reasons. 
Two reasons for refusing further inoculation were listed on the 
card; one being "pain" (i.e., the injection caused too great a reaction) 
and "immunity" (i.e., they never get influenza). 
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At the 28th day and at three months the sites of inoculation were 
examined for residual swellings or cysts and volunteers were asked 
about illness in the interven:tns period. 
Presentation of results: 
As the conditions of the trial are different the types of tables 
that were used in the first trial would not be suitable for the second. 
For each day of examination the distribution of reactions in grades 
is shown. The results are shown both for each category of volunteer 
and for the whole population. This is compared with the distribution 
for adjuvant vaccine in the previous trial on the same day after 















22 (95. 7) 
. 1 (4.3) 
Nurses Total 
"O" Vaccine 
27 (93.1) 93 (95.9) 141 (99.3) 
1 (3.45) 3 (3.1) 
1 (3.45) 1 (1.0) 1 (0.7) 
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No erythema was observed 7 days after inoculation. Differences in 
the incidence of erythema between "O" vaccine and that used in Trial 2 
could be due to chance (P = 0.161). 
(b) PAIN: -
The grade for this symptom was determined in the same w~ as in 
the previous trial. 
Students Nurses Total 
Male 'Female "O" Vaccine 
(Day 2) 
(68.9) (82.6? (41.4) 108 (76.0) 0 31 19 12 62 (63.9) . 
1 8 ( 17 .8) 2 (8.7) 10 (34.5) 20 (20.6) 18 (12.7) 2 
1 6 (13.3) 2 (8.7) 
I 
6 (20. 7) 14 (14.4-) 15 ( 10.6) 
2 1 (3.4) 1 (1.0) . 1 (o. 7) 
3 
(Day 7) J 
0 45 22 28 (96.6) 95 (99.0) 154 
1 
2 ' 
1 1 (3.4) · 1 (1.0) 
2 
3 
The overall results on the 2nd day are comparable with those found 
with the adjuvant vaccine 11 0" in the first trial (0.2>P>0.1). However. 
when the nurses are considered they show significantly more reactions 




The great majority had no complaint at the examination at 7 days. 
(c) TENDERNESS: 




0 26 (5.7.8) 12 (52.2) 17 (58.6) 55 (56.7) 76 (53.5) . .. 
1 7 (15.5) 7 (30.4) 9 (31.0) 23 (23.7) 47 (33.1) 2 
1 12 (26.7) 3 (13.0) 0 15 (15.-5) 14 (9.?) 




0 45 22 26 (89.7) 93 (96.9) 152 (98.7) , 
1 1 (3.4) 1 ( 1.0) 2 ( 1.3) 2 
1 2 (6.9) 2 (2.1) 
·2 
3 '. 
The incidence of tenderness on the second day was comparable 
within the three categories of volmiteer (0.9>P>0.8) and slightly, 
but no significantly, lower than :f'omid with "O" vaccine (0.2>P>0.1). 
However, it will be seen that the proportion graded as 11 1" or "2" 




The _severity of bruises was scored from f - 3 according to the . . 
I 
examiner's opinion. 




t:> 0 42 (93.3) 20 (87.0) 21 (72.4) 83 (85.6) 134 (94.4) 
1 2 (8.7) 2 (2.1) 3 (2.1) 2 
1 2 (1+.4) 1 (4.3) 5 (17.3) 8 (8.2) 4 (2.8) 
2 1 (2.2) 3 ( 10.3) 4 (4.1) 1 (o. 7) 
3 
Day 7 
0 45 22 22 (75.8) 89 (92.7) 151 (98.1) 
1 1 (3.5) 1 (1.0) 1 (o.6) 2 
1 5 (17.2) 5 (5.2) 2 ( 1.3) 
2 1 (3.5) 1 (1.0) 
3 
Here again the significant difference between the · "O" vaccine and 
the current trial (0.025 >P>0.01) was caused by the high incidence of 
bruises found in the nurses. The student group showed only a slight 
excess in incidence and this was not beyond the bol.ll'lds of chance 
occurrence (o.4>P>o.3). The persistence of the nurses' bruises was 
surprising. 
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( e) SWELLING-: 
visible swelling was seen in the case of three nurses
 and three 
I· . 
medical students, ( two o_f these being, females). Unlik
e the bruising this 
did not persist to 7 days. · 
· (f) MISCELLANEOUS: 
One nurse reported mild regional lymphadenitis 2 days
 after 
inoculation and one felt her a.rm ache when she lifted
 it. At 28 da37's 
' 
another nurse reportea that the inoculated arm still 
felt stiff. On 
examination nothing was found locally nor was there l
imitation of move-
ment. 
(g) SUBCUTANEOUS NODULES: 
At the examination at 28 days ' after inoculation, four vo
lunteers, 
two nurses and two female medical students, were foun
d to have subcutaneous 
nodules at the site of inoculation. These nodules we
re fairly well 
defined, separate from the skin and the muscle and we
re slightly tender 
on pressure. They were all first noticed by the volu
nteers about 2 
weeks after inoculation. The nodules varied in size 
from about 2 x 1.5cms. 
to 1 x 1 cm. 
These volunteers were followed up at intervals of a m
onth. The 
nodule, in one nurse, had disappeared by two months a
fter inoculation. 
In the other three volunteers the nodules regressed s
lowly. Six months 
after inoculation the lesions were barely detectable 
in two cases and 
very small in the third. Some residual t~nderness wa




With the possible exception of a localized "rash" at the 
inoculation site reported at the 28th day no allergic manifestations 
were observed. 
In the immediate post-inoculation phase one female medical 
student reported feeling faint for f - 3 hours after inoculation and 
a nurse reported a cold starting the same evening. Rather later were 
two complaints of nausea, with vomiting in one case, starting 26· - 36 
hours after inoculation. In one case, home contacts who had not ·been 
inoculated also had the same symptoms. One nurse reported the onset 




Day 2 1 cold 
Days 2 - 7 1 cold 2 colds 
1 faint during 
hockey 
Days 7 - 28 1 "gastric 5 colds 
'flu" 1 "'flu" 
2 '" flu" 1 bronchitis 
Days 28 - 90 1 cold 3 colds 
1 bronchial catarrh 
1 "' flu" 
Although there are a number of complaints no clear-cut pattern of 
systemic reactions emerges. The nurses seemed to have more colds than 
the students. The nurses might be more exposed to such infections in 
the course of their occupation. 
General Responses: 
On the 7th day after inoculation all volunteers were asked:-
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(1) Whether their arm troubled or hindered them. Of 96 questioned, 
87 (90.61&) answered "No", and 9 (9.4%) answered "Yes". All these 
9 were females and 8 were nurses. All graded the amount of nuisance 
as "slight" ( Grade 1 ) • 
(2) Whether the inoculation caused any, loss of work, play or social 
activity. No one reported that activities had been curtailed. 
(3) Whether they would have the inoculation again if it kept 
influenza away. 94 (97.9%) said they would, 2 (2.1%) said they 
would not. Both these were male students and the reason given 
in both cases was that they never got influenza. 
Reactions 
Animal Expe riments · 
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Because sub-cutaneous nodules develOJYed in a 
proportion of the volunteers in the second trial after 
adjuvant a number of experiments were· carried out on 
monkeys to examine the histology at the site of 
inoculation of adjuvant and aqueous · vaccines. Many 
studies of the reaction about oily adjuvants have included 
Mycobacterium species _in the adjuvant, have used reagents 
that woula. not be acc·eptable for use with current vaccines 
or have employed large volumes of inoculum (Friedewald, 
1944, Freund, Thomson, ' ommer, alter and Pisani, 1948 , 
Moore , Lamm , Lockman and choenberg , 1963 . 
Rhesus monkeys (Macaca mulatta , which were being 
used as a source of ~idneys for tissue culture, were uaed 
and they were inoculated, sometimes at s.everal sites during . 
the course of the exp.erimen t, ¢ th O. 25 ml. doses of 
adjuvant vaccine, as used in the · second trial, or 1.0 ml.. 
of aqueous vaccine nR". The injections were timed so that 
when the second kidney · was removed the heavil.y 
anaesthetized animals were perfused through the heart, 
first with isotonic saline and then with 10~ formol-s.aline. 
pecim~ns were taken for histology as require4 and fixed in 
5% formol-aaline. Blocks were · cut and processed anQ 
· paraffin sections were S}ained with haematoxylin and eosin. 
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1. 
The stained sections were prepared by Mr.- J .A • . Re'id 
F.I .M.L.T., of the Histopathological Laboratories of the 
Royal Victoria Hospital. 
Adjuvant Vaccine 
In the case of the adjuvant vaccine the pattern at the 
site of inoculation evolved slowly and a number of 
apecimens were studied. 
1. Intramuscular inoculation. 
Two day-s after inoculation the inoculum was aeen 
to have spread between the muscle bundles forcing them 
apart. The . oiJ.y material, . ., 1 naturally, disappeared during 
processing of the preparations and left spaces. However , a 
patchy cellular reaction was just appearing i .n the 
connective tissue around the drops of inoculum. 
osinophils, macrophages and lymphocytes were the pre-
dominant cell types and polymorphs were only rarely aeen 
(Figure l). 
In a specimen taken 7 day-s after inoculation, the 
cellular reaction around the oil dropleta, scattered over 
an area of 8 x 4 mm., had not progressed much but localised 
.areas of degenerating muscle fibres were seen (Figure 2). 
As this degeneration waa not observed all around the drop-
lets it was probabJ.y related to pressure rather than toxic 
effects of the vaccine. 
By 14 day-s a fully developed cellular reaction 
' 
was present. The drops of inoculum were surrounded by a 
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Figure 1. Two days a~ter inoculation of 
adjuvant vaccine intramuscularly. (x ~40) 
Figure 2. Degeneration of muscle fibres. 




leyer of eosinophils and.. lipoid-filled macrophages (Figure 
3). Flasma cells occurred in localised areas rather than 
,.. 
diffusely. Fibrosis was commencing between the areas of 
reaction around the drops of oil. Foreign body giant 
cells were seen and oc.casionally were prominent (Figure 4). 
A section of a specimen take~ 52 deys after 
inoculation shows that although the oil ·droplets are s.tilJ.. 
present, if reduced in size, the re-action has largely died 
down and fibrosi_s is. prominent '(Figure 5). 
2. Sub-cutaneous inoculation: 
As young momkeys lack a well~developed sub-
cutaneous tissue ·it is more difficult to reproduce the 
picture seen _in man. However, by 14 deys after inoculation 
a palpable nodule was present under the skin and on section 
measured 10 x 6 mm. Histologically, the picture was 
similar to that seen in the intramuscular site with the 01.l 
droplets surrounded by a mononuclear cell reaction but was 
in a more localised area (Figure 6). 
By 52 deys a similar lesion presented a firm 
nodule. Microscopically, the area had shrunk and the 
reaction around the persistent oil drops had receded. The 
sub-cutaneous tissue was swollen vvith fibrous tissue which 
was much infiltrated with lymphatic channels (Figure 7). 
3. Regional nodes: 
In· two cases the regional nodes were examined 
~wo weeks after inoculation. In one of these the nodes. 
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Figure 3. Vellular reaction surrounding oil dropleta 
of adjuvant vaccine. 
(X 120) 
Fourteen d03"s after inoculation. 
Figure 4. Foreign-body giant cells near oil droplet. 
Fourteen d03"s after inoculation. ( 240) 
Figure 5. 52 days after the inoculation of 
adjuvant vaccine intramuscularly. (X 120) 
Figure 6. Sub-cutaneous area, 14 days after 
~noculatio,n o':f adjuvant vaccine. (X 38) 
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Figure 7. ub-cutaneous area, 52 da.vs after 
inoculation of adjuvant vaccine (x 30). 
Figure 8. ub-cutaneous area, l day after 
inoculation .with aqueous. vaccine (x 240). 
12 D 
were a little swollen compared with those on the 
uninoculated side and reactive germinal centres were seen 
with any characteriatic changes. 
Aqueous Vaccine 
Aqueous vaccine produced a ver.1 different and 
much more transient type of response. ·one day- after sub-
cutaneous inoculation of aqueous vaccine t he tissues we.re 
.> 
swollen and oedemations and profusely infiltrated with 
polymorphs (Figure 8). This reaction also was visible 
between the underlying muscle bundlea. 
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CTION C 
- - - -
INFLUENZA ANTIBODY ~SPONSES 
The antibody response to the doses of vaccine given 
was determined by tests on sera taken from the volunteers 
as has been indicated above. The work was carried out in. 
three main sections. 
Trial l 
Group A 
In this section the sera taken before and 21 or 28 
days after the two inoculations were examined. Thus, 
there were four sera each from those volunteers who had 
taken part in both parts of the first trial and two aera 
from those who only attended one part of the trial. The 
period of surveillance after the inoculation in the first 
part of the trial was shorter because at this time only 3 
weeks were available before the students departed on 
vacation. 
All the sera were examined by the Haemagglutination 
Inhibition (H.I.) test and a proportion of the sera were 
also t~sted for neutralizing antibodies to the same 
viruses as were use·d in the H.I. tests. 
Group B · 
Here the sera that were taken 9-10 months after the 
second inoculation were tested. The previous two sera of 
1 ') -; tJ .&. 
each volunteer were tested at the same time to establish a 
base line. 
In addition to the two main influenza virus strain 
presenu in the vaccine many of these sera were tested by 
H.I. against a spectrum of d~fferent influenza viruses. 
(NOTE: Groups. and B of ~ri al 1 alluae to the way in 
which uhe a.b.1iibodyf_studies were divid.ed and are 
different to the ~arts I ana II of the Trial 
i tself . ) 
2:rial 2 
From the volunteers in the second Trial sera taken at 
the time of inoculation and ~ne month and three months 
after inoculation were available. These sera were tested 
by H.I. against a number of different strains of 
influenza virus. 
Materials and Methods 
Sera 
The bloods, when taken, were labelled with the name of 
the volunteer and the date. However, the separated sera 
we r e labelled , in addition, with the volunteer's number 
(between land 433 in the first trial and 501 anct 629 in 
the second - as the system was only partly consecutive) and 
a letter s i gnifying the time of bleeding. These code 






2l days after inoculation 
art II 
Pre-inoculation specimen 
28 days after inoculation 





One month after inoculation 


























As the sera of Trial 1, Group A and of Trial 2 were 
also tested for blood group antibodies the letters were 
chosen to avoid confusion with those commonly used in 
haematological practice. Unfortunately, this caused the 
letter "Vi" to refer to the first serum of Trial 1 as well 
as to the Placebo vaccine. 
Hameagglutination - Inhibition Test 
• 
The technique of the test and of the treatment of 
sera to remove non-specific inhibitors is described in 
Appendix 2. 
13 !; 
Ordering of the test 
1. In each section of the work all sera from a person 
were tested against any one virus at the same time so that 
any pattern of change of titre would not be affected by 
day-to-day variations in the test. 
2. Specific immune sera prepared in animals (Appendix 3) 
were included in all tests but titres were not adjusted 
from the results obtained from these controls. If the 
titres of the standard sera showed that the test done on a 
day was unsatisfactory the day's work was repeated . 
. 
3. While testing for antibodies to A/Singapore/L/57 and 
B/Bngland/939/59 in Trial 1, Groups A and B sera were 
tested against both viruses on the same day. In Trial 1, 
Group B other antigens were tested against only a limited 
number of sera and here, as in Trial 2, it was possible to 
test all the sera involved against any one antigen on the 
same day. 
4. Sera were tested in numerical order so that during 
the test there was no indication as to what vaccines had 
been administered to the volunteer conce~ned. 
Vaccine groups 
In Trial l four different inocula were given, two in 
November, 1962, and two in January, 1963. As a result the 
volunteers fell into different groups by virtue of the 
yaccines received. The inocula used were:-
November , 1962 1/ Placebo 0.5 ml. w. 
2/ Aqueous vaccine 0.5 ml. R' 
' January, 196 3 1/ Adjuvant vaccine 0 .25 ml. 0 
2/ Aqueous vaccine 1.0 ml. ~ .. R 
(The aqueous vaccines were identical bu~ R' sign~fies the 
0.5 ml. dose as distinct from the 1.0 ml. dose which is 
designated R. ) 
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' Therefore, the following vaccine groups were possible:-
W - received only placebo 
" " 0 . 5 ml. of aqueous vaccine 
WO Placebo in Part I followed by adjuvant vaccine in 
Part II 
WR - Placebo in Part I followed by aqueous vaccine in 
art II 
R'O - 0 .5 ml. aqueous vaccine followed by adjuvant vaccine 
R'R - '' " " " " "1.0 ml. aqueous 
vaccine 
Numbers 
The numbers of sets of sera examined in any vaccine 
group is not necessarily identical with the numbers of 
volunteers as shown in the section on vaccine reactions. 
" This is because the titres of sera in the first trial were 
onl31 included in the results when specimens before and 
after vaccine were available for comparison and when there 
was no doubt as to the vaccine received. A few sera were 
lost in laboratory accidents, e.g., tubes breaking in the 
centrifuge. In certain cases sera became short after 
repeated tests of various types and thus could not be 
tested against all the antigens. 
Presentation of results 
Results are generally presented in the form of . 
histograms showing the distribution of antibody titres 
and in graphs made up comparing the Median titres of sera. 
The Geometric Mean Titre (G.M.T.) is more frequently used 
and is both more sensitive and provides a better 
representation (Hirst et al., 1942 b). However, the 
Median Titre was used in the present work because, with 
some antigens, the number of titres found to be less than 
the lowest level of test would have produced a G.M.T. less 
than the level of test and hence quite invalid. 
The histograms also show the median. titre of each 
batch of sera tested. fuere this could not be shown for 
reasons of space the value in each case is less than 10. 
With each histogram a scale indicates the numbers of sera. 
However, with most of the influenza B antigens there were 
so many sera with titres of less than 10 that, where 
necessar.v, the width of this column had to be doubled and, 
therefore, in these double width columns the numbers of 
sera are twice that indicated by the- scale.· 
In the graphs the points depicting the median titres 
are joined by lines. These lines are included purely for 
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demonstration purposes: They do not ·attempt to indicate 





The titres of sera taken before and 21 days after the 
administration of Wand R' vaccines are shown in Figures 9, 
10 and 11. In thes·e and the following diagrams titres are 
expressed as the reciprocal of the serum dilution. 
Results are grouped in two-fold steps so. that columns 
marked, say 10 , include titres from 10 to 19. For the 
median values the interpolated titres are used . From 
those receiving placebo ( ) 181 pairs of sera were tested 
and 190 pairs from volunteers injected with R'. 
It is clear from the figures that whereas the placebo 
has not been associated with a general rise in titre, 
vaccine R' has caused a marked rise in titre. However , 
there is a sharp quantitative difference between antibody 
to A/Singapore/1/57 and B/~ngland/939/59 . The titres to 
. 
influenza Bare general y at a lower level and a very 
large proportion of sera have an initial level of less 
than 1:10. In addition, of the 101 volunteers receiving 
R' who had pre-inoculation H.I. titres to B/ ngland/939/59 
of less than 1:10, 25 did no~ respond to produce antibody 
detectable at this level. The proportion of "non-converters" 
is the same with the .influenza 
vastly different - 2 out of a. 
strain but the numb rs are 
A /SINGAPORE/ I/ 57 




Figure 9·. Histogram of antibody response in 
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Figure 11. Gr~ph of median titres during Trial i. 
Broken lines inaicate response after adjuvant vaccine. 
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.t'art II 
rom this part of the trial 15~ pairs of sera were 
available from those who had received adjuvan t and L83 
from t hose who were given aqueou vaccine in the second 









~ three volunt eers who only joined the trial at this 
stage · were counted as having received placebo ( ). 
Fi ure l shows that in the intervening month there 
no great change in antibody levels. This figure and 
Figures 12 and 14 show th~ the vaccines both produced a 
clear antibody response in those who previously had 
placebo. The adjuvanted v~ccine, containing but one-fifth 
the amount of anti gen present in 1.0 ml. of aqueous 
vaccine, R, has produced comparable titres to A/Singapore/ 
1/57 (0.3 > P 4> 0.2) but with influenza l3 the titres are 
-
distributed at a significantly lower level (0.025 '>P > O.Ol). 
In both cases, WO and . WR, the sera before inoculation were 
comparable. 
The median titres that result from this inoculation 
are not very sharply different from those conferred by R' 
which had only one-half the antigen given with R'. 
Regarding the "convel;'sion" of those with no antibody 
14 2 
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Figure 12. Antibody response in Trial 1, 
Part II, following an initial inoculation of placebo. 
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gure 13. Antibody response in Trial l, Part II, 
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Figure 1.4. tibody response in Trial. 1, Part II, 
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,Figure 15. Anti body response in Trial 1, 
Part II, following 0.5 ml. of aqueous 
vaccine initially. 
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to the influenza B str,a.in detectable at 1:10 before 
inoculation, one-third (lb of 48) of those receiving 
~ 
adjuvant had not shown antibody by 28 days after 
146 
inoculation but only one-fourteenth (4 of 55) of those 
receiving aqueous vaccine had not converted. This 
difference is significant (O.OOl > P > 0.0005). To a 
smaller extent the same is true with influenza where, in 
response to "0" vaccine 4 of 8 converted (50%) but 10 of 
13 (77%) showed antibody with "R" vaccine (P = 0.345). 
When the group receiving R' vaccine in the first part 
is considered in Figures 11, 13 and 15 it is clear that no 
clear secondary response, in the usually accepted sense, 
has occurred. The degree of rise of antibody level is 
small and in the case of influenza B there is no difference 
between the types of vaccine used. However, with influenza 
' A a higher median titre has ·been produced by the adjuvant 
' vaccine and the significance. of the degree of difference is 
confirmed when the distribution of the titres of those in 
the two vaccine groups are compared (0.005 > P > 0.001). In 
addition, the apparent efficacy of vaccines in causing 
"conversion" is reversed, with "0 11 p.roducing detectable 
~tibody in h9 of 13 (70%) and "R", 7 of 17 (41%) but the 
,. 
difference is not significant . (0.2 ~ P :::,--O.l) . 
After the titrations of Group A had been completed it 
was clear that the titres of antibody to B/England/939/59 
were abnormally low in ttose volunteers whose sera had 
been tested in the first weeks. It was shown that this 
14 7 
was due to a technical error when the same sera were tested 
during Group Band the titres compared. s a result all 
the titrations of B/Jmgland/939/59 in Group A were repeated 
and this time the titres were of a similar order throughout 
and corresponded with those obtained in Group B titrations. 
The results shown refer to the repeated titrations. A 
number of attempts to discover the cause of this 
discrepancy, involving the use of different batches of 
antigen to test for avidity, were unsuccessful. 
~all 
Group B 
In this section of the work the sera obtained in 
October/November, l9b3 (i.e. "B" sera), from those who had 
taken part in the second half of Trial land had received 
either adjuvant vaccine or 1.0 ml. of aqueous vaccine were 
compared with the Y and Z sera of the same volunteers in 
parallel titrations. 
301 sera were obtained from the 341 volunteers 
eligible. It was not possible to trace the rest. ome 
had left the university and others were working in 
different hospitals . Those volunteers who were bled were 
distributed among the vaccine groups as follows:-
Number 














Relatively more of those who had received adjuvant 
vaccine were bled. Although this distribution falls 
outside the chance level (0.05 > P > 0.025) it is difficult 
to know which factors could be blamed for this. To 
attribute it, say, to differences in reaction between the 
vaccines received months earlier would be presumptuous. 
All these sera were tested for antibodies to 
A/i ingapore/l/57 and :S/Engla d/939/59. The sera of 







Parainfluenza 1 (Sendai). 
-
These additional tests were done to examine for the 
greater antigenic spread attributed to adjuvant vaccines, 
to test whether there was any "recall" of antibodies to 
~ . 
past strains of influenza no longer prevalent and to 
examine whether the effect of adjuvant vaccine was 
related to any non-specific effect on antibody production 
14 9 
as might be suggested by the work of Neeper and Seastone 
(l9b3). One of the volunteers in vaccine group WO had to 
be excluded from the tests against additional antigens 
owing to the depletion of his "Z" serum by haematological 
tests. 
As the decision to test against B/Lee/40 was 
stimulated by the results of later work when the treated 
sera were exhausted and there was only a limited amount of 
cholera filtrate available it was necessary to remove 
inhibitors from som~ of the sera by the trypsin-periodate 
method (Appendix 2) and this required special 
representation. 
Part of the sera falling into vaccine groups R' O and 
R' R were tested against /.PR-8/34 and A/Swine (Shope 15) in 
order to test the effect of the vaccine on antibody to 
these old antigens. With some of these tests pigeon cells 
were employed in parallel with chicken red cells to 
exploit the greater sensitivity (Berlin, McQueen, Minuse 
and Davenport, 1963) of the former. 
It was not thought worth while to test the sera 
against the strain A/England/l/61, although it was 
-
incorporated in the vaccine, both because it is so closely 
related to A/ ingapore/1/57 and because this strain seems 
to have been an off-shoot from the main line of evolution 
of the sian ( 2) set of viruses and has not occurred 
elsewhere since (Pereira H. G., 1963). 
15 0 
. Resulta 
The results from tests with A/Singapore/1/57 re 
shown in Figures lb, 17 and 18 and those with B/.Jmgland/ 
939/59 in Figures 19, 20 and 21. In the graphs , broken 
lines connect the median titres in the vaccine groups 
receiving adjuvant vaccine. 
With influenza the titres achieved with adjuvant 
vaccine are clearly superior at the 9-10 month mark, both 
in the group which had received placebo and that which had 
had a preliminary dose of vaccina, R'. This superiority 
is reflected in the median titres and the distribution of 
the numbers of sera among the levels of antibody were 
significantly different (for WO/WR 0.01> P> 0 .005, and for 
R' 0/R' R, < . 005). 
Regarding antibodies to influenza B, the superior 
duration of effect of adjuvant vaccine i~ once more 
apparent although the difference between the vaccine 
groups '/0 and WR shown in the distribution among titres is 
within the limits of chance ( 0. 2> P > 0 .1). The graphs 
also show that the influenza B antibody response to 
a.djuvant vaccine is delaJ7ed, compared with that of 
influenza A. 
i th both viruses the serum titres of· a number of 
volunteers receiving aqueous vaccine had fallen to levels 
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Figure i. Graph showing persi tence of antibody 
titres after 9-10 months. 
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Figure l7 . . The persistence of antibody titres 
following a single inoculation of vaccine. Trial 1. 
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Figure 1.8. , The persistenc~ of antibody titres 
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Figure l9. Graph showing persistence of antibodies 
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]?.gure 20. Fersiatence of antibody levels 
after one dose of vaccine. Trial 1. 
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Figure 21. PePsiatence of antibodies following 
two doses of vaccine. Trial 1. 
156 
and antibody to influenza B this tendency is actually 
reversed showing that some people "converted" more than 
-
four weeks after receiving vaccine and their antibody 
remained at detectable levels for the remaining months. 
Titrations of other strains of influenza A 
15 7 
From Figures 22 and 23 it is clear that titres to the 
Asian variant A;Netherlands/65/63 were closely parallel to 
- ~ ' I 
these of the vaccine strain and Asian prototype, 
Aj; ingapore/l/57. This occurs with both vaccines. 
However, Figures 22 and 24 show that neither vaccine haa 
any effect upon antibodies to the A1 family prototype, FM1 . 
The results of titration of the R'O and R'R vaccine 
groups with A/.PR-8 and Aj; wine antigens are shown in 
Figure 25. In group R'O the sera of 31 volunteers were 
-
tested against A/PR-8 and 28 against A(: wine and in group 
R'R the numbers were 35 and 31 respectively. All the 
various classes of the students were represented in all 
groups but no specific randomising procedure was adopted. 
There was no indication that two inoculations of the 
vaccine recalled antibodies from a significant number of 
people nor is there evidence that the second inoculation, 
of either vaccine, caused more than a minimal increase of 
antibody in those who already possessed it. The three 
people who showed antibody to A/Swine were born in 1934, 
1936 and 1941. Two of these were African students. Only 
f-------------------------------~ ' l A/SINGAPORE/1/57 
FM1 
JAN. MAY OCT. 
Figure 22. G.raph showing effect of, vaccines on 
antibody to various. influenza A antigens. Trial l. 
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Figure 23,. Distribution of titres of an ti body 
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Figure 25. ·Distribution of titres of antibody 
to /FR-8 and Aj; wine strains. In all cases 
the median titre was less than lO. 
16 2 
one had antibody to A/PR-8 as well. 
Much more antigen was needed to prepare 8 H .• uni~ 
antigen for pigeon cells than for chicken cells. Pigeon 
cells, and the special antigen for it, were used with 
about half the sera titrated wlth each antigen. 
The sera of oO volunteers were tested with pigeon 
cells, half against /.PR-8 and half against A/Swine. In 
those casea where antibody had been detected using chicken 
red cells rather higher titres were obtained ~th pigeon 
cells but there were exceptions to this. The use of 
pigeon cells failed to reveal any reaction to the vaccines 
which the tes.t with chicken cells did not. 
Titration of antibody to other strains of influenza B virus. 
With the influenza B strains a rather different 
situation was observed. From Figure 26 and the histograms, 
Figure 27, it appears that the vaccines, cpntaining 
B/England/939/59, caused a rise in antibodies to B/e-ngland/ 
10/54 but that with adjuvant vaccine this rise seemed to be 
more transient than that to the homologous strain. In 
fact, the antibody to B/England/.L0/54 induced by both 
vaccines behaved like that to B/ ngland/939/59 produced by 
ag_ueous vaccine. However, ant:Lbodies to B/Taiwan/4/62 and 
B/Lee/40 (Figures 28 and 29) were affected to a much 
smaller extent. 
With B/Lee the antibody titres found in the sera 
inactivated by trypsin and periodate were slightly higher 
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Figure 26. Graph ahowing response of antibody to 
different strains of influenza B virus. To simplify 
the graph that line relating to the B/England/939/59 
antibody response to aqueous vaccine has been 
omitted. Trial 1. 
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Figure 27. Histogram showing response of 
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,Figure 28 . Histogram showing response of 






















Figure 29 . Histogram showing response .of antibodiea 
to B/Lee. he results from sera inactivated with 
Cholera filtrate and Trypsin-periodate are shown 
separately. In all cases the -median titres were 
less than 10. Trial l. 
166 
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than those from sera inactivated with cholera filtrate. 
This unexpected result could possibly be related either to 
incomplete removal of inhibitors in the one case or to the 
destruction of antibody in the other. In selecting sera. 
for one mode of treatment or the other an attempt was made 
to sp~ead each equally among vaccine groups and student 
classes. However, no specific means of randomisation were 
employed. It was, therefore, not possible to combine the 
results although the same general tendency, of showing 
only a slight response to the vaccine, was the same for 
sera treated in either manner. 
ara-influenza 1 ( endai}. 
,. 
As shown in Figure 30, neither vaccine affected the 
an ti body titres to Para- influenza J. al though, not 
unexpectedly, more than half of the volunteers had 
demonstrable antibody to this virus. 
Trial 2 
For the influenza antibody investigations of Trial 2, 
sera taken before inoculation and three months after 
inoculation were available from 97 volunteers but one· 
volun-teer;. was not bled at the session one men th after 
vaccination. In addition, so little blood was obtained 
from one student thr~e months after inoculation that there 
was insuffiodent material to titrate it against all the 
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' Figure 3 • Histogram showing the effect of the 





incorporated in the data throughout. 
In the graphs of this trial broken lines do not 
signify a particu:J.ar vaccine as all the volunteers 
received the same adjuvant vaccine. However, different 
patterns of lines were used fo
1
r different strains of virus. 
Results 
The graphs, igures 31 and 34 show t hat in respon e to 
adjuvant vaccine the an~ibody titres continued to rise 
after a month . 
From Figures 31 and 32 it would seem that the 
relation between the two variants of the ian et of 
virus es i even more apparent. The titrations against 
A/Netherlancts/05/63 were twice repeated and gave the same 
result. 
Although the titres of antibody to A/!M1 , shown in 
Figures 31 and 33, appear to be at a higher level than in 
Trial 1 - either because of the different population or 
because of an increased sensitivity of the test - the 
general result is unchanged . The vaccine had no 
appreciable effect upon the antibody to this viru. 
The results obtained with strains of influenza B, 
shown in Figures 34, 35 and 36 differed fairly markedly 
from those in the first trial . With B/En land/.l.0/54 the 
fall in titre after ·an initial rise , demonstrated in the 
first trial, is not shown although the differences 
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·Figure 31. Graph showing response of antibody to 
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' Fi,gure 33 . Histogram showin distribution of 
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Graph of response of antibody to 
various strains of influenza B virus. Trial 2. 
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'& / ENGLAND/939 /59 B /E NGLAND/10/54 
Figure 35. Histogram showing distribution of 
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:E:igure 3 b • Histogram showing distribution of 
antibody titres to B/Taiwan/4/b2 and B/Lee . 
Trial 2. 
17 
the difference in times . of collection of the serum 
specimens. The titres to both B/ ngland/939/59 and 
B/England/10/54 rose to greater levels than might have 
been suspected from the results obtained in the first 
trial. 
17 6 
Antibodies to B/Taiwan/4/62 and B/Lee/40 are both 
' ' clearly affected by the vaccine, in contrast to Trial 1. 
As this is hewn at one month also this difference is 
probably valid. 
The vaccine used in Trial 2 contained a new component 
in B/Taiwan/4/62, which differed fairly markedly from the 
previously prevalent virus. It is possible that when a 
volunteer already had antibody to B/England/939/59 a 
vaccine containing both this antigen and the new B/Taiwan 
might stimulate the formation of antibodies to the old, to 
the exclusion of those to the new strain, B/Taiwan. 
When the post-inoculation sera of those volunteers 
(24 in number) who had antibody to B/Bngland/59 before 
inoculation and none (at a 1:10 level) to B/Taiwan were 
compared with the post-inoculation sera of those 64 
volunteers who had antibody to neither virus before 
inoculation it was found that the median titres of B/Taiwan 
antibody were higher in the former group. 
• Median titre to B/Taiwan/4/b2 
at 1 month 







When the distribution of titres is studied there is 
no significant difference between the groups • . (For sera 
collected 1 month after inoculation 0.4> P > O.J; for 
those taken at 3 months O. 3 > P > o. 2) 
This does not provide evidence .that the formation of 
B/Taiwan antibody is suppressed by the presence of pre-
existing B/ ngland/59 antibody. 
Neutralization Tests 
Neutralization tests were carried out to determine 
the relation between the titres obtained by this method 
and by H.I. tests and, in particular, to discover whether 
the low ·titres to B/England/939/59 were caused by the low 
avidity of the test strain of virus rather than being a .. 
true reflection of the antibody present initially and 
after vaccination. 
s a result the sera tested - all from Trial 1 - were 
not selected at random but mostly to test the validity of 
low titres. 
-------------------------~~~-~-__...::~.,,,,__ ___ ____ 
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One hundred and forty-seven sera from 37 individuals 
were tested with A/ ingapore/1/57 and 419 sera from 105 
peopla with B/England/939/59. In order to conserve tissue 
-cultures an attempt was made to select likely dilutions by 
extrapolation from the H.I. titres. It was expected that 
the neutralization titres would be higher. This 
prediction was not always successful and thus some results 
were obtained only .as "more than" or "less than" the 
nearest dilution tested. 
The results are presented in the form of diagrams of · 
points comparing the neutralization and H.I. titres of the 
same serum. Where a neutralization titre has to be 
expressed as "more th.an'' or "less than" an arrow points in 
the appropriate direction. Where there are several sera 
in this situation the number involved is ringed. 
The method of the test is sh.own in Appendix 4. 
Figures 37 and 38 represent the results with 
A/Singapore/1/57 and B/England/939/59 respectively. In the 
former there is a fairly clear relation between the 
neutralizing and H.I. titres. A few sera that showed no 
antibody with H.I. had detectable neutralizing antibody. 
In general, the titres of neutralizing antibodies were 
found to be rather higher. However, titres of neutralizing 
antibody were read from the final serum dilution (i.e. in 
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Figure 37. Diagram comparing titres of H.I. and 
n utralizing antibody to /: ingapore/l/57 found 
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. Figure 38. Diagram comparing titres of H.I. and 
neutralizing antibody to B/ glana/939/59 found in 
the same ser . 
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read at the level of the initial serum dilution. 
In the case of the influenza B strain t he relation is 
less clearly shown, partly because the readings are so 
much more concentrated at the lower end of the scale. 
However, there is a fair measure of agreement. If those 
sera with an uncertain titre are excluded, each test shows 
an approximately equal nwnber of less than 10 readings 
where positive results occur with the other test. 
Certainly, the results seem to indicate that the H.I. 
titres generally represented true readings and that the 
results were not artificially depressed by the use of a 
non-avid strain in the H.I. tests. 
18 2 
E TION D 
RESPON ES OF ANTIBODY TO GROUP A SUBSTANCE 
As the article by Springer and Tritel (1962), which 
stimulated this section of the study , only came to view 
after the start of the first trial any investigations to 
examine the effect of the vaccines on antibodies to Group A 
substances had to make use of stored sera. In view of 
this, and the fact that Springer and Tritel had 
investigated anti-A isoagglutinins, it was decided to 
examine the sera collected during the first trial to find 
the effect of the vaccines upon these antibodies. As a 
result of the findings further investigations were carried 
out on a limited number of the sera. 
Because it was felt desirable to examine for the 
presence of antibodies that were associated .with 
immunization with Group A substance it was decided to test 
sera obtained in the second trial for the presence of 
anti-A1 haemolysins. Because of the high proportion of 
normal sera that contain anti- 1 lysins (Lockyer and 
Tovey, l9b0) and because of the apparent association with 
AB haemolytic disease shown (Tovey, Lockyer, Blades and 
Flavel, l9b2) with the presence of lysins to certain pig 
t • 
erythrocytes, tests for lysin active ainst P. cells 
( aison, oo win and oomba, 1955) were also set up. 
In addition, blood specimens were collected from 
18 
patients attending the asualty Department of the Royal 
Victoria Hospital, before and 10-30 days after they had 
received prophylactic doses of anti-tetanus serum (A. T. • ) • 
It has been shown that haemolysins to A1 cells (Crawford, 
Cutbush, Falconer and Mollison, 1952) and P cells 
(Lockyer, 1963) are stimulated by certain batches of thia 
substance and it was felt that the sera from these 
patients would act as a check upon the sensi ti vi ty of the 
test procedures used. 
Programme 
Trial 1 
1. Blood was taken for grouping from all volunteers in 
the second part of the trial. 
2. The sera of all Group O and B volunteers from whom 
four serum spe.cimens (W, X, Y and Z.) were available were 
examined for the titre of anti-A1 saline isoagglutinins. 
3. Of these volunteers, all that showed more than two 
fold rises of titxe of iso-agglutinins, all that showed 
traces of haemolysis during iso-agglutinin titration and 
others that showed high iso-agglutinin titres, to a total 
of 50, had a pair of sera (Wand Z) tested with added 
complement for haemolysins to AP (porcine) cells. 
4. p · Most of the volunteers who had haemolysins to k 
cells were given a further dose of influenza vaccine and 
serum samples taken before and after this were tested for . 
· 18 '1 
the presence of haemolysins. 
Trial 2 
1. After each bleeding session fresh serum SI,ecimens 
from all volunteers were tested for the presence of 
haemolysins to human A.1 , AP and oP, erythrocytes at room 
temperature and at 37° ~. The use of oP cells (Appendix 
6) was dictated by the need to differentiate lysis due to 
anti-species activity from lysis directed against that 
component of Group A cells which seems to be associated 
with ABO haemolytic disease. 
Fresh sera were. used so that there would be 
sufficient complement present for lysis to occur without 
the need of adding a further serum as source of complement.-
and thereby introducing yet more variable factors. 
2. All the stored serum specimens of Group O and Group B 
volunteers were tested for the titre ·of anti-A1 iso-
agglutinins. 
3. During the period of the trial samples of serum from 
some patients attending the Casual.ty Department at the 
Royal Victoria Hospital were tested for the presence of 
haemolysins to human A1, AP and if cells before and at 
various periods after receiving anti-tetanic serum. 
4. Over the winter, serum specimens from all Group 0 
donors bled by the Northern Ireland Blood Transfusion 
ervice were screened at .37° C. for the presence of anti-A1 
18~ 
haemolysins. 
The laboratory tests in this section of the work were 
carried out at the Northern Ireland Blood Transfusion 
Service Laboratory by Mr. T.E. -Wilson, F.I.M.L.T. and Mr. 
F. Corr, A.I.M.L.T . 
...Materials and Methods 
Sera 
Blood specimens from the volunteers were taken as 
previously described. V/here sera were to be tested for 
the pres,ence of haemolysins precautions were taken to 
preserve complement. 'flle majority were separated from the 
clot and tested in less than 8 hours aft~r being drawn. A 
few were kept overnight a-t -4 ° Where a longer delay 
., ' ' seemed inevitable the sera were separ ted and stored at r 
-70° c. 
Blood samples :(ram the patients in the Casualty 
Department were taken by members of the staff there. Many 
of the patients did not return for a second specimen to be 
taken. Al though disposable. syringes were supplied s.everal 
of the specimens were so severely haematlysed that tests 
,• 
for haemolysins were very difficult and only a proportion 
of the patients were Group O or B. These factors reduced 
the numbers of sera available. 
erever it was possible, as with ,specimens. from the 
vaccine trial., sera were tested for haemolysina in a 
186 
aingle batch in order to. reduce variables. However, there 
were always some absentees who had to be bled, and their 
sera tested, at a later date. 
Cella 
The manner of collection and source of red cells used 
in various tests is described in ppen~ix 6. 
Tests 
The technique of tests performed in this section of 
the work is described in Appendix o. 
ResuJ. ts 
Trial 1 
(a) Of the volunteers from whom all four sera (W, X, Y, Z) 
were available, 207 were Group O or B. These were titrated 
for the presence of saline anti-A1 iso-agglutinins. These 
results were examined to determine those volunteers in whom 
the titre -
i fell two-fold 
ii rose two-fold 
iii rose more than two-fold 
iv did not alter as much as two-fold 
Strict criteria for recognising an alteration in 
titre were adhered to and the two-fold change had to be 
clear. This was necessary owing to the drawn out end-
points which occur when the agglutination end-point was 
determined microscopically. 
18. 
Changes of titre associated with receiving vaccines 
W and R' could be compared between sera W and 
and Y or W and Y (2 months). 
era 
Vaccinea 
Titres fell 2-fol 
No clear change 
Titres rose 2-fold 
Titres roae 4-fold 




































There s no s i gnificant di ierence in the change 
between the vaccines at weeks ( • 95 > > u. 90 or between 
3 eeks ana. 2 months ( •. r> > . 2) . owever, t ere were 
~ 
i gni i~an"tly (o. 05 > > . o_ .L) more rises in i tre with 
R' vaccine than lacebo when the period ovem ber to 
-
January (sera to Y) is .consi ered. I will be 
. ,. 
appreciated that the changes of titre listed above cannot 
be simply added as minor variations in the titres not 
amounting to a clear two-fold change in themselve coul 
still alter t e number o valid changes recorde. 
ter serum Y (January, 1 o3) the administration of 
anot er vaccine complicated the situation and four 
ifferent vacci e grou shad to be con i ered between sera 
Y and z. 
1se 
Vaccine groups {O ra R'O R'R 
- . -· Titres fell 2-fold 0 0 2 0 
No change 40 43 48 52 
Titres rose 2-fold 3 10 2 5 
Titres rose 4-fold 0 1 0 1 
Titres rose 8-fold or more 0 0 0 0 
' This distribution falls just outside the bounds of 
chance (0.05 > P > 0.025). Whereas there is no significant 
difference associated with the nature of the first 
inoculation received when comparing vaccine groups WO and 
R'O (P = 0. 64) or WR and R'R (0.2 > P > 0.1), there are 
significantly more increases of titre associated with 
aqueous vaccine, R, than wi th adjuvant. This is shown 
when the combined results of WO and R' 0 are compared with 
rn and R'R combined (0.025 > P > O.Ol). 
(b) When the 50 pairs of sera (W and Z) which had shown 
lysins or suspicious iso~agglutinin titres were examined 
for haemolysins to AP red cells only 4 sera, all Z, 
produced even a trace of haemolysis. In this test, unlike 
others described later, papainized AP cells were used and 
the test run for 1 hour at room temperature. 
Of these 4 students 3 were males and a further dose 
of 1.0 ml. of aqueous (R) influenza vaccine was 
administered and serum taken before the inoculation and 
stored at -70° C. was ·compared with serum taken 11 days 
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after inocul ation. Of the second specimen part was snap-
frozen to -7 ° C. and thawed to make the comparison of the 
two samples more exact . This extra inoculation was given 
9 months after the previous dose of vaccine which they had 
received. 
All 3 volunteers had haemolysins to AP cells in both 
serum specimens. Two also had lysins to oP cells which 
suggested that the reaction could be merely anti-species 
activity. However, two of the three poasessed anti- 1 
haemolysins. The Antibody- bsorption test showed all 
>" 
three to have weak or moderate positive results. However, 
none of these results were affected -0y the inoculation. 
The lysins found in the sera taken before their booster 
inoculation were fractipnally more pronounced than those 
found in the sera taken after thi injection. 
Trial 2 
(a) Of 97 volunteers in the second trial 52 were Group 0 
or B. Only 51 fresh sera were available at 3 months as 
too little blood was obtain'~d from one volunteer. 
i Haemolysins 
sit was necessary to use fresh sera the tests were 
carried out soon after the sera were taken . Because of 
this the 3 sera of each person were not tested together 
and thus results are more strictly comparable in the mass , 
than when comparing individuals. However, results were 
1 
generally consistent. 
Although tests for haemolysins were carried out both 
at 37° C. and room temperatuxe, so few lysins were shown at 
0 room temperature that only the results at 37 c. will be 
considered. 
The results of the findings on fresh sera are shown 
below. 
Cells Human l 
C p T C 
era 
Before (F) 0 2 0 3 
0 1 0 1 1 month (G) 
3 months (H) 0 1 4 ~1 
C Complete Haemolysis 
P artial Haemolysis 
T Trace of haemolysis 
p ~ 
-~ C p 
' 
15 1 2 12 
22 0 0 18 
23 11 ' l 22 






sent to the South-West Regional Blood Transfusion Centre, 
outhmead, Bristol, to check these results. Here tha sera 
were absorbed with oP cells to remove anti-species 
activity before being tested against A1 and AP cells. In 
addition, the sera were tested for the presence of 
complement with sensitized sheep cells. Some 
discrepancies with the results obtained in Belfast were 
noted. The results from Bristol have added the following 




l month (G) 













Repeated efforts were made in Belfast to confirm 
these results. As the sera had, by now, been stored at 
-20° C. for months all sera were tested for complement 
with sensitized sheep cells. In parallel tests fresh, 
lysin-free, human Group O serum was added as a source of 
extra complement. It was not possible to confirm the 
existence of the complete lysins found in Bristol in any 
of the sera. In the po.st-inoculation sera of one 
volunteer the presence of trace levels of haemolysin to A1 
cells was confirmed, having not been detected during the 
examination of the fresh sera. 
ii !so-agglutinin titres 
In the absence of a control series the findings of 
iso-agglutinins were of less value. Here the titres were 
recorded and compared. 
Changes in titre are recorded in the table below. 






















(As mentioned above, there was too little serum from 
one volunteer to perform tests for lysins. By diluting 
the amount available an approximate iso-agglu~inin titre 
was measured and this is included in the results. This 
showed a two-fold increase over the previous sample.) 
(b) Casualty patients 
Pairs of sera were available from lo people who were 
Group O or B. Seven of these had been bled 9-15 days 
after receiving 1 ,500 units of A.T.S. and 9 a month after 
their inoculation. The initial serum of one of the first 
group and two of the second were so haemolysed as to make 
it impossible to test for lysins. Lysins -were detected so 
much more frequently in this group that a comparison 
between the results obtained from tests at room temperature 
are more revealing than those at 37° C. 
19 3 
Room Temperature 37° . 
. . 
Before After Before fter 
' 
. T.S. A. T • • 
AP op p oP p oP p oP 1 l l 1 l/ ' 10 a,y 
interval 
Trace 1 0 0 0 0 0 0 0 0 0 
artial 0 0 0 0 2 3 2 2 0 0 1 
Complete 2 0 1 4 1 1 2 1 2 6 4 
2/ 
1 month 
in te rval 
Tr a ce 0 0 0 0 0 0 0 0 0 0 
' 
artial l 0 4 l 4 0 1 1 4 
Complete 0 ·o 0 2 0 l 2 1 0 
On the serum specimens of two of these patients, one 
from each grou~, an .Antibody-Absorption test was carried 
out. Both had shown acquired· haemolyains. at A1 cells at 







Ti -trre Tit-re 
1/ ll day 
interval Pre-A.T.S. 32 8 
Post-A.T. S . 512 8 
2/ 30 day 
8 interval Pre-A. T .S . 32 
Post-A.T. S . 128 8 
This seems to indicate that the increase in titre has 
been primarily due to the increase of the anti-AP component. 
19 ~ 
The volunteers for the influenza vaccine trial had 
been questioned about past injections of anti-tetanic 
serum. Of those who were Group O or B, 4 had received 
A.T. S. within two y~ars and 2, 4 and 5 years previously, 
respectively. 
These numbers are small but there ~ppears to be no 
tendency for t he · potency of lysins present in these 
" people to be increased following influenza vaccine. 
Pre-inoculation l month 3 months 
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(c) Haemolysins in Donor Sera 
In order to provide an index of the normal incidence 
of anti- 1. lysins in the population of Northern Ireland 
the routine test used for screening Group O donor blood 
was brought to the same standards as t hat used in the 
trial and results were recorded for each donor bleeding 
session. i g cell s were not us ed. 
The relevant results from the vaccine trial 
volunteers are included for comparison. Whereas the 
donors are only Group O the volunteers have Group B 
people included. 
Month Haemol:vsins. No 
Domulete Partial Trace L:vsin 
1963 
Nov. 
(26th- Donors 0 16 38 288 
29th % (4.7 ) (11.1) (84.2) 
for Volunteers 0 2 0 50 
donors) % (3. 8 j (96.2) 
. . ' 
Dec. Donors l 52 166 1276 
% (0 .1) (3. 4) (11. l) (85.4) 
Volunteers 0 , l - ' 51 .. 
% ' (1.. 9) (98.1) 
1964 . - , 
Jan. Donors 0 37 146 1704 
% (2.0) (7.7) (90.3) 
, -
Feb. Donors 0 43 112 1~51 
- % (2. 9) (7.4) ( 9.7) 
Vol.un teers 0 4 l. 46 
% (7.8) (2.0) (90.2) 
. - . 












REACTION TO INFLUENZA VACCINES 
19 6 
In the trials constituting the present study local 
reactions were much more prominent than systemic ones. 
From the first part of the first trial. the association of 
symptoms with even the small dose of vaccine was 
established. It al.so appeared that the effect of vaccine, 
as distinct from that of the injection, took some hour to 
develop. 
I~ is difficult to understand why erythema was less 
frequent with 1. ml. of ~queous vaccine than ti.th 0 . 5 ml. 
of the same material 2 months previous~y. It is possib~e 
that the batch of vaccine, prepared for the trial, had had 
the extra period to age and lot some of its toxic 
properties. This is commonly thought to happen with some 
bacterial vaccines al though no proof exists. If this is 
so the erythrogenic property seems to be somewhat more 
labile and, at least, partly separate from the other toxic 
properties because pain and tenderness were not noticeably 
affecte by the period of storage . This , in turn , would 
afford an explanation why the presence of erythema, 
following sub-cutan ous inoculation, was not necessarily 
correlated with other symptoms.. When volunteers receiving 
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saline vaccine were conai9-ered the incidence of "fa.inn-
graded at more than "f tt was simi.Lar in those with and 
those without erythema ' (J. 6 . 6% and J.5%). However, the 
incidence of "':.i.:enderness" graded more 1ihan tti·"" was twice 
~ . 
as high in those who had erythema (25%, as against J.2:. 5%). 
It is also 1ikeJ.y that the relative absence of 
erythema foJ.J.o.wing adjuvant vaccine is related to the deep 
site of inocuJ.ation as much as to the smal1er amount of 
antigen contained in a dose. 
The s.i te of inocuJ.atio.n wou1d also affect aweJ.1.ing 
and induration. The incidence of these was. ama.11 and as, 
J.ike erythema, these symptoms are not disabJ.ing in. them-
seJ. ves, it would be misleading to em1>l.oy these as main 
criteria of J.ocaJ. reacti.ons (M.R.C., J.955) although they 
have the advantage of being objective findings and all. 
three were asso.ciated only with vaccine and not. with the· 
pJ.acebo. 
fhe degree of pain recorded wouJ.d cJ.earJ.y be, related 
partl.y to the temperament. of the recipient of the vaccine. 
However, it. is also clearly related to the mass of 
influenza antigen, as the incidence was much higher with 
the 1.. O mJ.. dose of aqueous vaccine than with O. 5 m.J.., and 
to the site of inoculation. Al though adjuvan t vaccine 
contained so much less antigen than the aqueous dose. the 
incidence of pain was only sJ.ightly less and the duration 
of symptoms was 1.o.nger. Probably this is· partJ.y reJ.ated. 
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to the fact. that. mus,cular movement would irritate the s.i te 
of intramuacular inoculation while t.he sub-cutaneous tissue 
is unaffected. That the nurses, more frequently engaged in 
manual work, were more affected in Trial 2 than the 
students would tend to support this contention.. 
Tenderness lasted equally long with both aqueous. and 
adjuvant vaccines. Certainly the amount of tenderness 
with adjuvant vaccine is, more than would be expected from 
the do~e of antigen it contains. The ethic.al position of 
inoculating volunteers with an oily adjuvant containing 
only placebo would 'be dubious but. without such a cont-rol 
group it was difficult to gauge how much tenderness waa 
due to the reactive process about the mineral oil droplets 
and how much due to the influenza antigen. 
The greater incidence. of bruising among those 
receiving adjuvant vaccine was probably due to the use of 
the heavy cartridge syringe and the deeper inoculation. · 
In the second trial the large needles used for the 
majority of the nursing staff might well explain the 
number and persistence of bru.ises in this group. Th.eae 
bruis.es were not. a cause of c.ompJ.aint. 
After the satisfactory absence of any definite 
residual lesi.ons following adjuvant vaccine in the first 
trial the occurrence of nodules in 4 volunteers -in the 
second trial was surprising and disappointing. In all 
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ca.sea the lesions were. clearly in the deep sub-cutaneous 
tissue so either the ino.culum had never been placed in the 
belly of the muscle or it had leaked back along the needle 
tract. As the long head of the triceps ia fairly deeply 
situated the .former is not unlikely. It would seem that 
this site was not a satisfactory one for the inoculation 
and while the del. toid ia a much poorer area for assessing 
reactions in a trial of this na.ture, it is undoubtedly a 
better site for routine use. 
The histology of the reaction about the oiJ.y adjuvant 
in the monkey experiments was that of an oil granuloma and 
was similar to the description of Humphrey and White 
(J.96J). It is int.a.resting that in the sub-cutaneous 
inoculations both in the 4 volunteers and in the animal 
experiments the large thin-walled cysts described by Salk 
and Laurent (1952) did not develop. This is possibly 
related to use of less toxic and purified oils and 
emulsifying agen "ts,. 
Systemic reactions were no,t prominent. The cases of 
allergic types of reaction are not convinc;i.ngly l.inked 
with the vaccine. The one florid attack of ·urticaria 
occurred in a student given placebo. Examining the cases 
ind=i:vidually possibly one student who had urtic.aria in the 
first part of the trial might have been affected by the 
vaccine but a later dose of adjuvant vaccine, as mentioned 
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above, did not eauae any allergic manifeatations. It 
would seem that the precautions of excluding aufferers 
from ,egg hypersensitivity and active asthma were 
sufficient. 
No definite pattern of other systemic symptoms 
developed in conjunction with the vaccines. In the first 
part of the trial as many, or more, reactions of all. kinds 
occurred with placebo as with the vaccine. In the second 
part symptoms occurred more frequently in those, given 
aqueous. vaccine with 15,000 H.A. units of virus than with 
1,900 H.A. units of virus in the adjuvant vaccine which 
might be significant but even here the numbers are so 
small that this ia within the bounda of chance. The 
incidence of caaea with definite malaise or shivers in the 
group receiving aqueous vaccine was just over 1%. 
Coryza in the first 36 hours after inoculation 
occurred more frequently in those receiving aqueous 
vaccine than thos.e getting adjuv~t in the second part bu"t 
more frequently after placebo than vaccine in the first 
part. 
In the second trial. the position is more difficu.L t , to 
assess in view of the smaller numbers, the lack of a 
control group and fewer examinations but here again no 
definite pattern appeared although the feeling of 
faintness in one student and the cold complained of by a 
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nurse might have been associated . with t he vacci ne. 
~enerally speaking, the lack of systemic reactions 
following the vaccines used in these trials was in sharp 
contrast to an incidence of 15% of sympt.oms of malaise and 
shivers in a class of students who were given 0.2 ml. of 
Tn>hoid-Paratyphoid A and :B-Tetanus Vaccine intradermally. 
In agreement with the report of Sadusk et al., 1949, 
females were affected more than males throughout. This 
occurred with the objective signs, like erythema, as weli. 
It is interesting that the subjective questioning did 
· not reveal any preference among the inocu1a. From the 
first part of the first trial it seemed that the assessment 
by the volunteers was a less sensitive gauge of reaction 
than the examinations. This is, perhaps, not surprising 
because the system employed must have discovered near1y 
every reaction whiie complaints would only have been 
elicited by reactions above a certain threshold. However, 
both sets of questions, on the acceptability of the 
vaccines or comparing the reactions, showed that the full 
doses of vaccine had felt worse and a significant number 
felt that they would not readily accept the latter 
vaccines. It was a pity that the reasons were not 
collected. 
Pain and tenderness were the most prominent symptoms 
recorded. If it is arbitrarily presumed that a record of 
these graded as more than "tn would merit a complaint the 
the incidence of local reactions were not strikingly 
different from those reported by Clarke (1962 ). 
Tenderness Pain 
Placebo 3.8% 10~7% 
R' 20;8% l.3 .l.% 
- -
R 34.2% 29.3% 
-
0 24-0% 20.5% 
Cl.arke (J.962) Local Reactions 32% 
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However, the incidence of systemic reactions and of 
local reactions which interfered with activities during 
all phases of the present studiea was in striking contrast 
to many of those previously reported and, in particuJ.ar, 
to those reports of Clarke (J.962) and Meichen et al.. (19 2) 
which concerned British ty:pes of vaccine. 
None of our volunteers felt that they had missed work, 
play or social activities through the vaccine. In the 
series investigated by Meichen et al.. (J.962) 10-15% were 
un.~ble to do a normal daJ''S work on the daJ' following 
vaccination. While systemic effects were rare in the 
present series, Cl.arke (1962) reported that 30% of the 
reci~ients suffered from general malaise and, again a 
particular difference, that 6% suffered from allergic 
complaints. Obviously, the order of reactions experienced 
by these workers was quite different from that observed in 
our trials which featured .multiple examinations but also 
203 
different vaecines and controls unknown to the volunteers. 
It is difficult to reconcile these differences adequately. 
However, while those responsible for the development 
of vaccines should never allow themselves to be entirely 
satisfied with the current product - a self-satisfaction 
that has delayed much-needed improvements in several 
vaccines - the acceptability of a vaccine by the general 
public is geared principally to the fear engendered by the 
severity and imminence of the disease in question and 
partly to the reaction caused by it. Leipoldt (1937) has 
commented on the ambivalent attitude of the public towards 
diseases - dreading the dramatic and scorning the familiar, 
regardless of which actually causes more harm. Influenza 
is both familiar and intermitt~nt and has a low case-
fatality rate. It is little feared. Rosenstock (1961) 
described the results of a survey made among 1, 600 
families in the summer of 1957 on the eve of the Asian 
influenza epidemic. Despite the massive publicity that 
influenza was receiving at the time only 25% of the 
families interviewed accepted the possibility that someone 
in the family would catch influenza. Less than 3% 
believed that an attack of influenza would cause them to 
alter their daily activities. 
Modern medicines are not always bitter. The 
inoculation of Salk~type poliomyelitis vaccine was 
particularly devoid of reactions. It could well be 
reasoned that a prophylactic against influenza should 
cause no worse reaction than that! 
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Although the vaccines used caused little interference 
with activities the incidence of pain and tenderness was 
not negligible. In children the degree of reaction would, 
undoubtedly, have been worse. While the present vaccine 
would be quite acceptable for groups of individuals with 
chronic pulmonary or cardiac disease who would 
particularly fear an attack of influenza the numbers of 
volunteers who felt that the vaccines would not be worth 
while might indicate that a more bland preparation is 
desirabl.e. 
Hoyle (1952) showed that the influenza virus particle 
could be fragmented by ether and that the nucleoprotein 
moiety could be precipitated by lanthanum acetate. 
Experiments of Davenport, Rott and Schafer (1960) showed 
that the haemagglutinin fraction was sufficiently antigenic 
and Mizutani, Beals, Hennessy and Davenport (1962) 
indicated how a satisfactory amount of a haemagglutinin 
fraction could be prepared using lanthanum acetate. This 
purified haemagglutinin fraction extracted from 
formalinized virus was proved (Davenport, Hennessy, 
Brandon, Webster, Barret and Lease, 1964) to be effective 
in eliciting antibody and very considerably less prone to 
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cause reactions than intact vaccine, even in small 
children. It is possible that a vaccine of this nature 
could effectively reduce the inc,idence of reactions to a 
still smaller degree. 
ANTIBODIES TO GROUP A SUBSTANCE 
Haemolytic disease of the newborn due to anti-A is, 
felt to be a common syndrome (Halbrecht, 1944, Hsia and 
Gellin, 1954),occurring at least 1:150 births, but it 
appears to be a mild condition in the vast majority of 
cases and rarely requires treatment (Mollison, 1956). 
Even the criteria for treatment are different from those 
with haemolytic disease due to the Rh factor (Tovey, 
., 
Gillespie, Guy, Valaes, Oppe and ~ewis, 1959). It has 
been shown tha,t where a pregnant woman is Group O and , her 
infant is &roup A the mother's anti-A iso-agglutinin 
ti~re frequently rises to considerable h~ights in the 
post-partum period (Boorman, Dodd and Mollison, 1945) and 
the ·i:;hermal amplitude of ·the anti-A agglutinins also 
changes (Hubinont, l949). 
It has been clear for a number of years that the 
inoculation of various therapeutic substances including 
bacterial vaccines (e.g., Typhoid-Paratyphoid A and B 
vaccine) and anti-tetanic serum frequently induce anti-A 
haemolysins in Group O recipients (Crawford et al., 1952). 
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~he parenteral administration of Rh substance, whether by 
injection, transf usion or previous pregnancy is known to, 
sensitise susceptible women to this substance and to 
increase the chances of haemolytic disease of the newborn 
in a subsequent pregnancy. 
me results obtained in the present study following 
the administration of influenza vaccine must be discussed 
in the light of these findings. 
Following the initial inoculation of the first t rial 
there was a slight f:\Od del~e~ tendency for titres of 
anti-A1 iso-agglutinin to rise. Whereas a 2-fold change 
titre i not signific.an t when comparing two indi vidua:J. 
,-
specimens, due to the degree of variation inherent in the 
test, in this case changes of titre were not randomly 
distributed between rises and falls and the tendency to 
rise, judged by these slight changes, was valid. The fact 
that there was .a rise, although smaller, in the titres of 
the group given placebo indicates that another factor 
besides the vaccine was o.pera.ti ve. In the second part of 
the trial the upward tendency of the iso-agglutinin titres 
was greater in those getting aqueous vaccine, with the 
J.arger antigenic mass and a rise was also evident in the 
second trial. 
While this increase was in agreement with the general 
statement of pringer and Tritel (1962) the degree and 
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uniformity of the change was quite different. 
The significance of this increase of iso-agglutinin 
in re~ation to disease is also open to question. The use 
of different tests discloses a wide range of different 
antibodies to -substance. However, whereas saline iso-
o agglutinins with optimum activity at 4 a. occur 
naturally, antibodies with properties of haemolysis 
(Crawford et. al., 1952), optimal activity at 37° a. 
(Hubinont, 1949) or of activity after partial 
neutralization (Witebsky, l948) are formed in response to 
immune stimuli. 
Tisdall, Garland, Szanto, Hand and Bennett (1946) 
showed that the titre of haemolysins present in a serum is 
usually proportional to the titre of agglutinins but 
numerous exceptions to thia have been recorded (Ervin, 
Christian and Young, 1950, Grove-Rasmussen, Shaw and 
Marceau, l953, Stevens and Finch, 1954) and the instances. 
of transfusion reaction that are described by these 
authors confirm that the dangerous qualities of a.era from 
Group O donors to Group A or B recipients do not reside in 
the natural anti-A or anti-B iso-agglutinins but in anti-
bodies showing "immune~ characteristics. Regarding 
- . 
haemolytic disease of the newborn the importance of 
natural saline iso-agglutinins must be small as the 
placenta is relatively impermeable to the large molecular 
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globulins which comprise these. antibodies (Tovey, 1945). 
Not all the tests for 1timm.une1t type anti- anti-
.. 
bodies are e.qual.ly applicabl.e to large numbers of sera and 
tests for haemolysis are the easieat to carry out 
(Crawford et al., 1952) as well as being a good index of 
these antibodies (Davidsohn, Goodman and Stem, 1956). 
L.A.D. Tov.ey (1957) felt that whereas a serum containing 
, 
an incomplete antibody will almost invariably contain a 
haemolysin the reverse does not hold so that tesi:sfor 
haemolysins will show a maximal incidence of relevant, 
immune-type, antibodies. The work of Gardner and Tovey 
(.L954) supports this contention. The incidence of anti-A1 
haemolysins in serum from Group O donors has been found to 
be so high by several workers (uhaplin, Wallace and Chang, 
l.956, McDermott and Muschel, 1956, L.ockyer and Tovey, 1960) 
that if the presence of these lysins was uaed as an index 
an excessive amount of Group O blood would be discarded as, 
being dangerous for emergency use in Group A or AB 
recipients. As a result Lockyer and ~ovey (1960) developed 
the test for lysins to .J..P · cells. (Winstanley, Konugrea and 
Coombs, J..957) to provide a screening test of more reasonable 
sensitivity. 
In the present study the technique adopted provided. 
degrees of sensitivity ranging from the detection of 
anti-Ai haemolysins at 3.7° c. to the detection of anti-AP 
1-ysin active at room temperature. Th.is would have 
provided for different levels of incidence of haemolysi.n 
in the pre-inoculation s:era. In the event, the most 
aensi ti ve index proved to be the most useful al though it 
was complicated by- non-specific J.ysfs of pig cells at 37° 
C. (Tovey, Lockyer, BJ.ades and Flavell, J.962}. 
The incidence and potency of anti-A1 haemoiysins 
occurring foll.owing the inoculation of influenza vaccine in 
Trial 2 is exceedingly low and well within the bounds of 
natural variation found (Tovey , L.A.D., l957). It is. 
difficult to explain the discrepancies between the results 
obtained in Bristol and Belfast. The sensitivity of teats 
for J.ysins is governed both by the concentration of 
complement present and the concentration of the celJ.s used 
(Chaplin et al., l95 6). However, the concentration of 
cells used in Bristoi (4%) was onJ.y slightly less than 
that used in Belfast and the test in Belfast employed 
either fresh sera or added complement. It is of possible 
value that thoae cases about which there is lack of 
agreement did not show significant increases in saline 
agglutinin titres. However, while these discrepant 
results are a source of doubt they do not alter the 
situation that the influenza vaccine used did not show a 
definite tendency to stimulate immune type antibodies to 
Group A1 cells. 
1.1:he resJll ts are markedly different from 
those found by Crawford at al. (1952) with bacterial 
vaccines, where 10 of 14 recipients acquired haemolysins 
after Typhoid, £aratyphoid and :B vaccine. 
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It is also of interest that, in agreement with 
pringer and Tritel (1962), there was no evidence that the 
. 
titres of anti-A1 saline agglutinins were enhanced by a 
repeated inoculation. fhia was shown both by the lack of 
difference, in the first trial, between the responses, to 
the second injection of those given placebo or vaccine 
initially and in the lack of response of the three 
volunteers given a further dose of vaccine. In addition, 
in the second trial, inf~uenza vaccine did not appear to 
stimulate any speci~ response in those volunteers who had 
previously received anti-tetanic serum. therefore, it is 
less likely that repeated doses of influenza vaccine will 
elicit antibodies not detected in the present study. 
:Because of the low overall incidence of anti- 1 
lysins in the serum of Group O donors in Northern Ireland 
it has been suggested (Tovey, 19 3) that the population is 
inherently resistant to antigenic stimuli of this nature. 
If that were so the results of the present work might not 
be universally applicable. This suggestion is difficult to 
disprove without further work but the higher incidence of 
lysins in the rather special group comprising the casualty 
patients ~d their response to anti-tetanic serum would 
21 
ten to indicate both that the tests employed were 
sufficiently sensitive and that an inherent resistance to 
stimuli of Group A substances is not present. 
It is beyond the competence of this study to provide 
evidence as to whether ABO haemolytic disease of the 
newborn is in fact stimulated by previous experience of 
Group A substance by the Group O mother of susceptible 
children. However, the high proportion of cases occurring 
in first-born children, estimated as 40-50% (Levine, Vogel 
and Roaenfield, 1953, Mollison, 1956) and the absence of 
the disease in a susceptible infant following severe 
disease in a previous pregnancy reported by Crawford, 
Cutbush and Mollison (1953) do not seem to support this. 
In his survey, Tovey (1957) also found no consistent 
factor, such as previous inoculations, that could be 
incriminated as a cause of this condition. It is clear, 
however, that only large-scale prospective trials could 













INFLUENZA ANTIBODY RESPONSES TO VACCINE 
Th~ results obtained from a trial of a vaccine need to 
be considered relative to certain reqµirements . 
Was the antigenic stimulus sufficient to eli cit an 
ade~uate antibody response ? 
The median titres appeared to indicate that 0 . 5 ml • 
of a~ueous vaccine produced as high a titre of antibody to 
A/Singapore/1/57 as 1 . 0 ml . of vaccine and, also, that the 
titres reached after the small dos e were not augmented by 
a further, larger dose . However, a study of the response 
of antibody to B/England/939/59 shows a rather differen t 
pattern . 
If the volunteers in Vaccine group R'R are divided 
into two groups, one of those whose initial serum had no 
detectabl e H. I . antibody to B/England/939/59 and the other 
of those with an initial antibody t itre of 10 or more the 
evolution of antibody titres after the doses of Vaccine was 
as follows:-
Initial levels 10 10 or more 
Median titres 
Serum w 10 20 
X 15 60 
y 15 60 

























SeveraJ. points are illustrated by this. 
1) Where an individual has had previous experience with 
an influenza antigen a small dose of vaccine is sufficient 
to cause a rise of antibody titre to a ttceiling" at which 
a further dose of vaccine does not cause any further rise. 
This was the case with A/Stngapore as nearly all the 
volunteers had antibody to this strain in their pre-
inoculation serum. 
This tendency for vaccination to bring antibody levels 
up to a "ceiling" has been freq_uently noticed in the past 
and has been shown to be responsible for the difficulty in 
making a serological diagnosis of influenza in people who 
had been vaccinated recently (Horsfall et al ., 1941b, : 
.. -
McDonald and Andrewes:, 1955). Beveridge _(Beveridge, 1944 'b, 
Beveridge, Stone and Lind, 194.4) attributed this to the. 
effect of existing antibody reducing ~he antigenicity of 
subseq_uent doses of virus. 
2) That where individuals had not had previous experience 
with an antigen the small dose did cause a rise in antibody 
but only to a low level and a further rise was stimulated 
by a second iqoculation. While the timing of the doses was 
probably not optimal, the median titre produced by ev.en two 
doses. was not hi.gh. 
The relative inadequacy of the half dose of vaccine 
was further indicated by comparing the ability of the 
different doses to induce antibody in those wno had none 
initially. No detectable anti body was found in 25% of those 
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receiving 0.5 ml . of vacQine and, in only 7% of those getting 
a dose of 1.0 ml. of the same vaccine. , 
Thus, there is evidence that while 0.5 ml. of vaccine 
was sufficient in those who already had antibody to the 
antigens it was inade quate for people without reating antibody. 
The graphs showing median titres at 9-10 momths show 
that two doses of vaccine did not appear to cause better 
persistence of antibody levels than only one inoculation. 
When incorporated with mineral oil in a water-in-oi.l 
emulsion it appeared that. 1 /5 of the amount of antigen gave 
rather .similar anti body titres to the full dose of antigen 
in an aqueous medium. 
Some differences in the antibody response between the 
aqueous and adjuvant vaccines appeared. W-ith influenza B 
it appeared that the effect. of the adjuvant vaccine waa 
delayed more than the aqueous vaccine. t 4 weeks the 
median titre of this group was lower than that of the group 
receiving aqueous vaccine. However, at 9-10 months the 
position was .reversed and the median titre of the group 
receiving adjuvant vaccine was higher at this time than at 
4 weeks. In the second trial the distr:!-bution of titres at 
1 and 3 months shows that antibody formation was delayed 
in those with no previous experience of the antigen but that 
this difference had partly disappeared at 3 months. However, 
unlike the aqueous vaccine, the adjuvant vaccine "Ott' seemed 
to be able to boost the titre of antibodies to A/Singapore 
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above the ttceiling 11 reached .after O. 5 ml. of acueous vaccine. 
While the second trial confirmed that the effect of 
adjuvant vaccine continued for more than a month, with 
antibody titres rising to considerably higher levels at 3 
months, the first trial showed the auperiority of the 
adjuvant vaccine over the aqueous vaccd.ne at maintaining 
titres. 
A very prominent feature was the marked difference 
between the antibody titres to A/Singapore/1/57 and 
B/England./939/59. This. was also shown with all the strains-
of influenza B virus tested.. While a much higher proportion 
of the volunteers had antibody to influenza A than to 
influenza B the table _ above shows _that even in those who 
had antibody in their firat serum doses of vaccine did not 
produce generally high levels of antibody to influenza B. 
It is difficult to propose a reason for this. If this low 
level of antibody was due to insufficient antigen in the 
vaccine why did half a dose bring the levels of those with 
antibody initially to their maximum? If it was caused by 
poor avidity of the virus strain used in the test (Isaacs 
and Andrewes, 1951) why was no great- discrepancy shown by 
the neutralization test? If this was an inherent property 
-0 of the influenza B virus why were much higher titres found 
in previous trials with 1940 and 1954 strains of influenza 
virus. (Francis et al., 1946, Davenport et al., 1962)? 
Probably a combination of these fac t ors was operating .in 
this case. Likewise, a change of atVidity of the test 
2f 6 
strain of B/England/939/59 during the course of ·passage in 
the laboratory was unlikely to have been the c.ause of the 
unduly low titres recorded in the early group of tests ~ 
done as no evidence for this was found on examination. 
However, although it was impossible to test this retrospect-
ively, the problem could have been related to the varied 
sensitivity of chicken red cells. Stuart-Harris (1943} .and 
Hirst (1943) found that individual variations in the 
sensitivity of chicken red cells affected influenza ·B virus 
estimations particularly . 
During the period covered by these two trials the only 
evidence of influenza came from an old people 's home where 
there was a sharp outbreak of influenza A in March, 1962. 
In these circumstances it was not possible to judge whether 
the high titres of antibody to A/Singapore/1/57 or the law 
titres to B/England/939/59 were associated with protection . 
Thus, a further requirement of these vaccines is con-
tained in the problem of whether the titre of H.I. antibody 
elicited constitutes a reliable index of the efficacy of 
the vaccines in giving protection against the disease. 
From the time when the difference between the Swine and 
Human Type A viruses was recognized it has been felt that 
protection was associated with the strain specific antigen 
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that was measured by the neutralization test rather than 
the type specific soluble antigen which dominated the 
ordinary complement-fixa~ion test (Fairbrother and Hoyle, 
1937}. While Hirst (1942a) showed a fairly close correlation 
between the H.I. test and a neutralization test in mice 
Walker and Horsfall (1949) demonstrated, by differential 
absorption, a lack of identity of neutralizing and H.I. 
antibody. Using randomized fragments of surviving 
chorio-allantoric membrane for a refined neutralization 
test Fazekas de St. Groth, Withell and Lafferty (1958) 
concluded that anti-haemagglutinin titres were not related 
to the neutralizing power of sera in any simpl'e manner. 
Ke~ble (1963), wo rking with inactivated Newcastle Disease 
vaccine, shoirad that the curves depicting the development 
and decline of neutralizing and H.I. antibody diverged 
considerably. 
In•the present study, while the neutralization test 
fulfilled its purpose of providing an estimate of the 
avidity of the viruses used in the haemagglutination test, 
it was not sufficiently presise for further conclusions to 
be drawn. Despite this the techni que was laborious and not 
well suited for the examination of large numbers of sera. 
The difficulties concerning the rela_tionship between 
titres of circulating antibody and i mmunity to influenza 
have been mentioned. earlier . already. It has been shown 
' 
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many times that clinical influenza tends to occur in those 
people with low serum antibody titres to the epidemic virus, 
including by Burnet (Burnet and Foley, 1940) and Meiklejohn 
(Meikl~john et al., 1952a), and Salk, Menke and Francis 
(1945), comparing vaccinated and unvaccinated populations, 
showed that attack rates of influenza were equal in those 
of both groups with the same acute phase titres. However, 
Hare (1940), using a mouse neutralization test, felt that 
the serum antibody titre in humans gave no indication of 
·susceptibility or i mmuni.ty to infection. The studies of 
Horsfall (Horsfall et al., 1941b) and Hirst (Hirst et al., 
1945) showing that high serum titres of antibody did not 
always confer protection, have already been mentioned . 
Trials reported by the ~edical Research Council (1957) 
showed a lack of protection despite raised antibody titres 
but, in other circumstances, protection was shown despite 
a poor H.I. antibody response (M.R.C., 1958, Rose, 1961) ! 
Experiments on conferring passive immunity to mice 
showed the superiority of an intra-nasal route over an 
intraperitoneal route for the administration of immune 
serum (Stokes and Shaw, 1939, Taylor, 1941). However, 
influenza in the ferret is a much more comparable disease 
to that in man and Zellat and Henle (1941) felt that intra-
nasal immune serum did not protect ferrets against normal 
influenza, only against pulmonary involvement. Burnet (Burnet, 
Lush and Jackson, 1939) and Francis (Francis, 1940a, 1941, 
,I: 
Francis and :Srigh tman, 194i, Francis, Pe arson,, Sullivan 
and Brown, 1943) studied the presence of virus 
neutralizing substance in nasal secretions and the latter 
' felt that this was antibody. However, as both workers 
1_1 
inserted cotton wool plugs into the nostrils to stimulate · 
and collect secretion it is possible that the resulting 
irritation may have produced a secretion not comparable 
to that found in the normal naso-phaxynx. 
Fazekas de St. Groth and Donnelley (1950a and b) 
showed in experiments with mice that ,while · no mice without 
circulating antibody showed resistance to influenza, 
serum antibody levels gave very little information about 
the specific protection afforded and that there was a 
strict correlation of immunity with the presence of 
haemagglutinin-inhibitor in the bronchial tract. 
These experiments seem to indicate that resistance 
to influenza might be a function both of the titre of 
circulating antibody and of the permeability of the naso-
pharynx Vv'hereby antibody might be present in the surface 
secretions. However, , influenza in mice is a primarily 
pulmonar,y disease and, as has been mentioned above, 
ferrets, which, like man, contract a more superficial form 
of influenza were not protected from this antibody but 
only by an alteration ·of the nasal epilhelium (Francis 
and Stuart-Harris, 1938). ,, 
Thus while the estimation of H.I. titres of antibody 
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are convenient and afford a measure of the efficacy of a 
vaccine the results gained in this manner must be 
interpreted with some reservations in view of the imperfect 
correlations of H.I. and neutralizing antibody and of 
circulating antibody and protection . 
What should the composition of influenza vaccines be? 
As the controversy over the fundamental concepts governing 
these vaccines is still unresolved it is clear that much 
difference of opinion exists. V hile Davidson (1961) 
suggested that a polyvalent vaccine, containing several 
strains of influenza A virus, might stimulate antibody to 
antigens of the past rather than to the new strain which 
was current, Jensen, Woodhour and Bailey (1960) claimed 
that the vaccine used in the U.S. Armed Forces containing 
6 strains of virus was better than a 4 strain vaccine 
even when an equal "mass" (by C. C. A. uni ts) of each was 
administered. The resul t -s shown above indicate that pre-
existing B/England/939/59 antibody did not seem to inter-
fere with the response to B/Taiwan/4/62 antigen. However, 
the significance of this is open to arguement as the 
antigenic relations between strains of influenza B virus 
are closer than between the sets of influenza A. 
It is of interest that the addition of R/Taiwan/4/62 
antigen to vaccine should also elicit antibodies to B/Lee 
and this unexpected obse~vation made it necessary to test 
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sera from the previous trial to show that no such anti-
bodies were produced by the vaccine containing only 
B/England/939/59. This result might either indicate 
that the increased amount of type B antigen resulted 
in a general rise of minor antigenic components or that 
there is some subtle relation between B/Taiwan/4/62 and 
B/Lee. Experiments with the convalescent ferret sera 
by Green, Hung, · Yu, Lee and Pereira (1964) and with 
specific chicken sera in the present study show a 
progressive antigenic drift with the strains of influenza 
B so that B/Lee showed no crossing with B/Taiwan/62 strains 
although p.yperimmune rooster sera (Green et al. ·, 1964) 
did show some relation. However, there is n'o clear 
evidence of the "closing" of any putative "ring". 
While there is controversy (Davenport, 1963) over 
the interpretation of the ~esults, there are inuications 
(Influenza Surveillance, 1963) from several studies that 
the polyvalent American vaccine failed to give adequate 
protection against the strains of As~an influenza that 
caused an epidemic in the United States during the winter 
of 1962-1963. If these studies are valid they might 
indicate that the amount of Asian antigen that could be 
incorporated in the polyvalent vaccine was inadequate, 
that the presence of type A antigens from other sets of 
virus (A and Ai) were 0f no assistance in making the 
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vaccine effective or that the degree -of variation shown 
by the prevalent A2 strain was too great for the earlier 
A2 strain in the vaccine to extend protection - or any 
combination of these possibilities. 
If· any of the circumstances above are correct, and 
particularly the first two, doubt is case on the validity 
of the concept underlying the polyvalent, American-type 
vaccine. In the case of the third an interesting relation 
between antibody and protection may be present. The 
strains isolated from the American epidemic were similar 
to AjNetherlands/65/63. It has been shown above that 
certainly in. a population with previous experience of A2 
strains of influenza - · almost a universal state - a 
vaccine containing A/Singapore/1/57 and a variant of a 
different type, A/England/L/61, stimulated a considerable 
rise of antibody to A/Netherlands/65/63. Does that 
indicate that the strain specificity of protection can 
be, at times, more precise than that indicated by H. I . 
antibody? In fact, from the reports already quoted, this 
appears to var-~ and there seems to be no certain way of 
predicting whether a new, but related, strain needs to be 
incorporated into vaccines or not. 
While Langmuir, Henderson and Serfling (1964) have 
called for a re-appraisal of .American influenza vaccines 
there do not seem to have been ade quate trials to compare 
the efficacy of vacQines compounded on the British and 
American systems with regard to either the production 
of antibody or the prevention of disease . 
It is .beyond the comp etence of the present study 
to comment upon the mode of action of mineral-oil 
adjuvants but the delayed response, shown with influenza 
I . 
B virus, t he maintenance of high titres of antibody to a 
greater extent than two doses of aqu eous vaccine and 
the forcing of antibody levels · above the ttceiling" 
determined by aqueous vaccine might argue in favour of 
an action of more general significance than the local 
retention of antigen . The work of Neeper and Seastone 
(1963) showing that an inoculation of adjuvant, without 
any specific antigen incorporated, would restore the 
ability of i mmunologically paralysed mice to produce 
antibody would support this. However, from the results 
with Sendai virus, and others, there is no indication 
of a general non-specific effect upon antibody forming 
cells. 
There was, likewise, no evidence that adjuvant vaccine 
elicited antibody of a substantially broader specificity 
than the aqueous vaccine nor was there a superior capacity 
' to recall anti body to past, and only distantly related, 
antigens. 
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THE USE OF INFLUENZA VACCINES. 
The protection of the individual and the protection 
of the community are problems that are related but not 
identical and thua the solutions adopted may- not be the 
Saine. 
The recent article of Langmuir et al., (1964} once 
more emphasizes the vunerable position of the elderly 
and the chronic invalid during an influenza epidemic. 
The burden of mortality falls on these people and all 
recommendations for vaccination stress the priority to be 
given to these groups. Langmuir et al., (1964) feel ~hat 
even the use of 40 million doses- of vaccine had little 
effect upon the excess mortality associated with the 
epidemic of 1962~1963 but, considerations of vaccine 
efficacy apart, Davenport (1963) pointed out that only 
about 16% of those particularly a~ risk received vaccine. 
There is no evidence as ye.t that would indicate that 
annual vaccination is unne.cessary for individuals who 
regµire protection. 
In the more general population the use of influenza 
vaccine by industries to prevent disruption of .VyQiki.ng 
schedules has: its. limitations. It has to be appreciated 
that the vaccine can only prevent influenza -and not other 
respiratory ailments. whether labelled t1•flu."' or not and 
that the resul ta of vaccination are bound to be disappoin.ting 
in non-epidemic years. Although the reactions caused by 
current vaccines did not appear serious they might elicit 
consumer resistance - particularly in the absence of 
epidemics. While the development of more bland vaccines 
might reduce reactions they would not reduce apathy 
unless an epidemic. waa c-onfiden tly predicted (Davenport, 
196 3). 
As the i mpo_rtance of schoolchildren in propagating 
.. 
influenza epidemtca appears to have been ~hewn, it is 
possible that the control of influenza in this gro-up 
might have benefits. to the communi.ty o.ut- of proportion to 
the number of individuals. immunised. It might, theoreti.c-
ally, be possi bl.e to provide a level of immunity .which it 
did not protect, might so reduce virus multiplication and 
excretion that the clinical case might be a mach less 
· potent source of infection. This, however, ha~ not been 
demonstrated . During outbreaks among old people and a 
summer outbreak (Forsyth, 1962) the attack rate in the 
limited community was high but virus isolation, which 
might be related to virus excretio-n, was difficult. 
Vaccination of children would be limited by the 
difficulty ·and, probably, undesirability of annual 
inoculation. In addition, vaccine reactions in children 
tend to be severe and antibody production, particularly 
to new strains, inadequate. These objections might be 
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overcome by the use of haemagglut inin-fracti on vaccines 
in adjuvant. However, in view of the poss ible relation 
of adjuvant vaccines with hypersensitivity states 
(Becker, Sparks, Feinberg, Patterson, PruzansKy and 
Feinberg, 1961, Beebe et al., 1964) and the fibrosis shown 
to follow th~ vaccine in the present study t he indiscriminate 
use of adjuvant vaccines in children could only be 
recommended with some reservation. 
However, there is a strong indication for this 
aspect of control of the disease to be studied. both in 
relation to the normal i ncidence of influenza and to the 
possibility of the recurrence of a lethal pandemic. For 
while t here is still uncertainty as to t he mode of action 
and t he best method of comp ounding and using in~luenza 
vaccine there is even less under s tanding of the nature and 




The literature relating to tpe development of in-
activated influenza vaccines, their efficacy_ and reactions 
to these vaccines has been reviewed and a brief survey 
has been made of t he events which stimulated the demand 
for vaccines and those properties of the disease which · 
complicate the fulfilment of this demand . 
Two trials were carried out on volunteers in which 
the effects of different doses of aqueous influenza 
vaccine and different adjuvant vdccines were investigated. 
The volunteers were examined and questioned to 
detennine the nature and incidence of reactions following 
the administration of .these vaccines. Systemic reactions 
were not a problem and while local pain and tenderness 
were common there was little indication that the vaccine 
caused interference with normal ac t ivities. Following 
the discovery of subcutaneous nodules after adjuvant 
vaccines these lesions were reproduced in animals in 
order that they might be examined histologically. 
The antibody response of the volunteers to the 
vaccines was studied by the haemagglutination-inhibition 
(H . I . ) test and it was shown that antibody t itres pro-
duced by the adjuvant vaccines persist.~d longer than those 
elicited by aqueous vaccines . The eff e~t of the vaccines 
on antibody to other strains of influenza virus was 
investigated and the similarity of response of 
antibodies to A/Netherlands/65/63 and A/Singapore/1/57 
was demonstrat ed . The sensitivity of the H.I. test was 
checked by neutralization tests on a limited number of 
sera. 
The effect of influenza vaccines on anti-Aliso-
agglutinins and haemolysins was investigated in Group 0 
and Group B volunteers. 
The results and their relation to the efficacy and 
acceptability of the vaccines were di scussed and some 
cozmnents on the use of influenza vaccines in the light 
of the present study were made. 
l:
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Appendix 2 Ha.emagglutination - Inhibition Tests. 
(a) Treatment of sera 
All sera to be used in the H.I. test were treated to remove non-
specific inhibitors (Hirst, 1942a, Francis et al., 1946, McCrea, 1946, 
Chu, 1951, Sampaio, 1952). Two methods were used during the present 
work. 
i Cholera filtrate or Receptor-destroying enzyme (Burnet, 
McCrea and Anderson, 1947)~ 
Ampoules of tested, lyophilized cholera filtrate were 
obtained commercially (N.V. Philips-Duphar, .Amsterdam). The cholera 
filtrate was reconstituted with 10 ml. of sterile distilled water per 
ampoule according to the manufacturer's instructions and the solution 
was dispensed in the required amounts in sterile 3 x finch Kahn tubes. 
Serum was added to make a 1 in 6 dilution of serum and this was in-
cubated in waterbaths at 37° C~for 18 hours and at 56° C.for 1 hour. 
Saline was added to bring the inactivated serum to a dilution of 1:10 
and the treated sera were stored at ~20° C.until used. 
ii Trypsin-period.ate: 
The technique used was derived from the descriptions of 
.Ananthanarayan and Paniker (1960) and Jensen (1961). 
To one volume of serum was added f volume of a solution of 
trypsin containing 8 mgs. of trypsin powder (Trypsin 1:250, Difeo 
Laboratories, Detroit) per millilitre in pH 8.0 M /15 Sorenson's 
phospate buffer (Appendix 5). The serum/trypsin mixture was in-
cubated in a water bath at 56° for 30 minutes. To the cooled solution 
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3 volumes of M/90 Potassium period.ate (G.P.R., Hopkin and Williams, 
Ltd.) were added and then was allowed to stand at room temperature. 
for an hour before 3 volumes of~ Glycerol in saline were added. 
This, in turn, was allowed to stand for 15 minutes before being made 
up to a final serum dilution of 1: 10 with saline. 
Because of the lesser effect upon antibody (Tyrrell and Horsfall, 
1952) Cholera filtrate was used to inactivate all the human sera in 
the study except one batch which is mentioned in the text. 
(b) Red cell suspensions 
i Chicken red cells. Blood was drawn from young fowls by 
cardiac puncture or from a wing vein. The blood was collected into 
sterile Alsever's solution (Appendix 5) and stored at 4° C. Before 
use the red cells were washed thrice in saline and finally packed in 
a graduated tube by centrifugation and made up with saline to a 0.5~ 
suspension (Lepine, 1954). 
It was impossible to use the same fowls throughout this work and 
young fowls, mostly Light Sussex crosses, were obtained at intervals 
as needed. 
Even in Alsever's solution blood was not kept for more than 4 days 
and it was usually used within 24 hours of being taken. 
ii Pigeon red cells. Pigeon blood was collected by sectioning 
a wing vein and collecting the blood in Alsever's solution. This was 
stored at 40 C and used within 48 hours. The cells were washed with 
saline and made up to a 0.514 suspension as with chicken red cells. 
(c) Virus antigen 
Seed virus came from a variety of sources. 
1/ A/Singapore/1/57. A fully avid strain was supplied by Dr. A.S. 
Beare from the Central Public Health Laboratory, Colindale. 
2/ B/England/939/59. This strain was supplied by Dr. D. Hobson, 
Evans Medical, Ltd., and was ·selected as possessing slightly 
greater avidity from three other similar strains. In addition, 
this was the strain in the vaccine. 




A/Swine (Shope - 15). These were obtained as lyophilized 
allantoic fluid from Dr. H.G. Pereira, World Influenza Centre. 
4/ B/Taiwan/4/62 
A/Netherlands/65/63 were supplied, as early passage allantoie 
fluid, by Dr. D. Hobson. 
5/ Para-influenza 1 (Sendai). A strain adapted to grow in the egg 
allantoic cavity was supplied as a lyophilized culture by Dr. 
Marguerite Pereira, Colindale. 
Preparation of antigen 
Lyophilized ampoules were reconstituted with appropriate volumes 
of sterile distilled water and all allantoic fluids were passaged at a 
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dilution of 10-3 and with an inoculum of 0.1 ml. in the allantoic 
cavities of fertile eggs incubated for 11 days. After a further 48 
hours of incubation the eggs were chilled to reduce bleeding, the ' 
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shell over the air space was removed and the allantoic fluid harvested. 
Fluids were tested for the presence of haemagglutinin with a 0.5% sus-
pension of chicken red cells. Positive fluids were pooled, clarified 
by light centrifugationt and the haemagglutinating titre determined. 
Only large batches of a sufficiently high titre were used as antigen. 
To these thiomersal was added to a concentration of 1:10,000 and the 
allantoic fluid was dispensed in 4-5 ml. amo'lll'lts and stored at 4° C. 
Special precautions were taken to avoid mixing of cultures. 
Formalinized antigens 
Dr. D. Hobson kindly supplied some concentrated, formalinized 
batches of A/Singapore/1/57 (Colindale strain), B/England/939/59 and 
B/Taiwan/4/62. Owing to the high H.A. titre of this material it was 
possible to complete large sections of the work with a single batch. 
The behaviour of the formalinized antigens in the test did not differ 
from that of active antigens. 
( d) Apparatus and diluents: 
Perspex plates: Standard W.H.O. haemagglutination plates with 
80 cavities (10 x 8) were obtained from R.B. Turner, Ltd. or 
Prestware, Ltd., London. 




obtained from R.B. Turner, Ltd. and modified to an accurate 
measurement in the laboratory workshop. An 8 x 0.4 ems. glasa 
tube was attached to the Luer fitting nozzle by plastic tubing 
so that the solution pipetted did not enter the barrel of the 
syringe and so that material could be taken from a Kahn tube. 
Cornwall syringes: Cornwall automatic delivery syringes were 
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supplied by F. Froud and Sons, Ltd., London. These were adjusted 
to deliver 0.2 ml. volumes (Fig. 39). 
Diluent: Initially, "physiological" saline (0.85 gms. of sodium 
chloride per 100 mls.) was used but this was soon supplanted by 
0.01 M Phosphate-buffered saline. This was made up and stored 
in 10 x concentrated form (Appendix 5) and diluted with water 
as needed. Ea.oh batch of the diluted, isotonic, buffer was 
tested for pH (7.0 - 7.1) and for satisfactory red cell 
sedimentation qualities before being used. The word "saline" 
will be used indifferently for the "physiological" and phosphate-
buffered solutions. The H.I. titres were not affected by the 
use of either diluent but red cells tended to go brown in the 
non-buffered solution~ 
It was found that the type of water used for preparing 
the solutions was important. Demineralized water (Permutit 
Portable "Deminrolit" Plant Mk. 4) in the buffer solution was; 
associated with poor red cell sedimentation. The red cells 
failed to form a neat, close button when fully settled. This 











Figure 39. Automatic pipette, haemagglutination plate and Cornwall 
syringe as used in the H.1. tests. 
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distilled in glass. 
(e) Technique: 
Stock virus antigen was titrated by ma.king doubling dilutions with 
saline f'rcm 1:2 - l:1024 or 1:2048 in a row of cavities in a 
perspex plate. Volumes of 0.2 ml. were used and pipettes were 
changed at every dilution. One volume of 0.5~ suspension of 
chicken red cells was added to each dilution and to a control 
cavity with one volume of saline. The haemagglut ination pat tern 
was inspected at the end of an hour when the cells in the control 
cavity had settled completely. Haemagglutination in each cavity 
was scored according to the following scheme - taken from the 
pamphlet on the H.I. test circulated by the World Influenza Centre:-
i ++ Complete agglutination. The agglutinated cells fonn a 
granular disc over the bottom of the cavity. 
ii ±!: about 7514 agglutination. Here the disc is incomplete and 
a portion of the cells are not agglutinated. 
iii + 50% agglutination. Whereas there is a "halo" of 
agglutinated cells, a wide ring of non-agglutinated cells 
is present as well. 
iv ± 25% agglutination. A narz:ow ring of non-agglutinated 
cells at the bottom of the plate cavity has some clumps 
of agglut inated cell s around it. 
v - No agglutination. The red cells settle into a tight 
discrete button of cells at the bottom of the cavity. 
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The end-point was read .at 50~ agglutination and, where necessary, 
the titre was deduced by interpolation according to the pamphlet 
mentioned above. 
The stock virus was diluted so as to give a sufficient volume of 
antigen of ·8 H.A. unit concentration. Before use the haemagglutinin . 
titre was checked and adjustments and further titrations carried out 
as required in order to have antigen of the correct strength. 
Doubling dilutions of the trehted sera were carried out in the 
perspex plates from 1:10 - 1:5120. 8 sera were titrated per plate. 
The initial volume of saline ~or dilution was distributed with a 
Cornwall syringe. Automatic pipettes were used to mix and to carry 
the 0.2 ml. volumes of serum dilution from cavity to cavity. At the 
end of a row the surplus volume of 1:5120 dilution was discarded and 
the pipette washed by pipetting and discarding clean saline before a 
new serum was started. As the thawed sera sometimes produced 
precipitates and often the colour was seen to be in layers it was 
necessary to mix the sera before sampling. 
To each volume of serum dilution was added one volume of the 
appropriate virus antigen and, 20 minutes later, a volume of 0.5% 
chicken red cell suspension. The 20 minute period was introduced 
mainly for reasons of convenience. For the early part of the work the 
antigen was dispensed with automatic pipettes but they were replaced 
by Cornwall syringes for this purpose. The plates containing the three 
volumes were allowed to stand at 4Q e. until the red cells had settled 
" 
satisfactorily - usually 75-90 minutes. Settling at 4°c. was 
introduced because the temperature of the laboratory frequently rose 
to so° Fah. (27.7° C.) or more and as large numbers of sera were dealt 
with there was need of elasticity in timing. 
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When ready the plates were read over a translucent pearl ,plass 
plate illuminated from below. A hand lens was used to check agg-
lutination when necessary. Cavities were scored from - to++ as 
previously indicated and the result entered directly on to special fonns. 
These forms had "blocks" of 8 squares cyclostyled on, representing the 
perspex plate with its 80 cavities. Against each row of squares the 
number and letter of the serum was previously entered and against ea.ch 
''block" was the number with which the relevant plate was labelled. 
(Fig. 40). There was no indication on these forms of the vaccine group 
of the volunteers from whom the sera came so that the test was performed 
and read "blind". Titres were calculated from the records later. 
Where 5o% agglutination was not present the titre was calculated 
by means of the following scheme - taken from the World Influenza 
Centre leaflet: 
Cavity number 5~ end point Arithmetic reading 
2 3 4 Cavity number (if cavity 2 is 1:20) 
± ++- Y.t 1 :50 
+ ++ 3 1:40 
±:t ++ 22. 4 1:35 
++ ++ 21 1:30 
± ±± ~ 1:6
0 
• 
,,-. ( • 0 ,,_ . ( . • • 
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Figure 40. H.1. plate with system of marking results. 
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In the presence of serum the settling pattern of the cells varied 
and in reading the plates allowance had to be made for this factor. 
The presence of much haemolysis in the serum initially tended to make 
the tests difficult to read owing to the abnormal red cell patterns at 
low dilutions. The method of inactivation also influenced this serum 
effect. It was not possible to use the trypsin-periodate method on 
rabbit sera because abnormal agglutination obscured the H.I. activity 
of the serum. 
Disposal and cleaning of apparatus: 
After being read the perspex plates were immersed in water until 
the red cells were lysed or washed off. The plates were then transferred 
to soak for 1 - 2 hours each in normal hydrochloric acid and normal 
sodium hydroxide successively, with a wash in water between. After 
soaking in the sodium hydroxide solution the plates were repeatedly 
washed in running wat~r then soaked in running water for a further 1 - 2 
hours or more before receiving a final wash in demineralized water and 
being dried in the hot room (37° C.). By this means it was possible to 
use the same plates day after day. To the initial water wash, con-• 
te.minated with virus and red cells, Chloros Bleach (Imperial Chemical 
Industries) was added and allowed to act before the water was discarded. 
Cornwall syringes and automatic pipettes: 
These were washed through with saline, 70% ~lcohol and water before 
being stored. Both were frequently stripped and all springs, valves and 
working surfaces cleaned to maintain them in working order. 
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Appendix 3: 
Preparation of specific immune sera: 
Immune sera, to incorporate into tests as standards, were prepare
d 
in animals. 
Sera to A/Singapore/1/57 and B/Japan/56 were initially prepared i
n 
rabbits, as recommended by Lepine (1954), by three, weekly, intra
.peritoneal 
inoculations of infected allantoic fluid. The rabbits were bled 
a week 
a.:f'ter the last inoculation. 
Latterly, sera to all the viruses used were prepared in young 
fowls by a schedule of inoculation on a single day. An emulsion 
of 
infected allantoic fluid and complete Freund's adjuvant (Difeo 
Laboratories) was made by repeatedly sucking and squirting a 1:1 
mixture of the two fluids with a syringe. The emulsion was inocu
lated 
in 0.25 ml. a.momts in both legs and into the breast muscles on b
oth 
sides. Allantoic fluid without adjuvant was inoculated intraperi
toneally. 
The fowls were bled before and three weeks a.:f'ter inoculation and 
the 
sera tested before the birds were bled out. 
The bloods were allowed to stand at 37° C. in an incubator for 
about two hours to clot and then put at 4° C. overnight for clot 
retraction to take place. The separated sera were stored at -20°
 C. 





The technique of the neutralization test used was virtually 
identical with that described by Beare (1962) and McDonald, Zuckerman, 
Beare and Tyrrell (1962) and was based on the recognition of influenza 
virus multiplication in monkey kidney tissue culture by haemadsorption 
{Vogel and Shelokov 1957). 
Materials: 
Tissue culture: 
Monkey kidney tissue cultures were prepared 
after the method of Melnick (1955). Kidneys were removed from rhesus 
monkeys under sodium pentobarbitone anaesthesia. The kidney was washed 
in Hanks' balanced salt solution (Appendix 5) ~th 0.5j6 Lactalbumin 
hydrolysate and ahtibiotica added, decapaulated and the cortex cut off 
in small pieces. The medulla was discarded. The fragments of cortical 
tissue were washed in the Hanks' baaed solution above to remove exceaa 
0 
blood, placed in a conical flask and warmed (37 C.) 0.2~ trypsin 
0 
solution (Appendix 5) added. The mixture was kept in the 37 C. room, 
stirred with a magnetic stirrer for 30 minutes and the first amount 
of trypsin discarded. Then trypsin solution was allowed to drip 
slowly into the bunged flask from a round-bellied funnel in such a 
way that the increasing pressure thus caused, forced trypsin solution, 
now containing detached kidney cells in suspension, to rise up a 
collecting tube which runs from the bottom of the flask through the 
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btmg and flow into a collecting bottle (Fig. 41). The collecting 
bottle was packed in ice to inhibit further tryptic action. The 
rate of inflow of fresh trypsin was controlled, by a pinch cock, to 
al.low adequate separation of cells to occur. Stirring continued 
throughout. The process was allowed to continue tmtil the kidney 
material was digested free of cells. The collected cell suspension 
was then gently centrifuged to recover the kidney cells. These .were 
wa~ed free of trypsin and diluted in a. growth medium of Hanks' 
balanced ·salt solution with 0.5% Lactalbumin hydrolysate, 10.cy& ox 
serum and O.OJ?}b sodium bicarbonate. 
The cells from two kidneys were ma.de up to 500 - 700 ml. depending 
on the yield and the dilute suspension was dispensed into 6 xi inch 
tubes at 0.5 ml. per tube. The tubes, ·fitted with bungs, were 
incubated stationary., lying at a gentle tilt, for 4 - 5 days and were 
then rolled in drums (Ma:tburn, Ltd., London). When the metabolism of 
the growing cells made the medium acid the tubes were fed with medium 
199 (Morgan., Morton and Parker, 1950, Appendix 5) containing ~ calf 
serum. Tubes were ready for use in 8 deys • 
.An attempt was made to use a continuous diploid line of vervet 
monkey kidney tidue culture cells. However, haemadsorption was not 
satisfactory with these cultures and they were not used in the tests. 
Virus seeds: 
The same strains of A/Singapore/1/57 and B/Englana/939/59 that 
were used in H. I . tests were used in neutralization tests . Virus was 
grown in the allantoio cavities of developing eggs as described above. 
Figure 41. Apparatus for trypsinizing monkey kidney. The ice container has been removed to show the collecting bottle. 
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Batches of clarified infected allantoic fluid with satisfactory H.A. 
titres wer e dispensed into labelled s oft glass ampoules and these· 
were sealed and snap-frozen in a freezing mixture of dry ice and 
alcohol and stored in an electrical -70° C. r efrigerator (Revco 
. Subzero Equipment). Sample ampoules were rapidly thaweq. and ten-fold 
dilutions made in Medium 199. Each dilution was inoculated into four 
monkey kidney tissue culture tubes. After two days' incubation at 
37° C. 0.2 ml. of a o.~ guine~-pig red cell suspension (see below) 
was added to each tube and to control, uninoculated tubes. The tubes 
were sloped at room temperature for 20 minutes so that the red cells 
could lie in contact with the tissue culture monolayers. Then the 
tubes were stood upright to allow non-adherent cells to settle and 
• 
the monolayers were examined microscopically for the characteristic 
red cell adherence shown in the haemadsorption phenomenon where groups 
of red cells stick to virus infected cells on the monolayer (~igs. 42 
and 43). The end point was determined by the method of Kaerber 
(Irwin and Cheeseman, 1~39) as Haemadsorption doses (H.D.). When 
repeated tests had shown the titre of a batch of virus to b.e high, 
constant and stable it could be used. in the tests . 
Sera: 
All sera to be tested were inactivated at 56° C. for 30 minutes. 
All the sera of a volunteer were tested at the same time. 
Dilutions were made in Medium 199. An initial dilution of 
0.5 ml. serum in 2.0 mls . of medium was made followed by doubling 
dilutions of 2.0 ml. volumes up to the titre required. One pipette 
' ' 
Figure 42. Primary monkey kidney tissue culture, 
negative haemadsorption. (x 48) 
Figure 4.3. Primary monkey kidney tissue culture, 
positive haema.dsorption. (x 48) 
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was used per serum. The serum dilutions were dispensed in 3 xi inch 
Kahn tubes so that 1.0 ml. · was available :f'or each virus that was to be 
used at that dilution. The dilutions were performed the day before the 
test and stored overnight at 4° C. 
Guinea-pig cells: 
Guinea-pigs, under ether anaesthesia, were bled by heart puncture 
into Alsever's solution and the blood stored at 4° C. Prior to use 
the cells were washed three times in saline and made up to o.~ 
suspension in saline. It was found essential to use the cells within 
a day or two of bleeding as cells which were stored for longer than a 
few days often adsorbed to the tissue cultures in a non-specific 
manner which, although confusing, could usually be distinguished from 
haemadsorption caused by the multiplication of influenza virus. 
The test: 
Ampoules of virus seed were rapidly thawed and diluted in Medium 
199 to give 200 H.D. per millilitre. 1.0 ml. of virus was added to 
each millilitre of serum dilution and the virus-serum mixtures wer~ 
shaken and allov,ed to stand at room temperature :f'or an hour. Controls, 
without serum, were set up with virus at 100 H.D., 10 H.D., 1 H.D. and 
O.l H.D. per ml. 
Then 1.0 ml. of each virus-serum mixture and of the controls was. 
inoculated into each o:f' two tissue culture tubes from which the medium 
had been poured off. The inoculated tubes were rolled at 37° C. for an 
• • 
hour, the inocula poured off and each tube fed with 2 mls. of Medium 
199 and then rolled for 2 days at 37° C. 
As feeding the inoculated tubes involved large numbers and as a 
non-touch technique was essential a Struers (Camlab (~lass) Ltd., 
Cambridge) electral automatic pipette was adapted for the purpose 
(Fig. 44-). The syringe, valve, inflow and outflow assemblage was 
autoclaved and connected to t he machine just before use. Medium was 
fed in by gravity and the machine set to dispense 2.0 mls. on the 
touch of the switch button. No problems with contamination arose with 
this and trials showed that the tissue cultures were not adversely 
affected by the medium having passed through the apparatus. 
Arter the inoculated tubes had rolled for two days, 0.2 ml. of 
o.~ guinea-pig cells were added to each tube and they were tested and 
examined for haemadsorption as mentioned above. 
The control tubes were read before the tubes inoculated with the 
serum dilutions. The highest serum dilution with no . visible haemad-
sorption in either of the tubes was taken as the neutralizing titre. 
From the system of dilution employed only 0.5 ml. of each serum diluted 
1:5 was available. This was enough for the inoculation of only one tube 
and could only be tested against one virus. As, in the neutralization 
test, the final serum dilution was read this meant that readings at the 
level of 1:10, unlike other dilutions, were based on one tube only. 
• 
•• 
• • • ' 
Figure 44. Struers electrical automatic pipette 






The composition or derivation of solutions used 
in the experimental work, and which have not been specified in the 
text, are as follows:-
Alsever's solution 
. Glucose 20.5 g. 
Trisodium citrate 8.0 g. 
Sodium chloride 4.2 g. 
Citric acid 0.55 g. 
per Litre. 
Phosphate-buffered saline: 
a/ 0.01 M pH 7.0 
Made up as 10 x concentrated solution and 
diluted before use. 
NaCl 
b/ Sorenson's 1V'l5 
Stock solution A 
85 g. 
10.61 g. 
3.89 g. per Litre 
9.08 g./Litre 
Stock solution B No2 HP04 
2H20 11.88 g./Litre 
For pH 8.0 mix A - 5</o, B - 95% 
For pH 7.3 mix A - 20, B - ~ 
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Hanks' Bala.need Salt ·solution: 
Containing NaCl a.o g. 
KCl 0.4 g. 
Mgso4• 7H20 
0.1 g. 





Glucose 1.0 g. 
Phenol Red 0.01 g. per Litre 
Penicillin and Streptomycin were added to a concentration of 
100 units and 100 ug./ml., respectively. 
Trypsin solution: 
2.5 g. of Trypsin 1:250 Difeo (Difeo Laboratories) 
in 1 Litre of balanced pH 7.5 Phosphate-buffered saline 
(Dulbecco a.na ~gt, 1954) 
Medium 199: 
Obtained commercially from 
1/ Glaxo Laboratories, Ltd., Greenford, Middlesex - rea~ to us
e. 
2/ Burroughs Wellcome and Co., Ltd., London - as a 10 x 
concentrated solution without bicarbonate or antibiotics. 500 m
ls. of 
the concentrate was made up to 5 litres with distilled water and anti-
biotics added - as to Hanks' solution aboye. Sodium bicarbonate 
was 
added to a conpentration of 0.035 g.% and the resulting solution 
was 
filtered through a sintesed glass filter and dispensed in 500 ml.
 
amounts. Further sodium bicarbonate was added as required. 
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Appendix 6 
Tests performed in the study of antibodies to Group A substance • . 
( a) Solutions: 
Saline 
Saline used in these tests contained 0.85 g. sodium chloride in 
100 ml. of distilled water. 
For washing pig cells prior to the Antibody-Absorption test a 
saline solution containing 1.5 g. sodium chloride in 100 ml. water was 
used. 
Acid-citrate-dextrose 
This solution was made up after Loutit and Mollison (1943) in the 
following manner: 






This volume of water was added to ea.oh standard 540 ml. blood 
transfusion bottle for receiving donor blood. 
Phosphate-buffered saline 
For use in papainizing red cells Sorenson's pH 7.3 (Appendix 5) 
buffer was diluted 1:10 with isotonic saline. This resulting solution 
is diluted l in 10 with isotonic saline (see above) for papainizing 
red cells. 
(b) Erythrocytes used in tests: 
1 Human A1 cells: Group A donor blood
 was collected into 
acid-citrate-dextrose solution and stored at 4° C. The cells were 
grouped and sub-typed with specific anti-Ar'serum. Before use the 
cells were washed three times in saline by centrifugation and re- . 
suspension. The cells were finally made into a 5% suspension in 
saline. The batch of red cells was changed weekl;y\. 
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Other Human cells, as for g~ouping, were obtained 'and prepared 
in a similar manner. 
2. Pig cells: Pig blood was collected at the abattoirs 
weekly. Blood from each of 18 pigs was added to 7 ml. of 3.4t~ sodium 
citrate solution to fill a 30 ml. container. The citrated blood was 
stored at 4° C. 
Pig cells were washed three times in saline and made up to a 5?6 
suspension. The cells were grouped into "AP" and1'0P" cells in two 
stages. 
i/ Screening: Cells were tested for haemolysis with 
a human serum lmown to have anti-AP specific lysins. To one volume 
of serum and one volume of fresh, lysin-free, human Group O serum 
{as a source of complement) was added one volume of the cells to be 
tested. The mixture was incubated for an hour at ' 37° C if the lysin 
containing human serum was derived from a post-natal case, or at room 
temperature if the serum came from a pre-natal case, and examined for 
lysis. Cells showing complete lysis were provisionally described as 
AP. cells. 
ii/ Agglutination with pig sera: Cells provisionally 
grouped as AP by the screening technique above had the group confirmed 
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with pig sera after Faistlough (1963). 
The cells to be grouped were papainized (Dtm.sford and Bowley, 
1955). To two volumes of papain solution, containing 1 gram of 
papain powder per litre of isotonic pH 7.3, M/150 phosphate buffered 
saline, one volume of packed pig cells were added and incubated at 
37° C. for 30 minutes. The cells were then centrifuged from the 
papain solution and washed three times in saline. One volume of a 5~ 
suspension of papainized cells in saline was added to one volume of 
serum from a "Group 011 pig and, in parallel, to a volume of serum 
from a "Group A" pig. The mixture was incubated. at 370 C. for an hour 
and examined for agglutination. The 11 Group 011
 pig serum strongly 
agglutinated papainized AP cells. The "Group A" pig serum acted as a 
control . 
(c) Blood grouping: 
The bloods of all voltm.teers in the trials were grouped using 
both serum and cells. 
i/ Grouping the cells: 
A drop of the volunteers' cells 
suspended in saline was added to each of three round-bottomed 
2 x I inch agglutination tubes containing a drop of anti-A1, 
anti-Band Group O serum respectively. The mixture was left 
at room temperature for an hour and the tubes examined for 
agglutination. 
Grouping sera are supplied to branches 
• 
of the National Blood Transfusion Service by the Medical 
Research Council Blood Group Reference Laboratory, London • 
. H/ Serum grouping: 
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To a drop of the volunteer's serum in 
each of three agglutination tubes was added a drop of a 
' suspension of Ai, B, and O cells, respectively. The tubes were 
examined for agglutination after an hour at room temperature. 
These tests were carried out and read separately. Further tests 
were carried out if there was ambiguity or lack of agreement. 
(d) Titration of anti-AJ iso-agglutinins: 
Using a marked Pasteur pipette, one volume of saline was added to 
each of a row of 10 round-bottomed agglutination tubes except the 
first. To the first and second tube one volume of the serum to be 
tested was added. After mixing, one volume from the second tube was 
transferred to the third for mixing. Thus, doubling dilutions were 
made f'rom 1:1 to 1:512. The final surplus volume was discarded from 
, ... 
the last tube and the pipette washed, by repeatedly pipetting and dis-
carding clean saline, before another serum was started. 
To each tube one volume of a 5'/6 suspension of standard Ai cells 
(see above) in saline was added. The tubes were shaken and allowed to 
stand .at room temperature for l! hours. Tubes were then examined for . 
agglutination and the end point determined microscopically. If titres 
were read they were taken at the last tube showing agglutination to a 
degree greater than a microscopic trace. 
All the sera from _one volunteer were titrated together. 
(e) Tests for haemolysins: 
Duplicate sets of three round-bottomed agglutination tubes were 
set up for each serum to be examined. A drop of serum was put· into 
every tube and to these a drop of a 5% suspension in ·saline of 
human A1 , OP or AP cells was added. One set was incubated ·at 37° C. 
and the other at room temperature. 
After lf hours each set was examined and the degree of haemolysis 





slight colouring of the supernatant fluid 
stronger colouring of the supernatant but 
non-haemolysed cells are always visible 
complete haemolysis 
(f) Antibody-Absorption test (Tovey. Lockyer, Blades and Flavell,1962) 
AP cells were washed three times in 1.5% saline and finally 
packed by centrifugation at 3,000 r.p.m. for 15 minutes. 
The serum to be tested was inactivated at 56° C. for 30 minutes. 
To one volume of serum was added an equal volume of packed AP cells. 
The mixture was allowed to stand .for an hour at room temperature and 
then centrifuged to obtain a clear supernatant fluid for testing. 
Doubling dilutions in saline were made of the serum 1 ) before 
absorption and 2) after absorption. To each dilution was added a 
volume of a 5% saline suspension of A1 cells. After l hour at roan 
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temperature the tubes of all dilutions were centrifuged for 1 minute 
at 1,000 r.p.m. and examined for agglutination. 
The result was expressed in terms of a comparison of the anti-Ai 
agglutinin titres before and after absorption with AP cells. In a 
weak positive a difference of 1 or 2 tubes (2 or 4 fold) would be 
noted, a moderate positive - 3 to 4 tubes, and a strong positive -
5 tubes or more. 
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